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The overarching aim of this thesis is to understand how sialic acids are transported into the 
bacterial cell and then degraded by bacterial pathogens. In heavily sialylated environments, 
bacterial pathogens utilise host-derived sialic acid as a nutrient source, and this pathway 
constitutes a novel and unexploited target for antibiotic drug design. 
Three sialic acid transporters, from two distinct gene families were investigated to probe 
how sialic acid is transported across the cytoplasmic membrane. The Yersinia pestis sugar 
proton symporter (NanT) exists as a single species in solution, while the Staphylococcus 
aureus sodium solute symporter (SSS) and Proteus mirabilis SSS appear to be in a self-
association. It is likely that the SSS sialic acid transporters exist in a monomer-dimer 
equilibrium, although higher oligomeric structures cannot be ruled out. The structure of the 
P. mirabilis SSS sialic acid transporter was solved, which is the first known structure of a 
sialic acid transporter to be presented. It was solved in complex with sialic acid and two 
sodium ions, providing insight into how this transporter mediates the movement of sialic 
acid across the membrane. In addition, the structure presents a novel conformation among 
sodium symporters and the structural basis for the movement of sialic acid across the 
membrane is elucidated. 
Following the import of sialic acid into the bacterial cell, N-acetylneuraminate lyase is the 
first enzyme involved in its degradation. The structure, function and inhibition of 
methicillin-resistant S. aureus (MRSA) N-acetylneuraminate lyase were investigated. 
Solution and structural studies confirmed that this enzyme is tetrameric. Kinetic analysis 
was employed to test an inhibitor of N-acetylneuraminate lyase enzymes. This molecule 
demonstrated strong species-specific inhibition against MRSA N-acetylneuraminate lyase. 
The structure of MRSA N-acetylneuraminate lyase in complex with this inhibitor 
demonstrated that altered binding modes between N-acetylneuraminate lyase enzymes may 
account for variable inhibition between species. In addition, evidence for a protein-protein 
interaction between the S. aureus SSS sialic acid transporter and MRSA N-
acetylneuraminate lyase is presented. Thus, these proteins may interact at the cytoplasmic 
membrane, allowing the degradation of sialic acid to be initiated upon entering the cell. 
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The structure, function and catalytic mechanism of the third enzyme involved in sialic acid 
degradation, N-acetylmannosamine-6-phosphate 2-epimerase, were explored from MRSA. 
This enzyme was demonstrated to adopt a dimeric architecture in solution, consistent with 
the crystal structure that was solved and presented. A multi-enzyme coupled assay was 
developed to assess N-acetylmannosamine-6-phosphate 2-epimerase activity in real time. 
Residues were probed that may be important for catalysis and tested by mutagenesis and 
kinetic analysis. A novel mechanism of carbohydrate epimerisation is proposed for this 
enzyme, whereby catalysis occurs via a proton displacement mechanism mediated by the 
substrate. 
Overall, this work provides new data that enriches our understanding of the import and 
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The following is a general introduction to the field of sialobiology in the context of 
bacterial sialic acid metabolism. Subsequent chapters include more detailed, specific 
introductions to the chapter topics, as these are intended to be independent bodies of work.   
1.1 Sialic acid 
Sialic acid is the designation given to a large family comprising over 50 structurally 
distinct nine carbon amino sugars. All are derived from the most common compound 2-
keto-3-deoxy-5-acetamido-D-glycero-D-galacto-nonulosonic acid, more commonly known 
as N-acetylneuraminic acid (Figure 1.1) (Vimr et al., 2004; Almagro-Moreno & Boyd, 
2009a). Derivatives of this molecule carry various substituents at the amino or hydroxyl 
groups (Varki, 1992; Schauer, 2000; Angata & Varki, 2002). Interestingly, N-
acetylneuraminic acid is the only sialic acid that is ubiquitous in all organisms (Schauer, 
2004). Throughout this thesis, the term sialic acid refers to N-acetylneuraminic acid. 




















1.2 Sialic acid utilisation by bacterial pathogens 
Eukaryotic cell surfaces are decorated with a complex array of glycoconjugates. 
Negatively charged sialic acids are found attached to the terminal sugar positions of these 
cell surface glycoconjugates where they mediate a diverse array of cellular interactions, 
recognition and adhesion (Varki, 1993; Schauer, 2000; Vimr et al., 2004). In the human 
respiratory and gastrointestinal tract, sialic acid coated glycoconjugates are highly 
abundant (Vimr, 2013) and glucose tends to be limited in supply (Jeong et al., 2009). Thus, 
bacterial pathogens that colonise these environments, along with commensal competitors, 
have evolved mechanisms by which they can utilise host-derived sialic acid (Vimr et al., 
2004; Severi et al., 2007; Almagro-Moreno & Boyd, 2009a). 
Although the concentration of sialic acid present in human serum is relatively high at 
approximately 1.6 to 2.2 mM/L, it is bound to glycoconjugates under normal physiological 
conditions (Sillanaukee et al., 1999). By definition, these sialoglycoconjugates are 
unavailable for utilisation by bacterial pathogens. In order to make sialic acid available, it 
needs to be released by a neuraminidase, which hydrolyses the linkage between the sialic 
acid molecule and the sub-terminal sugar of the glycoconjugate (Vimr, 1994; Vimr, 2013). 
Neuraminidases are produced either endogenously by the host in response to inflammation 
(Sohanpal et al., 2004; Sohanpal et al., 2007) or exogenously by neuraminidase expressing 
bacteria present in the heavily sialylated niche (Shakhnovich et al., 2002; Vimr, 2013). 
Once available, bacterial pathogens can utilise host-derived sialic acid in multiple ways. 
This includes a strategy known as molecular mimicry, where bacterial pathogens coat their 
outer surfaces in sialic acid to circumvent the host’s innate immune response (Bouchet et 
al., 2003; Vimr et al., 2004; Severi et al., 2007). But most importantly, sialic acid can be 
degraded by some bacterial pathogens into a source of carbon, nitrogen and energy (Vimr 
& Troy, 1985; Olson et al., 2013). Given that glucose is limited in the human respiratory 
or gastrointestinal tract, the utilisation of host-derived sialic acid as an alternate nutrient 
source provides bacterial pathogens with a selective advantage in the human host 
(Martinez et al., 1995; Chang et al., 2004; Vimr et al., 2004; Severi et al., 2005; 
Steenbergen et al., 2005; Almagro-Moreno & Boyd, 2009b; Jeong et al., 2009). The 
utilisation of sialic acid by bacterial pathogens is described in detail below. 
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1.3 Bacterial pathogens evade the host immune 
response by molecular mimicry 
Some bacterial pathogens have evolved the capacity to incorporate sialic acid into cell 
surface macromolecules known as lipopolysaccharides and lipooligosaccharides or to 
produce capsules containing homopolymers of sialic acid (Vimr et al., 2004). This allows 
for the bacterial pathogen to circumvent the host immune response through molecular 
mimicry. The evolutionary advantage of such mimicry is so pronounced that at least four 
pathways of cell surface sialylation have evolved (Vimr & Lichtensteiger, 2002). These 
include precursor scavenging, de novo biosynthesis, donor scavenging and trans-
neuraminidase activity (Figure 1.2). 
Figure 1.2. The pathways of bacterial cell surface sialylation. Four pathways have evolved that allow 
sialic acid to be incorporated into cell surface macromolecules. (A) The precursor scavenging pathway. (B) 
































1.3.1 Precursor scavenging 
A recently discovered method of cell surface sialylation known as precursor scavenging 
(Figure 1.2 A) has been revealed in Haemophilus influenzae. This organism scavenges 
host-derived sialic acid by importing it into its cell. Once imported, H. influenzae activates 
the sialic acid by converting it into cytidine monophosphate (CMP) sialic acid, which is 
incorporated into appropriate acceptors by a sialyltransferase, with the resultant 
sialoconjugate exported to the cell surface (Vimr & Lichtensteiger, 2002). Appropriate 
acceptors include lipopolysaccharides, lipooligosaccharides or capsules containing 
homopolymers of sialic acid. Alternatively, the imported sialic acid can be degraded into a 
carbon, nitrogen and energy source (Section 1.5) (Almagro-Moreno & Boyd, 2009a). 
Thus, H. influenzae must make an important metabolic decision between cell surface 
sialylation or sialic acid degradation so that a fine balance is maintained between the need 
to evade the host’s immune response and any nutritional requirements (Vimr & 
Lichtensteiger, 2002). 
1.3.2 De novo biosynthesis  
De novo biosynthesis of sialic acid (Figure 1.2 B) is used by a number of bacteria 
including Neisseria meningitides and Escherichia coli (Vimr et al., 2004). This route 
involves synthesising sialic acid from uridine diphosphate (UDP) N-acetylglucosamine, a 
simple metabolite produced by most cells. Once synthesised, sialic acid is converted into 
its activated form, CMP sialic acid, which is incorporated into appropriate acceptors by a 
sialyltransferase, with the resultant sialoconjugate exported to the cell surface (Vimr & 
Lichtensteiger, 2002). 
1.3.3 Donor scavenging 
The donor scavenging pathway of cell surface sialylation (Figure 1.2 C) has been 
discovered in Neisseria gonorrhoeae, which enables a considerably truncated sialylation 
pathway. Like de novo biosynthesis, this mechanism also involves the addition of CMP 
sialic acid to appropriate acceptors. But instead of synthesising it from simple metabolites 
endogenously, CMP sialic acid is scavenged directly from the exogenous environment and 
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incorporated into appropriate acceptors by a sialyltransferase, with the resultant 
sialoconjugate exported to the cell surface (Shell et al., 2002). 
1.3.4 Trans-neuraminidase activity 
As described in Section 1.2, neuraminidases can hydrolytically remove sialic acid from 
host glycoconjugates, making it available for utilisation by bacterial pathogens (Vimr, 
1994; Vimr, 2013). A trans-neuraminidase enzyme for cell surface sialylation (Figure 1.2 
D) has been discovered in Trypanosoma cruzi with both hydrolytic and sialyltransferase 
activity. The hydrolytic activity is responsible for cleaving sialic acid from host 
glycoconjugates, while the sialyltransferase activity is responsible for directly transferring 










1.4 Importation of sialic acid into bacterial 
pathogens 
For bacterial pathogens to utilise the precursor scavenging mechanism of cell surface 
sialylation or degrade host-derived sialic acid into a carbon, nitrogen and energy source 
(Section 1.5), sialic acid must be transported across the cytoplasmic membrane and into the 
bacterial cell. For gram negative bacterial pathogens, sialic acid must first cross the outer 
cell membrane into the periplasmic space before it can be imported into the cell. Sialic acid 
transport across the outer cell membrane of bacterial pathogens is not well understood 
(Severi et al., 2007). However, a sialic acid inducible outer membrane porin known as 
NanC has been well characterised in E. coli (Condemine et al., 2005; Wirth et al., 2009). 
Bacterial pathogens have evolved multiple mechanisms of sialic acid transport across the 
cytoplasmic membrane, which vary between species (Almagro-Moreno & Boyd, 2009a). 
To date, four different types of transporter have been recognised, including: 1) an 
adenosine triphosphate (ATP) binding cassette (ABC) transporter (Post et al., 2005); 2) a 
tripartite ATP independent periplasmic transporter (TRAP) (Allen et al., 2005; Severi et 
al., 2005; Chowdhury et al., 2012; Mulligan et al., 2012); 3) a single component sugar 
proton symporter (NanT) (Vimr & Troy, 1985; Martinez et al., 1995); and 4) a single 
component sodium solute symporter (SSS) (Severi et al., 2010). Each type of sialic acid 
transporter is described below and depicted in Figure 1.3. 
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Figure 1.3. Sialic acid transporter types. In ABC and TRAP transporter systems, a periplasmic or cell 
surface associated substrate binding protein (green circles) interacts with two membrane protein domains 
(blue rectangles) to transport the sialic acid (red circles) across the membrane. ABC transporters are primary 
transporters that couple solute translocation with the hydrolysis of ATP by the ATPase domains harbouring 
the Walker motifs (dark blue circles). TRAP, NanT and SSS transporters are secondary transporters that 
couple solute translocation with an electrochemical gradient. It is unclear whether TRAP sialic acid 
transporters are proton or sodium ion dependent; but NanT sialic acid transporters have been shown to be 
proton dependent (Mulligan et al., 2012), while SSS sialic acid transporters have been shown to be sodium 
ion dependent (Severi et al., 2010). The stoichiometry of ions required for transport is not well understood. 
1.4.1 ATP binding cassette transporters for sialic acid 
transport 
The ABC superfamily of transporters is one of the largest families of transporters with 
representatives in all phyla (Jones & George, 2004). Containing uptake and efflux systems, 
this superfamily is made up of dozens of families that vary in their substrate specificity 
(Saurin et al., 1999). ABC transporters are known as primary transporters because they 
utilise the energy generated from ATP hydrolysis to transport solutes across a membrane 
(Higgins, 1992). They transport a variety of substrates across both extracellular and 
intracellular membranes, including ions, sugars, amino acids, peptides, polysaccharides 
and even proteins.  
All ABC transporters are composed of four domains, two transmembrane domains that 
form the translocation pathway and two cytoplasmic nucleotide binding domains that 
extracellular
intracellular











hydrolyse ATP (Higgins, 1992). Prokaryotic ABC transporters contain an additional 
periplasmic or cell surface associated binding protein that bind substrates with high affinity 
and deliver them to the transmembrane domains. Since the first high resolution structure of 
the E. coli vitamin B12 ABC transporter (Locher et al., 2002), crystal structures of a 
handful of others have been solved (Oldham et al., 2007; Hohl et al., 2012; Woo et al., 
2012; Shintre et al., 2013), some of which have been solved in complex with their 
substrate binding proteins (Hollenstein et al., 2007; Oldham et al., 2007). 
The first sialic acid ABC transport system was identified and characterised in Haemophilus 
ducreyi (Post et al., 2005). More recently, an ABC transporter system for sialic acid has 
been identified in Streptococcus pneumoniae (Marion et al., 2011a; Marion et al., 2011b). 
Although the import of sialic acid by ABC transporters is not well characterised in other 
organisms, Streptococcus agalactiae, Streptococcus gordonii, Streptococcus pyogenes and 
Streptococcus sanguinis are predicted to utilise this type of sialic acid transport system 
(Almagro-Moreno & Boyd, 2009a). The components that make up the H. ducreyi ABC 
transporter include a periplasmic substrate binding protein (SatA), integral membrane 
permease domains (SatB/SatC) and an ATPase domain (SatD). S. pneumoniae has a 
similar structural organisation, except that the ATPase domain is a shared ATPase (msmK) 
that is responsible for energising multiple carbohydrate transporters (Marion et al., 2011a). 
1.4.2 Tripartite ATP independent periplasmic transporters 
for sialic acid transport 
TRAP transporters constitute a large family of specific solute transporters, all of which 
transport organic acids. Solutes transported include a range of C4-dicarboxylates, α-keto 
acids, aromatic substrates and amino acids (Mulligan et al., 2011). All known TRAP 
transporters are secondary transporters that use an electrochemical gradient to facilitate 
solute transport (Kelly & Thomas, 2001). Secondary transporters couple the movement of 
an ion down an electrochemical gradient with the movement of another ion or molecule 
against a concentration and/or electrochemical gradient.  Unlike primary transporters, there 
is no direct coupling of ATP to allow movement of an ion or molecule across the 
membrane. By definition, secondary transporters can operate in both directions, depending 
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on the direction and magnitude of the concentration and/or electrochemical gradient 
(Poolman & Konings, 1993; Severi et al., 2010). 
TRAP transporters are composed of three protein domains; these include the substrate 
binding protein, a small membrane spanning domain and a large membrane spanning 
domain. The purpose of the substrate binding protein is to bind substrate with high affinity 
and specificity and present it to the membrane spanning domains of the transporter for 
transport across the membrane (Doeven et al., 2004; Mulligan et al., 2009). Conveniently, 
it is found either free in the periplasm of gram negative bacteria or anchored to the 
cytoplasmic membrane in gram positive bacteria and archaea (Kelly & Thomas, 2001). For 
drug discovery, TRAP transporters are of particular interest because they are widespread 
across bacteria and archaea but are not found in eukaryotes (Kelly & Thomas, 2001). 
The first C4-dicarboxylate TRAP transport system to be described was from Rhodobacter 
capsulatus (Forward et al., 1997). Although TRAP transporters are not well characterised, 
the large membrane spanning domain is predicted to form the membrane translocation 
pathway through which the substrate passes (Mulligan et al., 2012). Whereas the small 
membrane spanning domain has been shown to be essential for transport, but the function 
remains unknown (Forward et al., 1997; Mulligan et al., 2012). It is unclear whether 
TRAP sialic acid transporters are proton or sodium ion dependent (Mulligan et al., 2012). 
1.4.3 Sugar proton symporters for sialic acid transport 
The first sialic acid transporter to be discovered was NanT from E. coli (Vimr & Troy, 
1985). NanT is a secondary transporter belonging to the major facilitator superfamily 
(Martinez et al., 1995; Vimr et al., 2004). NanT is a single component system that is 
predicted to be a sugar proton symporter, specifically co-transporting sialic acid with a 
proton into the cell (Vimr et al., 2004; Severi et al., 2010). The stoichiometry of protons 
required for the transport of sialic acid by NanT is yet to be confirmed. Unfortunately, our 
understanding of NanT at the molecular level is limited (Martinez et al., 1995). In Chapter 
Four of this thesis, I will attempt to address this by investigating a sialic acid transporter of 
this type from Yersinia pestis, a gram negative bacterial pathogen that can infect humans 
and animals causing the Bubonic plague (Almagro-Moreno & Boyd, 2009a). 
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1.4.4 Sodium solute symporters for sialic acid transport 
More recently, a novel type of sialic acid transporter has been discovered from Salmonella 
enterica (Severi et al., 2010), belonging to the sodium solute symporter (SSS) family of 
secondary transporters that co-transport sodium ions with sugars, amino acids, inorganic 
ions or vitamins (Wright et al., 2004). Like NanT, the SSS transporters are also single 
component systems. The S. enterica sialic acid transporter was established as a typical 
member of the SSS family because its functionality was dependent upon the presence of 
sodium ions (Severi et al., 2010). The genes encoding the SSS sialic acid transporters are 
widespread among both gram positive and gram negative species of bacteria, whereas 
other types of sialic acid transporters do not appear to be as widespread (Severi et al., 
2010). An SSS sialic acid transporter from S. aureus and Proteus mirabilis will be 
explored in more detail in Chapter Four. 
1.4.5 Sialic acid is transported using a specific transporter 
A functional sialic acid transporter has proven to be essential for the uptake of sialic acid 
in a range of human bacterial pathogens, including E. coli, H. influenzae, S. aureus and V. 
cholerae (Vimr & Troy, 1985; Vimr et al., 2004; Severi et al., 2005; Severi et al., 2010; 
Mulligan et al., 2012; Olson et al., 2013). This means that these organisms possess one 
specific type of transporter that is the sole route for sialic acid uptake. Thus, developing 
novel antibiotic drugs that target these transporters is a plausible mechanism for blocking 
pathogen colonisation. Indeed, inhibition of sialic acid transporters has lead to bacterial 
non-virulence in animal models (Fuller et al., 2000; Chang et al., 2004; Severi et al., 
2007). However, to date there are no structural data to explain how sialic acid transporters 
mediate transport across the plasma membrane or how specificity is achieved. 
Understanding this will be critical for the design of future antibiotics. 
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1.5 Sialic acid degradation by bacterial 
pathogens 
Following the transport of host-derived sialic acid into the cell, some bacterial pathogens 
will utilise it by degrading it into a carbon, nitrogen and energy source (Vimr & Troy, 
1985; Olson et al., 2013). The genes required for the sequestration and subsequent 
degradation of host-derived sialic acid are known as the ‘nan nag cluster,’ and are confined 
to pathogenic species of bacteria and mammalian commensals (Almagro-Moreno & Boyd, 
2009a). The nan nag cluster encodes the transporter responsible for importing sialic acid 
into the bacterial cell and five catalytic enzymes that successively degrade it into fructose-
6-phosphate, a key metabolite for glycolysis.  
The sialic acid degradation pathway is depicted in Figure 1.4 and each of the catalytic 
enzymes will be described in more detail below. Briefly, the degradation of sialic acid is 
initiated by N-acetylneuraminate lyase, an enzyme that catalyses the retro-aldol cleavage 
of open chain sialic acid to form N-acetylmannosamine and pyruvate (Izard et al., 1994; 
Barbosa et al., 2000). N-Acetylmannosamine kinase then uses ATP to phosphorylate N-
acetylmannosamine, generating N-acetylmannosamine-6-phosphate and adenosine 
diphosphate (ADP) (North et al., 2014b). Thereafter, N-acetylmannosamine-6-phosphate 
2-epimerase converts N-acetylmannosamine-6-phosphate into N-acetylglucosamine-6-
phosphate via an epimerisation reaction (North et al., 2014a). Next, N-acetylglucosamine-
6-phosphate deacetylase removes the acetyl group from N-acetylglucosamine-6-phosphate 
and yields glucosamine-6-phosphate. Glucosamine-6-phosphate deaminase then catalyses 
the isomerisation and deamination of glucosamine-6-phosphate into fructose-6-phosphate 






Figure 1.4.  The sialic acid degradation pathway. Following the import of sialic acid into the bacterial 
cell, it is successively degraded into fructose-6-phosphate by N-acetylneuraminate lyase, N-
acetylmannosamine-6-phosphate, N-acetylmannosamine-6-phosphate 2-epimerase, N-acetylglucosamine-6-
phosphate deacetylase and glucosamine-6-phosphate deaminase. 
1.5.1 N-Acetylneuraminate lyase 
N-Acetylneuraminate lyase (which will be discussed in more detail in Chapter Two) 
catalyses the retro-aldol cleavage of open chain sialic acid to form N-acetylmannosamine 
and pyruvate (Figure 1.5) via a Schiff base intermediate (Izard et al., 1994; Lawrence et 
al., 1997; Barbosa et al., 2000). This reaction represents the first and the committed step of 
the degradation pathway. Structurally, N-acetylneuraminate lyase is classified within the 
N-acetylneuraminate lyase sub-family of triosephosphate isomerase barrel [(β/α)8-barrel] 
enzymes. Members of this sub-family identified thus far include the archetype N-
acetylneuraminate lyase, 4-hydroxy-tetrahydrodipicolinic acid synthase [formally known 
as dihydrodipicolinate synthase (DHDPS)] (Mirwaldt et al., 1995), D-5-keto-4-
deoxyglucarate dehydratase (Jeffcoat et al., 1969b; Jeffcoat et al., 1969a), 2-keto-3-





















hydratase-aldolase (Eaton, 1994) and trans-2’-carboxybenzalpyruvate hydratase-aldolase 
(Iwabuchi & Harayama, 1998). All of which share a common structural framework, but 
catalyse reactions in separate biochemical pathways (Lawrence et al., 1997).  
Figure 1.5. The reaction catalysed by N-acetylneuraminate lyase. N-Acetylneuraminate lyase catalyses 
the retro-aldol cleavage of open chain sialic acid to form N-acetylmannosamine and pyruvate. 
The structure of N-acetylneuraminate lyase has been well characterised in various 
organisms including, E. coli (Izard et al., 1994; Lawrence et al., 1997; Joerger et al., 2003; 
Campeotto et al., 2009; Campeotto et al., 2010; Daniels et al., 2014), H. influenzae 
(Barbosa et al., 2000), Pasteurella multocida (Huynh et al., 2013) and S. aureus (Timms et 
al., 2013). Further analysis of N-acetylneuraminate lyase in complex with substrate 
analogues has revealed the mechanism of substrate binding within the active site 
(Lawrence et al., 1997; Barbosa et al., 2000; Huynh et al., 2013; Daniels et al., 2014). As 
with all members of the N-acetylneuraminate lyase sub-family of (β/α)8-barrel enzymes, 
catalysis is proposed to involve the formation of a Schiff base between the amine of a 
highly conserved lysine residue and the C2 carbon of the α-keto acid moiety on the 
substrate (Izard et al., 1994; Blickling et al., 1997; Lawrence et al., 1997). In recent years, 
N-acetylneuraminate lyase has received considerable attention from both mechanistic and 
structural viewpoints and has been recognised as a viable antibiotic drug target (Severi et 
al., 2007; von Itzstein, 2007). 
1.5.2 N-Acetylmannosamine kinase 
Following the reaction catalysed by N-acetylneuraminate lyase, N-acetylmannosamine 




















generating N-acetylmannosamine-6-phosphate and ADP (Figure 1.6). N-
Acetylmannosamine kinase is a phosphotransferase belonging to the repressor, open 
reading frame, kinase (ROK) superfamily. ROK kinases usually contain a conserved N-
terminal ATP binding motif and a zinc binding motif (Holmes et al., 1993; Larion et al., 
2007). Zinc is proposed to play a key structural role in the active site of many ROK 
kinases (Larion et al., 2007). However, this zinc binding motif is not obvious in N-
acetylmannosamine kinase from S. aureus and Streptococcus mitis (North et al., 2014b). 
The lack of a zinc binding motif in these organisms suggests that the geometry and 
stability of the active site may be affected in some other way. This difference could be 
explored as a target for inhibitory molecules. 
Figure 1.6. The reaction catalysed by N-acetylmannosamine kinase. N-Acetylmannosamine kinase 
transfers a phosphate group from ATP to the C6 position of N-acetylmannosamine, generating N-
acetylmannosamine-6-phosphate and ADP. 
There is a lack of literature published on the bacterial N-acetylmannosamine kinase, but 
much is known about its bifunctional eukaryotic homologue UDP N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase. In mammals, this enzyme is proposed to be 
involved in sialic acid biosynthesis (Hinderlich et al., 1997). Crystal structures of the 
Homo sapiens N-acetylmannosamine kinase domain of UDP N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase have been solved (Martinez et al., 2012). Yet, 
only one bacterial crystal structure of N-acetylmannosamine kinase has been determined 
from E. coli (New York Structural Genomics Research Centre, unpublished work). 
1.5.3 N-Acetylmannosamine-6-phosphate 2-epimerase 
N-Acetylmannosamine-6-phosphate 2-epimerase (which will be investigated in more detail 


















6-phosphate (Figure 1.7). N-acetylmannosamine-6-phosphate 2-epimerase and two other 
amino sugar 2-epimerase enzymes have been implicated in pathways that utilise sialic acid 
in both eukaryotes and prokaryotes, all of which use N-acetylmannosamine as the essential 
sugar precursor (Ferrero et al., 2007). In eukaryotes, N-acetylglucosamine 2-epimerase is 
responsible for the degradation of sialic acid, whereas the previously discussed 
bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase is 
involved in the biosynthesis of sialic acid. An evolutionarily and mechanistically related 
UDP N-acetylglucosamine 2-epimerase has been implicated in the biosynthesis of sialic 
acid in prokaryotes (Tanner, 2005), but it lacks the bifunctional kinase activity. 
Figure 1.7. The reaction catalysed by N-acetylmannosamine-6-phosphate 2-epimerase. N-
Acetylmannosamine-6-phosphate 2-epimerase epimerises N-acetylmannosamine-6-phosphate into N-
acetylglucosamine-6-phosphate. 
Crystal structures of N-acetylmannosamine-6-phosphate 2-epimerase from methicillin-
resistant S. aureus (MRSA) (Midwest Centre for Structural Genomics, unpublished work), 
S. enterica (Centre for Structural Genomics of Infectious Diseases, unpublished work) and 
S. pyogenes (Midwest Centre for Structural Genomics, unpublished work) have been 
solved. However, these structures have not yet been published in the literature. Recently 
however, the structure of Clostridium perfringens N-acetylmannosamine-6-phosphate 2-
epimerase has been solved and published (Pelissier et al., 2014). 
1.5.4 N-Acetylglucosamine-6-phosphate deacetylase 
Following the reaction catalysed by N-acetylmannosamine-6-phosphate 2-epimerase, N-
acetylglucosamine-6-phosphate deacetylase catalyses the deacetylation of N-
acetylglucosamine-6-phosphate with water to form glucosamine-6-phosphate and acetate 













reported from E. coli in a metal free state (Ferreira et al., 2006), E. coli in a metal bound 
state (Hall et al., 2007), Bacillus subtilis in a metal bound state (Vincent et al., 2004) and 
Thermotoga maritima in a metal bound state (Joint Centre for Structural Genomics, 
unpublished work). These structures show that the N-acetylglucosamine-6-phosphate 
deacetylases belong to the metal dependent amidohydrolase superfamily (Vincent et al., 
2004). This family of enzymes can bind one or more divalent metal ions in the active site, 
including Fe2+, Zn2+, Co2+ and Cu2+ (Ferreira et al., 2006). A comparison of these crystal 
structures reveals different active site motifs for the complexation of divalent metal ions. 
The structure for B. subtilis N-acetylglucosamine-6-phosphate deacetylase contains a 
binuclear Fe2+ centre, whereas the T. maritima structure N-acetylglucosamine-6-phosphate 
deacetylase has a mononuclear Fe2+ centre (Vincent et al., 2004). The structure of the E. 
coli enzyme in a metal bound state has a mononuclear Fe2+ centre (Hall et al., 2007), yet 
this enzyme has also been shown to bind other metal ions (Ferreira et al., 2006).  
Figure 1.8. The reaction catalysed by N-acetylglucosamine-6-phosphate deacetylase. N-
Acetylglucosamine-6-phosphate deacetylase catalyses the deacetylation of N-acetylglucosamine-6-phosphate 
with water to form glucosamine-6-phosphate and acetate. 
1.5.5 Glucosamine-6-phosphate deaminase 
The final enzyme involved in the degradation of sialic acid is glucosamine-6-phosphate 
deaminase. This enzyme catalyses the isomerisation and deamination of glucosamine-6-
phosphate with water into fructose-6-phosphate and ammonia (Figure 1.9). Fructose-6-
phosphate is an essential metabolite that is used in glycolysis (Almagro-Moreno & Boyd, 
2009a). Glucosamine-6-phosphate deaminase belongs to an aldose ketose isomerase class 
of proteins, all of which catalyse the removal of one hydrogen from the C2 position of the 
aldose and add back a hydrogen to the C1 position of the ketose through a cis-enediol 


















animal, fungus and bacteria, where it is involved in sialic acid degradation for nutritional 
purposes or amino sugar synthesis for peptidoglycan formation (Liu et al., 2008). The 
equilibrium of the reaction favours the degradation reaction (Calcagno et al., 1984). 
Figure 1.9. The reaction catalysed by glucosamine-6-phosphate deaminase. Glucosamine-6-phosphate 
deaminase catalyses the isomerisation and deamination of glucosamine-6-phosphate with water into fructose-
6-phosphate and ammonia. 
Crystal structures of glucosamine-6-phosphate deaminase have been published from a 
range of bacterial species including, B. subtilis (Vincent et al., 2005), E. coli (Oliva et al., 
1995; Horjales et al., 1999; Rudino-Pinera et al., 2002) and Streptococcus mutans (Liu et 
al., 2008). The crystal structure of glucosamine-6-phosphate deaminase from E. coli shows 
that the enzyme is hexameric and allosterically activated by N-acetylglucosamine-6-
phosphate (Horjales et al., 1999). In contrast, glucosamine-6-phosphate deaminase from B. 
subtilis and S. mutans is monomeric and not allosterically regulated (Vincent et al., 2005; 
Liu et al., 2008). It has been proposed that through evolution, glucosamine-6-phosphate 
deaminase from gram positive bacteria has diverged into a monomeric family, causing it to 




















1.6 Regulation of the nan nag cluster 
Interestingly, sialic acid degradation does not appear to be under strict allosteric control, 
apart from the activation of glucosamine-6-phosphate deaminase by N-acetylglucosamine-
6-phosphate. Instead, expression of the enzymes involved in the transport and degradation 
of sialic acid is controlled by a transcriptional regulator, known as the nanRepressor 
(Kalivoda et al., 2003; Johnston et al., 2007; Hwang et al., 2013; Kalivoda et al., 2013; 
Olson et al., 2013). The nanRepressor belongs to the RpiR family of transcriptional 
regulators and contains a helix-turn-helix motif and a sugar isomerase domain (Jaeger & 
Mayer, 2008). An exception to the RpiR family of transcriptional regulators is the 
nanRepressor found in E. coli, which belongs to the GntR superfamily. Despite this 
exception, all nanRepressor proteins are responsible for regulating the expression of the 
sialic acid degradation operon, thus they are also known as ‘sialoregulators’. 
Helix-turn-helix motifs are often found in proteins that are known to bind 
deoxyribonucleic acid (DNA) and regulate gene expression. The motif is characterised by 
two α-helices that make intimate contacts with the DNA, one of which is important for 
sequence recognition, while the other assists in stabilising the structure (Sauer et al., 1982; 
Brennan & Matthews, 1989). For nanRepressor proteins belonging to the RpiR 
superfamily, positively charged amino acid residues of the helix-turn-helix domain are 
speculated to interact with the nan promoter. For the S. aureus nanRepressor in particular, 
the positively charged amino acid residues of the helix-turn-helix domain specifically 
interact with the nan promoter at the nanAT and nanE transcripts (Olson et al., 2013). 
The sugar isomerase domain of the nanRepressor has a key regulatory role in the 
expression of the enzymes involved in sialic acid degradation. Depending on the organism, 
the sugar isomerase domain interacts with the sugar-like structure of sialic acid or 
degradation products within the pathway (Kalivoda et al., 2003; Kalivoda et al., 2013; 
Olson et al., 2013). For E. coli, sialic acid has been implicated as the inducer of nan 
expression (Brennan, 1993; Busby & Ebright, 1999; Blanco et al., 2002; Kalivoda et al., 
2003; Kalivoda et al., 2013). The second and third substrate/product involved in the 
degradation of sialic acid (N-acetylmannosamine and N-acetylmannosamine-6-phosphate, 
respectively), act as inducers of nan expression in S. pneumoniae (Gualdi et al., 2012). N-
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acetylmannosamine-6-phosphate alone acts as the inducer for V. vulnificus (Kim et al., 
2011) and S. aureus (Olson et al., 2013). For H. influenzae, glucosamine-6-phosphate is 
responsible for both the induction and the repression of nan expression (Johnston et al., 
2007). 
To date, the only crystal structure that has been solved for a nanRepressor protein belongs 
to V. vulnificus in complex with its regulatory ligand, N-acetylmannosamine-6-phosphate 
(Hwang et al., 2013). This nanRepressor been demonstrated to form a dimer where the 
positioning of each monomer creates a positively charged arched tunnel-like DNA binding 
pocket. N-Acetylmannosamine-6-phosphate is known to block DNA binding. This is 
proposed to be mediated by relocation of residues that alleviate the interaction between the 
nanRepresor and DNA, relieving the repressive effect and thus inducing transcription of 










1.7 Antibiotic resistance in bacterial pathogens 
The discovery of potent antibiotic agents was one of the greatest advances in the control of 
bacterial diseases in the 20th century (Cohen, 1992). In the United States of America alone, 
it is estimated that more than 2 million people are infected with antibiotic resistant bacteria 
resulting in 23 000 deaths annually (Hampton, 2013). There are no reliable estimates of the 
number of infection cases globally, but there is evidence that antibiotic resistance is 
significantly worse in developing countries (Toner et al., 2015). The rise in antibiotic 
resistant bacteria stems from a multitude of factors including the widespread and 
sometimes inappropriate administration of antibiotics in both human medicine and 
agriculture (Lowy, 2003; Blair et al., 2015). Frighteningly, this increasing resistance has 
resulted in a pronounced lack in the development of new antibiotics (Blair et al., 2015). 
Thus, the search for antibiotic compounds has recently taken on a new urgency. 
The global increase in antibiotic resistance is of particular concern for S. aureus; a gram 
positive bacterial pathogen with an ability to cause a diverse range of life threatening 
infections (Furuya & Lowy, 2006). Since Alexander Fleming’s first observation in 1928 
that penicillin had antibiotic properties against staphylococci (Hare, 1982), S. aureus has 
continuously evolved resistance mechanisms against novel antibiotic compounds (Furuya 
& Lowy, 2006). In 1959, the first semi synthetic β-lactam antibiotic named methicillin was 
introduced. Despite initial successes, by 1961 the first MRSA strains were emerging, 
which were resistant to virtually all β-lactam antibiotics and their derivatives (Jevons, 
1961). As a result of this selective pressure, there has been a dramatic increase in the 
number of multi-drug resistant S. aureus infections worldwide (McDonald et al., 1981; 
Chambers, 1988; Panlilio et al., 1992; Boyce et al., 2005). Previously associated with 
exposure in healthcare settings, this superbug now accounts for an increasing number of 





1.8 Sialic acid degradation is essential for 
pathogen colonisation and persistence 
The sialic acid degradation pathway has been well documented in several bacterial 
pathogens that colonise heavily sialylated niches, including E. coli, H. influenzae, S. 
aureus, V. cholerae, V. vulnificus and Y. pestis (Chang et al., 2004; Almagro-Moreno & 
Boyd, 2009b; Almagro-Moreno & Boyd, 2009a; Jeong et al., 2009; Olson et al., 2013). As 
described in Section 1.2, glucose is limited in heavily sialylated niches, such as the human 
respiratory and gastrointestinal tract (Jeong et al., 2009). Thus, the capability of these 
organisms to utilise sialic acid as an alternate source of carbon, nitrogen and energy is 
important for their survival (Almagro-Moreno & Boyd, 2009b). 
Various in vitro and in vivo studies demonstrate that the degradation of sialic acid is crucial 
for the colonisation and persistence of several human bacterial pathogens. Deletion of one 
or more of the genes encoded by the nan nag cluster rendered E. coli, S. aureus, V. 
cholerae, V. vulnificus and S. aureus incapable of growing on sialic acid as a sole carbon, 
nitrogen and energy source in vitro (Vimr & Troy, 1985; Almagro-Moreno & Boyd, 
2009b; Jeong et al., 2009; Vogel-Scheel et al., 2010; Olson et al., 2013), which suggests 
that this is the only pathway for sialic degradation in these bacteria. More importantly, the 
ability to degrade sialic acid has proven necessary for pathogen colonisation and 
persistence in vivo, with mouse models for E. coli (Chang et al., 2004), V. cholerae 
(Almagro-Moreno & Boyd, 2009b) and V. vulnificus (Jeong et al., 2009). In addition to the 
essentiality of sialic acid transporters for the uptake of sialic acid into the bacterial cell, 
described in Section 1.4.5, these findings demonstrate that the nan nag cluster constitutes a 





1.9 Aims and objectives of this thesis 
The overall aim of this research is to understand how sialic acid is transported into the 
bacterial cell and subsequently degraded. Following the import of sialic acid into the 
bacterial pathogen, five successive enzymes degrade it into a carbon, nitrogen and energy 
source. Given the importance of sialic acid transport and degradation for the colonisation 
and persistence of clinically important human pathogens, surprisingly little structural data 
exists for this pathway. Enzymology and structural biology is used to gain valuable 
information on how this pathway functions. These data underpin and inform future drug 
design and expand our understanding of this important, but poorly understood, metabolic 
pathway. 
Chapter Two investigates the structure, function and inhibition of MRSA N-
acetylneuraminate lyase. Biophysical characterisation, kinetic analysis and a structural 
analysis of MRSA N-acetylneuraminate lyase are presented. A previously characterised 
molecule that has been shown to inhibit C. perfringens N-acetylneuraminate lyase was 
synthesised in collaboration with Professor Antony Fairbanks (University of Canterbury). 
The ability of this molecule to inhibit MRSA N-acetylneuraminate lyase was tested by 
kinetic analysis. To probe how inhibition is achieved in this organism, the structure was 
solved in complex with this molecule. 
Chapter Three investigates the structure and catalytic mechanism of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase. A sequence and structural analysis of my 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase was used to probe amino acid 
residues that may be important for catalysis. These residues were mutated and a multi-
enzyme coupled assay that I specifically designed for N-acetylmannosamine-6-phosphate 
2-epimerase was used to assess the importance of these residues. During the course of this 
thesis, a structural analysis and proton nuclear magnetic resonance spectroscopy (1H 
NMR) based kinetic analysis of C. perfringens N-acetylmannosamine-6-phosphate 2-
epimerase was published (Pelissier et al., 2014). From this data, the authors proposed that 
the catalytic mechanism employed by N-acetylmannosamine-6-phosphate 2-epimerase 
enzymes is a deprotonation/reprotonation mechanism. A critical analysis of their structures 
suggests that this proposed mechanism is unlikely. Alternatively, I propose that catalysis 
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may occur via the formation of a Schiff base or a proton displacement mechanism 
mediated by the substrate. 
Chapter Four explores three sialic acid transporter proteins, belonging to two distinct 
families, the NanT sialic acid transporter from Y. pestis and the SSS sialic acid transporters 
from P. mirabilis and S. aureus. There are no structural data available for any of the known 
sialic acid transporters to explain how they mediate sialic acid transport across the 
cytoplasmic membrane. This chapter describes the expression, purification, quaternary 
structure and attempts at crystallisation of these transporters, which is a significant step 
towards a structural and functional understanding of these inherently difficult to work with 
proteins. This work was completed in collaboration with Dr Rosmarie Friemann’s 
laboratory (University of Gothenburg). Excitingly, the structure of the P. mirabilis SSS 
sialic acid transporter was solved in Dr Rosmarie Friemann’s laboratory and I completed a 
structural analysis, which is presented in this chapter. In addition, Chapter Four also 
addresses a potential protein-protein interaction between the S. aureus SSS sialic acid 
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The structure, function and inhibition 
of methicillin-resistant Staphylococcus 
aureus N-acetylneuraminate lyase 
Part of the work presented in this chapter has been published in: 
North, R. A., Kessans, S. A., Atkinson, S. A., Suzuki, H., Watson, A. J. A., Burgess, B., 
Angley, L., Hudson, A. O., Varsani, A., Griffin, M. D. W., Fairbanks, A. J., Dobson, R. C. 
J. (2013). Cloning, expression, purification, crystallisation and preliminary X-ray 
diffraction studies of N-acetylneuraminate lyase from methicillin resistant Staphylococcus 
aureus. Acta Crystallographica Section F, Structural Biology and Crystallisation 
Communications, 69, 306-312. 
2.1 Introduction 
2.1.1 N-Acetylneuraminate lyase is a target for drug design 
In low glucose and heavily sialylated niches, such as the human respiratory and 
gastrointestinal tract, highly abundant sialic acid molecules provide an alternate source of 
carbon, nitrogen and energy for bacterial pathogens residing within the host (Martinez et 
al., 1995; Chang et al., 2004; Vimr et al., 2004; Severi et al., 2005). Some bacterial 
pathogens have evolved a mechanism by which they can degrade these host-derived sialic 
acid into fructose-6-phosphate, a metabolite necessary for the survival of such pathogens 




various in vitro and in vivo studies have implicated the sialic acid degradation pathway as a 
novel candidate for antibiotic drug development (Chang et al., 2004; Almagro-Moreno & 
Boyd, 2009b; Jeong et al., 2009; Pezzicoli et al., 2012; Olson et al., 2013). Following the 
import of sialic acid from host to pathogen, the first and committed enzyme involved in 
sialic acid degradation is known as N-acetylneuraminate lyase. This enzyme has been 
recognised as a viable antibiotic drug target (Severi et al., 2007; von Itzstein, 2007). 
Deletion of the nanA gene coding for N-acetylneuraminate lyase in Escherichia coli (Vimr 
& Troy, 1985; Vogel-Scheel et al., 2010), Staphylococcus aureus (Olson et al., 2013), 
Vibrio cholerae (Almagro-Moreno & Boyd, 2009b) and Vibrio vulnificus (Jeong et al., 
2009) renders the organisms incapable of growing on sialic acid in vitro. Moreover, the 
nanA deletion strains of V. cholerae and V. vulnificus were defective for intestinal 
colonisation in mouse models, indicative of an impaired ability to colonise, persist and 
survive within the mouse intestine (Almagro-Moreno & Boyd, 2009b; Jeong et al., 2009). 
N-Acetylneuraminate lyase therefore plays a significant role in the virulence inflicted by a 
range of human bacterial pathogens and understanding the structure and function of this 
enzyme will underpin the design of inhibitors that specifically target this enzyme. 
2.1.2 The reaction catalysed by N-acetylneuraminate lyase 
N-Acetylneuraminate lyase is an enzyme belonging to the aldolase class I superfamily, 
which shares a common structural framework to that of related triose phosphate isomerase 
barrel [(β/α)8-barrel] enzymes, including 4-hydroxy-tetrahydrodipicolinic acid synthase 
[formally known as dihydrodipicolinate synthase (DHDPS)] (Mirwaldt et al., 1995; 
Dobson et al., 2005; Burgess et al., 2008; Kefala et al., 2008), D-5-keto-4-deoxyglucarate 
dehydratase (Jeffcoat et al., 1969b; Jeffcoat et al., 1969a), 2-keto-3-deoxygluconate 
aldolase (Buchanan et al., 1999), trans-o-hydroxybenzylidenepyruvate hydratase-aldolase 
(Eaton, 1994) and trans-2’-carboxybenzalpyruvate hydratase-aldolase (Iwabuchi & 
Harayama, 1998). Although these enzymes all share a common structural framework, they 
are responsible for catalysing different reactions on separate biochemical pathways. N-
Acetylneuraminate lyase catalyses the retro-aldol cleavage of open chain sialic acid, which 
yields N-acetylmannosamine and pyruvate (Figure 2.1) (Izard et al., 1994). The 
equilibrium of this reaction strongly favours the cleavage of sialic acid, although the 




convenient route for the synthesis of sialic acids (Lilley et al., 1992; Li et al., 2008; 
Campeotto et al., 2009; Campeotto et al., 2010; Huynh et al., 2013). 
Figure 2.1. The reaction catalysed by N-acetylneuraminate lyase. Sialic acid is cleaved to yield N-
acetylmannosamine and pyruvate. 
2.1.3 The catalytic mechanism of N-acetylneuraminate lyase 
Although members of the N-acetylneuraminate lyase sub-family of enzymes catalyse 
unique reactions on separate biochemical pathways, these enzymes share a unifying step in 
their reaction pathway, which involves the formation of a Schiff base between the amine 
nitrogen of a strictly conserved lysine residue and the C2 carbon of an α-keto acid moiety 
on respective substrates (Izard et al., 1994). The first X-ray structural analyses of E. coli N-
acetylneuraminate lyase (Lawrence et al., 1997) and E. coli DHDPS (Blickling et al., 
1997) in complex with pyruvate and analogues thereof supported this notion.  
These structures allowed for residues involved in the binding of pyruvate and the 
associated aldol cleavage/condensation step to be identified. For the E. coli N-
acetylneuraminate lyase in particular, a highly conserved Lys165 residue is responsible for 
the formation of a Schiff base with the C2 carbon of the α-keto acid moiety of open chain 
sialic acid in the retro-aldol direction of catalysis. Hydrogen bonds are also formed 
between the carboxylate moiety of the substrate and the hydroxyl of Tyr137, as well as the 
backbone amides of Ser47 and Thr48, which form the respective second and third residues 
of a highly conserved GxxGE motif (Lawrence et al., 1997). A catalytic triad is formed 






















DHDPS enzymes, a similar catalytic triad acts as a proton shuttle during catalysis (Dobson 
et al., 2004; Dobson et al., 2005). Thus, the presence of this triad in N-acetylneuraminate 
lyase enzymes provides strong evidence that it also plays a key role in catalysis (Daniels et 
al., 2014). 
Mutagenesis, kinetic analysis and further structures of N-acetylneuraminate lyase enzymes 
in complex with sialic acid or sialic acid analogues have provided additional insight into 
residues involved in substrate binding and the chemistry that is catalysed (Figure 2.2) 
(Barbosa et al., 2000; Kruger et al., 2001; Huynh et al., 2013; Daniels et al., 2014). In E. 
coli N-acetylneuraminate lyase in particular, residues Thr167, Gly189, Asp191, Glu192 
and Ser208 have also been implicated in substrate binding (Daniels et al., 2014). 
Importantly, all residues demonstrated to be involved in catalysis are highly conserved 
between bacterial species within the N-acetylneuraminate lyase sub-family of enzymes, 
illustrating the importance of these residues to the structure and function of these enzymes 
(Blickling et al., 1997; Lawrence et al., 1997; Barbosa et al., 2000; Kruger et al., 2001; 
Huynh et al., 2013; North et al., 2013). 
Figure 2.2. The proposed catalytic mechanism of N-acetylneuraminate lyase. The enzymatic reaction 
showing the involvement of a conserved lysine residue in catalysis. The lysine residue is involved in the 
formation of a Schiff base with the C2 carbon of the α-keto acid moiety of open chain sialic acid in the retro-






2.1.4 The structure of N-acetylneuraminate lyase 
Various structures of N-acetylneuraminate lyase enzymes have been solved and studied, 
including N-acetylneuraminate lyase from E. coli (Izard et al., 1994; Lawrence et al., 
1997; Joerger et al., 2003; Campeotto et al., 2009; Campeotto et al., 2010; Daniels et al., 
2014), Haemophilus influenzae (Barbosa et al., 2000), Pasteurella multocida (Huynh et 
al., 2013) and S. aureus (Timms et al., 2013). In all structures published, N-
acetylneuraminate lyase has been shown to be a tetramer with four identical (β/α)8-barrel 
monomers, each followed by an extension of three α-helices at the C-terminus (Izard et al., 
1994). Similar to DHDPS, the tetrameric structure of E. coli N-acetylneuraminate lyase can 
be described as a dimer of dimers, where monomers a and b form one dimer and 
monomers c and d form the other (Figure 2.3 A). The association between monomers 
leaves a large pore in the central cavity of the tetramer. 
Within the monomer of E. coli N-acetylneuraminate lyase, the consecutive β-strands are 
labelled a through h and the α-helices are labelled A through K with the three additional C-
terminal α-helices denoted as I, J, and K, respectively (Figure 2.3 B) (Izard et al., 1994). 
As with all (β/α)8-barrel enzymes, the active site is located in the centre of the barrel at the 
C-terminal end of the β-strands (Wierenga, 2001). For N-acetylneuraminate lyase, these C-












Figure 2.3. The structure of E. coli N-acetylneuraminate lyase. (A) The tetrameric structure of E. coli 
N-acetylneuraminate lyase. Monomers are labelled a through d. The active site of each monomer is oriented 
towards the central cavity of the tetramer. (B) The monomeric structure of E. coli N-acetylneuraminate lyase. 
The β-strands are labelled a through h and the α-helices are labelled A through K. The active site is located in 
the centre of the barrel at the C-terminal end of the β-strands. 
2.1.5 Overview of this chapter 
This chapter will address the structure, function and inhibition of N-acetylneuraminate 
lyase from methicillin-resistant S. aureus (MRSA), a pathogen that causes significant 
disease globally (Grundmann et al., 2006; Chambers & Deleo, 2009). The overarching aim 
of this chapter is to investigate the structure and function of MRSA N-acetylneuraminate 




solution based characterisation of MRSA N-acetylneuraminate lyase to ensure that the 
enzyme was stable and folded. In addition, the quaternary structure was investigated, 
which is important for the interaction study presented in Chapter Four. A kinetic and 
structural analysis of MRSA N-acetylneuraminate lyase with and without a successful first 
generation inhibitor is presented and the mechanism of inhibition is analysed. Although the 
structure of S. aureus N-acetylneuraminate lyase (PDB entry 4ahp) (Timms et al., 2013) 
was solved and published during the course of this study, the structure of MRSA N-
acetylneuraminate lyase presented in this thesis is of a significantly higher resolution and 
contains information that is missing from PDB entry 4ahp. Combined, this type of data is 
important for further optimisation of inhibitors, leading to the development of novel 















2.2 Results and discussion 
2.2.1 Purification of MRSA N-acetylneuraminate lyase 
The nanA gene encoding N-acetylneuraminate lyase from MRSA252 (Appendix) was 
supplied in a pET11a expression plasmid. The construct was transformed into E. coli 
BL21(DE3) bacterial cells, cultured and expressed in Luria Bertani medium, harvested, 
and lysed (Chapter Six, Sections 6.6.1-6.6.3). This construct was subjected to purification 
by anion exchange chromatography, hydrophobic interaction chromatography and size 
exclusion chromatography (Chapter Six, Section 6.6.8). The increasing purity of MRSA N-
acetylneuraminate lyase from each purification procedure is shown in Figure 2.4. The 
resulting purity was visually estimated to be at least 95%, which can be observed by the 
single band at 33 kilodalton (kDa) following size exclusion chromatography (Figure 2.4, 
lane 4). The mass of MRSA N-acetylneuraminate lyase was confirmed by electrospray 
ionisation mass spectrometry following purification. 
Figure 2.4. Purification of MRSA N-acetylneuraminate lyase. Sodium dodecyl sulfate polyacrylamide 
gel electrophpresis (SDS-PAGE) analysis showing the increasing purity of MRSA N-acetylneuraminate lyase 
at each purification step. Lane 1, protein ladder (kDa); lane 2, crude; lane 3, pooled fractions from anion 
exchange chromatography; lane 4, pooled fractions from hydrophobic interaction chromatography; lane 5, 
post size exclusion chromatography. 
















2.2.2 Solution structure of MRSA N-acetylneuraminate lyase 
2.2.2.1 Secondary structure as determined by circular dichroism spectroscopy 
To ensure that MRSA N-acetylneuraminate lyase was folded, the secondary structure was 
examined by circular dichroism (CD) spectroscopy. The spectrum recorded showed that 
the enzyme is folded (Figure 2.5). A double minimum is apparent at 208 and 222 nm. This 
was also observed for the closely related DHDPS enzymes (Burgess et al., 2008; Griffin et 
al., 2008). 
Figure 2.5. CD spectrum of MRSA N-acetylneuraminate lyase. CD spectroscopy was conducted at 0.1 
mg/mL in 20 mM 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris), pH 8.0. Mean residue ellipticity is 
plotted as a function of wavelength. Data are represented as open circles (o). 
2.2.2.2 Quaternary structure as determined by analytical ultracentrifugation 
Sedimentation velocity experiments using analytical ultracentrifugation were used to 
characterise the quaternary structure of MRSA N-acetylneuraminate lyase in solution for 
the first time. Interestingly, the related MRSA DHDPS enzyme exists in a monomer-dimer 
equilibrium in solution (Burgess et al., 2008), while nearly all other studied DHDPS and 
N-acetylneuraminate lyase enzymes share a tetrameric arrangement. Data were fitted to a 
continuous sedimentation coefficient distribution [c(s)] model, resulting in a distinct 
single, narrow and symmetrical peak with a sedimentation coefficient of 6.6 S (Figure 2.6 




This data was then fitted to a continuous mass distribution [c(M)] to calculate the apparent 
molecular mass of the species (Figure 2.6 B), which was determined to be 133 kDa. 
Considering the theoretical monomeric mass of MRSA N-acetylneuraminate lyase is 33 
kDa, this is consistent with a theoretical tetrameric mass of 129 kDa. The absorbance at 
280 nm versus radial position of MRSA N-acetylneuraminate lyase shows a single 
sedimenting boundary, consistent with the presence of a single species and the randomly 
distributed residuals indicate a good fit to the data (Figure 2.6 C) (Lebowitz et al., 2002). 
Figure 2.6. Sedimentation velocity analysis of MRSA N-acetylneuraminate lyase using analytical 
ultracentrifugation. The experiment was conducted at 0.5 mg/mL (15.1 µM) of freshly purified protein in 
20 mM Tris, pH 8.0, 150 mM sodium chloride. Data were collected at 280 nm, 50 000 rpm and 20 °C. 
SEDNTERP was used to calculate the partial specific volume of MRSA N-acetylneuraminate lyase (0.7404 
g/ml), solvent density (1.0029 g/ml) and viscosity (0.0102 poise) (Laue et al., 1992). Data were fitted to a 
c(s) and c(M) model at a resolution of 300 and a confidence level of 0.95 using SEDFIT (Schuck, 2000). (A) 
The c(s) model plotted as a function of sedimentation coefficient. Data were fitted with an s value ranging 
between 4 S and 10 S. The fit resulted in a frictional ratio (f/f0) of 1.3394. (B) The c(M) model plotted as a 
function of molecular mass (kDa). Data were fitted with a minimum mass of 20 kDa and a maximum mass of 
180 kDa. (C) Absorbance at 280 nm plotted as a function of radial position (cm). The raw data are 
represented as open symbols (o) and overlaid with the non-linear least squares best fit. The residuals for this 
fit are shown above. 
2.2.2.3 Small angle X-ray scattering analysis of the solution structure 
Small angle X-ray scattering (SAXS) data further verifies the solution structure of MRSA 
N-acetylneuraminate lyase determined by sedimentation velocity analysis. Sample and data 
quality were assessed by Guinier analysis of the SAXS scattering curve at low angles. The 





acetylneuraminate lyase is reliable and no sample aggregation and/or interparticle 
interference is present (Putnam et al., 2007). Scattering data are presented as an intensity 
plot (Figure 2.7 B) and a real space distance distribution function P(r) plot (Figure 2.7 C). 
The maximum dimension of the scattering particle (Dmax) was calculated by 
AUTOPOROD (Petoukhov & Svergun, 2007) as 88.7 Å. The radius of gyration (Rg) 
determined by GNOM (Svergun, 1992) was calculated as 32.8 Å, which is in agreement 
with the Rg determined by Guinier analysis. The molecular mass for MRSA N-
acetylneuraminate lyase extracted from the SAXS data is 112 kDa, which is slightly 
smaller than the theoretical tetrameric mass of 129 kDa and the apparent molecular mass 
of 133 kDa derived from sedimentation velocity analysis. However, the resolution of 
SAXS data is low, which would account for this small discrepancy in size (Putnam et al., 
2007). The P(r) distribution shows a single peak that is symmetrical in shape, with no 
positively skewed tail at long distances. This indicates that MRSA N-acetylneuraminate 
lyase is globular in shape and not elongated in solution. 
Figure 2.7. SAXS data for MRSA N-acetylneuraminate lyase. (A) A Guinier plot determined using 
GNOM, which is linear. (B) Experimental scattering data presented as an intensity plot. (C) A P(r) plot 
determined using GNOM. 
It is important to directly compare SAXS curves with a crystal structure, since the crystal 
lattice can influence the observed structure (Putnam et al., 2007). Thus, in an effort to 
determine whether the structure in solution accurately reflects my crystal structure (Section 
2.2.7), the experimental scattering data were compared with the theoretical scattering 
generated from atomic coordinates of the crystal structure using CRYSOL (Svergun et al., 
1995). In addition, the experimental scattering was also compared with the theoretical 
scattering of the published S. aureus N-acetylneuraminate lyase structure (PDB entry 4ahp) 





MRSA N-acetylneuraminate lyase fits the experimental scattering data (χ2 = 0.8), 
confirming that the crystal structure is an accurate representation of the solution based 
structure. Whereas, the theoretical scattering calculated for PDB entry 4ahp does not 
statistically fit the experimental scattering data (χ2 = 1.9) (Figure 2.8). A poor fit is usually 
indicative of a difference between the protein in solution and the crystallised state (Putnam 
et al., 2007). Even though these two structures share a 100% sequence identity, they have 
been crystallised in different conditions (Section 2.2.5). The difference may therefore be 
attributed to variable crystal packing between the structures (Section 2.2.9), or different 
protein dynamics in solution that are constrained in the crystal (Griffin et al., 2008). 
Figure 2.8. Comparison of the experimental scattering and theoretical scattering data. The 
experimental scattering profile of MRSA N-acetylneuraminate lyase (presented as open circles, o) overlaid 
with theoretical scattering profile of the MRSA N-acetylneuraminate lyase structure in magenta, and the 
theoretical scattering profile of the S. aureus N-acetylneuraminate lyase structure (PDB entry 4ahp) in blue.  
2.2.3 Kinetic analysis of MRSA N-acetylneuraminate lyase 
To characterise the kinetic properties of MRSA N-acetylneuraminate lyase, the absorbance 
of reduced nicotinamide adenine dinucleotide (NADH) at 340 nm was followed using a 
lactate dehydrogenase coupled assay (Chapter Six, Section 6.9.1) (Devenish & Gerrard, 
2009). Briefly, the assay is initiated by the addition of substrate (sialic acid), which is 
converted into N-acetylmannosamine and pyruvate by MRSA N-acetylneuraminate lyase; 




reducing NADH into the oxidised form of nicotinamide adenine dinucleotide (NAD+). 
Because NAD+ does not absorb at 340 nm, it is the reduction in absorbance at this 
wavelength that is followed spectrophotometrically, allowing the rate of catalysis by 
MRSA N-acetylneuraminate lyase to be followed. 
2.2.3.1 Validity of a coupled enzyme assay 
Prior to extensive kinetic analysis, various controls had to be performed to ensure that the 
conditions of the experiment allowed for accurate and reproducible measurements to be 
made. This means that although the assay is conducted under in vitro conditions, the 
results can be extrapolated to the expected activity occurring in vivo (Scopes, 2002). 
Firstly, in a coupled enzyme assay, it is important that the coupling enzyme is in excess so 
that it is not limiting the rate of the reaction being measured (Cornish-Bowden, 2004). This 
ensures that intermediate products do not accumulate and the coupled reactions can rapidly 
respond. For kinetic analysis of MRSA N-acetylneuraminate lyase, ensuring that the 
concentration of LDH is in excess meant that the rate of the reaction depended entirely 
upon MRSA N-acetylneuraminate lyase. The LDH concentration was tested between 3 and 
400 µg per assay (Figure 2.9 A). Consistent with the concentration of LDH used previously 
(Devenish & Gerrard, 2009), a final amount of 100 µg per assay could be used as excess. 
When utilising a coupled enzyme assay, it is also necessary that the rate of the reaction 
being measured is proportional to the amount of enzyme that is present (Cornish-Bowden, 
2004). To test this, the initial velocity was analysed with 0.7 to 22.6 µg of MRSA N-
acetylneuraminate lyase per assay. A final concentration of 1.4 µg was selected for the 
kinetic analysis of MRSA N-acetylneuraminate lyase, as this amount was proportional to 
the initial velocity, depicted by the linearity seen in Figure 2.9 B. In addition, this 
concentration resulted in an adequate amount of time for the reaction to reach completion, 
meaning that the initial velocity could be measured when less than 5% of the substrate had 
been depleted, minimising the effect of the reverse reaction, inhibition by a product or 
inactivation of the enzyme (Cornish-Bowden, 2004). 
In addition, the effect of temperature on MRSA N-acetylneuraminate lyase activity was 
evaluated. This ensured that the temperatures selected to run the assays were appropriate. 




conducted at 30 °C. However, inhibition studies have the potential to be translated into the 
development of antibiotic drugs, thus it is important that these analyses were performed at 
a physiological temperature of 37 °C. To test the effect of temperature on the function of 
MRSA N-acetylneuraminate lyase, the initial velocity of this enzyme between 20 °C and 
80 °C was analysed (Figure 2.9 C). As depicted, MRSA N-acetylneuraminate lyase is 
stable up until approximately 70 °C, before the initial velocity begins to decline. Thus, it is 
safe to perform assays at a physiological temperature of 37 °C. 
Figure 2.9. The initial velocity of MRSA N-acetylneuraminate lyase as a function of LDH 
concentration, the amount of enzyme present and temperature. (A) The initial velocity across a range of 
LDH concentrations. (B) The initial velocity in response to different concentrations of MRSA N-
acetylneuraminate lyase. (C) The initial velocity plotted across a range of temperatures. 
2.2.3.2 Michaelis-Menten kinetic analysis of MRSA N-acetylneuraminate lyase 
The initial velocity of MRSA N-acetylneuraminate lyase with varying concentrations of 
sialic acid was measured and fitted to the Michaelis-Menten kinetic model, displaying a 
hyperbolic dependence of initial velocity on substrate concentration (Figure 2.10). The 
Michaelis-Menten constant (KM) was calculated as 3.2  ±  0.1 mM, the maximum velocity 
(Vmax) was calculated as 40.0  ± 0.2 µmol/min/mg and the catalytic turnover number (kcat) 
was determined to be 22.1 ± 0.1 s-1. These values are consistent with the kinetic parameters 
obtained for other N-acetylneuraminate lyase enzymes in the literature. For example, the E. 
coli N-acetylneuraminate lyase (Devenish & Gerrard, 2009) displayed a KM of 4.1 mM and 
the Clostridium perfringens N-acetylneuraminate lyase (Kruger et al., 2001) displayed a 
KM of 3.2 mM. Further kinetic analyses of the S. aureus ((Timms et al., 2013) and E. coli 





however, the kinetic parameters presented are identical for both enzymes, which is 
unlikely. Thus, this may be the first kinetic analysis of MRSA N-acetylneuraminate lyase. 
Figure 2.10. Michaelis-Menten kinetic analysis of MRSA N-acetylneuraminate lyase. Data were fitted 
to the Michaelis-Menten equation with an R2 value of 0.99. 
2.2.4 Inhibition of MRSA N-acetylneuraminate lyase 
Analogues of sialic acid, including sialic acid alditol, 4-deoxy sialic acid and 4-oxo sialic 
acid have been shown to inhibit N-acetylneuraminate lyase to varying degrees. For 
comparison, the chemical structure of sialic acid is shown in Figure 2.11 A. The sialic acid 
alditols (Figure 2.11 B) have a hydroxyl group at the C2 position, as opposed to an 
aldehyde group, which is required for Schiff base formation with a conserved lysine 
residue (Deijl & Vliegenthart, 1983; Barbosa et al., 2000; Ooi et al., 2000). Conversely, 4-
deoxy sialic acid (Figure 2.11 C) (Hagedorn & Brossmer, 1986; Zbiral et al., 1992; Ooi et 
al., 1999) and 4-oxo sialic acid (Figure 2.11 D) (Gross & Brossmer, 1988) are capable of 
Schiff base formation, but because they do not have a hydroxyl group at the C4 position, 
they cannot undergo aldol cleavage (Barbosa et al., 2000). The inhibition constant (Ki) for 
the sialic acid alditols is 4.1 mM (Deijl & Vliegenthart, 1983), for 4-deoxy sialic acid it is 
0.90 mM (Zbiral et al., 1992) and for 4-oxo sialic acid it is 0.03 mM against C. perfringens 
N-acetylneuraminate lyase (Gross & Brossmer, 1988). The sialic acid alditols were 
synthesised in Professor Antony Fairbanks’ laboratory (University of Canterbury) as a 




inhibit MRSA N-acetylneuraminate lyase was tested by kinetic analysis. This type of data 
is important for further optimisation of inhibitors that target this bacterial pathogen. 
Figure 2.11. The chemical structure of N-acetylneuraminate lyase inhibitors. (A) The chemical 
structure of sialic acid for comparison. (B) The chemical structure of the 2R-diastereoisomer (left) and 2S-
diastereoisomer (right) of sialic acid alditol. (C) The chemical structure of 4-deoxy sialic acid. (D) The 
chemical structure of 4-oxo sialic acid. Carbons are numbered one through to nine. 
To determine the Ki for the sialic acid alditol mixture, the initial velocity of MRSA N-
acetylneuraminate lyase with 0.16 to 20 mM of sialic acid against 0 to 5 mM of the sialic 
acid alditols was measured. These data were fitted to the competitive model of inhibition, 
non-competitive model of inhibition, un-competitive model of inhibition and the mixed 
model of inhibition. The kinetic parameters and R2 value for these fits are shown in Table 
2.1. The competitive inhibition model provided the best fit (Figure 2.12) and yielded a Ki 
of 0.39 mM ± 0.01. Interestingly, the Ki for the sialic acid alditols against MRSA N-
acetylneuraminate lyase is considerably less than that demonstrated for the C. perfringens 
N-acetylneuraminate lyase (4.1 mM). Despite having identical active site residues in 
regards to those that are involved in catalysis (Kruger et al., 2001) and the highly 
conserved active site configuration seen in N-acetylneuraminate lyase crystal structures, 
there appears to be species-specific inhibition of N-acetylneuraminate lyase enzymes from 
different bacterial pathogens. Consistent with Michaelis-Menten kinetic analysis, the KM 
and Vmax for the competitive inhibition model was determined to be 3.7 ± 0.1 mM and 37.8 




Table 2.1. Kinetic parameters for the inhibition of MRSA N-acetylneuraminate lyase. The Ki, KM, 
Vmax and R2 for each fit were calculated in OriginPro. 
Model of inhibition Ki (mM) KM (mM) Vmax  (µmol/min/mg) R2 
Competitive 0.39 ± 0.01 3.7 ± 0.1 37.8 ± 0.4 0.99 
Non-competitive 1.57 ± 0.08 6.3 ± 0.3 44.7 ± 1.1 0.98 
Un-competitive 0.94 ± 0.09 8.5 ± 0.8 49.3 ± 2.5 0.95 
Mixed 1.21 ± 171.1 1.9 ± 784.6 5.82 ± 1566.7 0.76 
 
Figure 2.12. Kinetic analyses of MRSA N-acetylneuraminate lyase with varying concentrations of 
sialic acid and the sialic acid alditol mixture. Data were fitted to the competitive model of inhibition. 
Black corresponds to 0 mM, red corresponds to 0.156 mM, green corresponds to 0.313 mM, blue 
corresponds to 0.625, magenta corresponds to 1.25 mM, orange corresponds to 2.5 mM and purple 
corresponds to 5 mM of the sialic acid alditols. 
2.2.5 Crystallisation of MRSA N-acetylneuraminate lyase 
2.2.5.1 Crystallisation of ligand free MRSA N-acetylneuraminate lyase  
To gain molecular insight into MRSA N-acetylneuraminate lyase, the crystal structure was 
solved. Crystallisation of ligand free MRSA N-acetylneuraminate lyase was successful 
using the JCSG+ Suite screen, which produced crystals with a needle-like morphology at 
20 °C in various conditions. In-house optimisation of the JCSG+ Suite condition H7 (25% 
(w/v) polyethylene glycol 3350, 200 mM ammonium sulfate, 100 mM Bis Tris, pH 5.5) 
produced larger crystals of a similar morphology (Chapter Six, Section 6.7.1). An X-ray 




2.2.5.2 Co-crystallisation of MRSA N-acetylneuraminate lyase and sialic acid alditol 
For molecular insight into the inhibition of MRSA N-acetylneuraminate lyase by the sialic 
acid alditols, the structure was solved in complex with this strong inhibitor. Co-
crystallisation of MRSA N-acetylneuraminate lyase with the sialic acid alditols was not 
successful in the crystallisation conditions used for ligand free MRSA N-
acetylneuraminate lyase. Thus, co-crystallisation was performed in conditions used to 
grow crystals of S. aureus N-acetylneuraminate lyase (Timms et al., 2013). The condition 
comprised 25% (w/v) polyethylene glycol 3350, 200 mM sodium chloride and 100 mM 
Tris, pH 5.5, with the addition of 5 mM of the sialic acid alditol mixture. Under these 
conditions, the crystals were small and rod-like in morphology. An X-ray diffraction data 
set to 2.33 Å was collected from one of these crystals. 
2.2.6 Data processing and structure refinement 
2.2.6.1 MRSA N-acetylneuraminate lyase in a ligand free form 
X-ray diffraction data was processed and solved as described in Chapter Six, Section 6.7.2. 
Initially, the data was processed in the space group P212121 and solved by molecular 
replacement using the monomer of H. influenzae N-acetylneuraminate lyase as the search 
model (PDB entry 1f6p, 54 % sequence identity) (Barbosa et al., 2000). In this space 
group, numerous rounds of refinement failed to reduce the residual factor (Rfactor) below 
27%. This was because the data were twinned, with the twin law h;-k;-l, and an l-statistic  
of 0.379 (un-twinned = 0.5, perfect twin = 0.375), as implemented in PHENIX XTRIAGE 
(Adams et al., 2010) (Figure 2.13). To account for twinning, data were scaled in a lower 
symmetry monoclinic space group (P21). Here, the asymmetric unit contains eight 
monomers, corresponding to two tetramers. Following refinement, identification and 
inclusion of the twinning law reduced the final Rfactor to 15.5% and the free Rfactor (Rfree) to 
20.2%. All residues were modelled into the electron density, except for the methionine 
residue at position one of each chain, which was too disordered. A highly conserved 
Tyr111 residue is in the ‘disallowed’ region of the Ramachandran plot in each chain. This 
is not unexpected as it is the case for the corresponding residue in all N-acetylneuraminate 




Burgess et al., 2008; Kefala et al., 2008; Devenish & Gerrard, 2009). All relevant data 
collection statistics and structure and refinement statistics are provided in Table 2.2. 
Figure 2.13. Twinning detection using the L-test. |L| is plotted against N(|L|). L is given by (I1-I2)/(I1+I2), 
where I1 and I2 are the intensities of unrelated reflections and N(|L|) is the cumulative probability distribution 
of L. The L-test suggests the acentric data could be twinned (0.379). Acentric expected and un-twinned is 
shown in green, acentric expected and twinned is shown in red, whereas the observed is shown in blue. 
2.2.6.2 MRSA N-acetylneuraminate lyase in complex with the sialic acid alditols 
This data was processed in the space group P212121 and solved by molecular replacement 
using the monomer of S. aureus N-acetylneuraminate lyase as the search model (PDB 
entry 4ahp) (Timms et al., 2013). Unlike my ligand free structure, this data did not appear 
to be twinned, which is likely to be a result of using different crystallisation conditions. In 
this space group, the asymmetric unit contains four monomers that correspond to one 
tetramer. Following iterative rounds of refinement, the Rfactor and Rfree were reduced to 19.6 
and 26.3%, respectively. This model does not include methionine at position one, or 
residues Ala138 to Asn146 in each monomer. The latter residues are located within a 
disordered loop and could not be modelled into the structure. Similarly, this loop could not 
be modelled into the previously published ligand free structure of S. aureus N-
acetylneuraminate lyase (Timms et al., 2013). Again, Tyr111 of each chain is in the 
‘disallowed’ region of the Ramachandran plot. All relevant data collection statistics and 




Table 2.2. X-ray data collection and refinement statistics for ligand free, and sialic acid alditol 
bound MRSA N-acetylneuraminate lyase. Statistical values for the highest resolution shells are given in 
parentheses. Each monomer within the asymmetric unit has a molecular weight of 33 042.5 Da. 
 
Ligand free MRSA                 
N-acetylneuraminate lyase 
Sialic acid alditol bound MRSA       
N-acetylneuraminate lyase 
data collection statistics   
wavelength (Å) 0.95369 0.95369 
number of images 360 360 
oscillations (°) 0.5 0.5 
space group P21 P212121 
unit cell parameters (Å, °) 
a = 80.2, b = 108.6, c = 130.8   
β = 90.14 
a = 81.48, b = 109.4, c = 130.8  
α = β = γ = 90 
resolution range (Å) 32.3-1.70 (1.79-1.70) 46.22-2.33 (2.41-2.33) 
observed reflections 823916 (91713) 367079 (29172) 
unique reflections 242175 (33054) 49980 (4071) 
mean I/σ(I) 8.0 (2.6) 14.2 (2.6) 
ompleteness (%) 98.5 (92.4) 99.1 (89.8) 
Rmerge† 0.101 (0.376) 0.108 (0.812) 
Rr.i.m.‡ 0.118 (0.457) 0.125 (0.944) 
Rp.i.m.§ 0.061 (0.254) 0.063 (0.478) 
wilson B value (Å2) 
molecules per asymmetric unit 
VM (Å3 Da-1) 









structure and refinement statistics   
Rfactor (%) 15.5 19.6 
Rfree (%) 20.2 26.3 
number of atoms   
protein 18608 9080 
water 942 180 
ligands 40 84 
root-mean-square deviation (rmsd)   
bonds (Å) 0.008 0.009 
angles (°) 1.102 1.217 
average B factors (Å2)   
protein 14.62 37.50 
water 16.78 35.06 
ligands 19.10 42.79 
Ramachandran plot, residues (%)   
favoured region 97.07 96.3 
allowed region 2.59 3.3 
disallowed region 0.34 0.36 
Rmerge  = hkl i |Ii (hkl) - <I(hkl)>| / hkliIi (hkl). 
Rr.i.m  = hkl {N(hkl)/[N(hkl) - 1]}1/2 i |Ii (hkl) – <I(hkl)>| / hkliIi (hkl). 






2.2.7 The structure of MRSA N-acetylneuraminate lyase  
Consistent with the structure in solution, the crystal structure of MRSA N-
acetylneuraminate lyase is a tetramer. The tetramer can be described as a dimer of dimers, 
with monomers a and b forming one dimer and monomers c and d forming the second 
dimer (Figure 2.14 A). This arrangement is identical to that observed for all structures of 
N-acetylneuraminate lyase enzymes studied to date, including the orientation of the active 
sites towards the central cavity of the tetramer. Like the E. coli N-acetylneuraminate lyase 
enzyme (Devenish & Gerrard, 2009), the intradimeric interface of MRSA N-
acetylneuraminate lyase is significantly stronger than the interdimeric interface, with 1429 
Å and 1147 Å of surface area buried, respectively. Within the monomer of MRSA N-
acetylneuraminate lyase, consecutive β-strands are labelled a through h and the α-helices 
are labelled A through K with the three additional C-terminal α-helices denoted as I, J, and 
K, respectively (Figure 2.14 B). As with all (β/α)8-barrel enzymes, the active site is located 
in the centre of the barrel at the C-terminal end of the β-strands (Wierenga, 2001).  
As described in Section 2.1.3, mutagenesis, kinetic analysis and structural analysis of N-
acetylneuraminate lyase enzymes in complex with substrates and substrate analogues have 
elucidated key residues that are involved in substrate binding and catalysis (Izard et al., 
1994; Lawrence et al., 1997; Barbosa et al., 2000; Kruger et al., 2001; Huynh et al., 2013; 
Daniels et al., 2014). In combination with a sequence analysis of N-acetylneuraminate 
lyase from six bacterial species (Figure 2.15), the residues that are likely to be important 
for the chemistry catalysed by MRSA N-acetylneuraminate lyase include Ser48, Ser49, 
Tyr111, Lys165, Thr167 Gly189, Glu191, Asp192 and Ser208. Although Ser49 is a 
threonine residue in other organisms, this substitution is considered conservative as these 
amino acids have very similar properties. The positions of these residues are highlighted in 






Figure 2.14. The structure of MRSA N-acetylneuraminate lyase. (A) The tetrameric structure of MRSA 
N-acetylneuraminate lyase. Monomers are labelled a through d. The active site of each monomer is oriented 
towards the central cavity of the tetramer. (B) The monomeric structure of MRSA N-acetylneuraminate 
lyase. The β-strands are labelled a through h and the α-helices are labelled A through K. The active site is 
located in the centre of the barrel at the C-terminal end of the β-strands. (C) A stereo view of the residues 





Figure 2.15. Sequence alignment of N-acetylneuraminate lyase enzymes from seven bacterial species. 
Species include S. aureus, Gamella haemolysans, H. influenzae, P. multocida, Clostridium botulinum, E. coli 
and C. perfringens. Highly conserved residues are highlighted with blue boxes, while those that have been 
implicated in substrate binding and catalysis are highlighted with black boxes. Conserved residues are 
numbered at the top of the sequence according to S. aureus. The alignment was generated using ClustalW 
(Larkin et al., 2007) (http:// www.genome.jp/tools/clustalw/). 
2.2.8 A sulfate ion residing in the active site 
In the ligand free structures of E. coli and H. influenzae N-acetylneuraminate lyase (PDB 
entries 1nal and 1f6p, respectively), a sulfate ion was found in the active site, presumably 






































































































S. aureus       MNKDLKGLYAALLVPFDENGQVNEQGLKQIAQNAIETEELDGLYVNGSSGENFLLNTEQK [60]
G. haemolysans  -MKDLKGLYSALLIPFDENGEVKEEGLRQVIEHNINVSKIDGLYVNGSSGENFLLNTAQK [59]
H. influenzae   -MRDLKGIFSALLVSFNEDGTINEKGLRQIIRHNIDKMKVDGLYVGGSTGENFMLSTEEK [59]
P. multocida    -MKNLKGIFSALLVSFNADGSINEKGLRQIVRYNIDKMKVDGLYVGGSTGENFMLSTEEK [59]
C. botulinum    ----MRGIFSALLVPYDENGNIKEEGLKQLVRYNIDVCGVDGLYVGGSTGENFMLSTDEK [56]
E. coli         MNSNLRGVMAALLTPFDQQQALDKASLRRLVQFNIQQG-IDGLYVGGSTGEAFVQSLSER [59]
C. perfringens  ----MKGIYSALLVSFDKDGNINEKGLREIIRHNIDVCKIDGLYVGGSTGENFMLSTDEK [56]
S. aureus       KQVFKVAKEAVGDKVKLIAQVGSLDLNEAIELGKYATELGYDALSAVTPFYYPFTFEEIR [120]
G. haemolysans  KQIFKFVKEVVGDRVKLIAQVGSLDLNEAVELAKYATELGYDSLSAVTPFYYPLSFNEIK [119]
H. influenzae   KEIFRIAKDEAKDQIALIAQVGSVNLKEAVELGKYATELGYDCLSAVTPFYYKFSFPEIK [119]
P. multocida    KEIFRIAKDEAKDEIALIAQVGSVNLQEAIELGKYATELGYDSLSAVTPFYYKFSFPEIK [119]
C. botulinum    KRIFEIVKEEAKQEVKLIAQVGSINLKESVELGKFATNLGYDSLSAVTPFYYKFDFEEIK [116]
E. coli         EQVLEIVAEEGKGKIKLIAHVGCVTTAESQQLAASAKRYGFDAVSAVTPFYYPFSFEEHC [119]
C. perfringens  KRIFEIAMDEAKGQVKLIAQVGSVNLKEAVELAKFTTDLGYDAISAVTPFYYKFDFNEIK [116]
                
S. aureus       DYYFDIIE-ATQNNMIIYAIPDLTGVNISIEQFSELFNHEKIVGVKYTAPNFFLLERIRK [179]
G. haemolysans  HYYKTIID-TDN-SMILYYIPFLTGVKISLDQFAELLEDEKVIGVKYTAADFYQLERFRK [177]
H. influenzae   HYYDTIIA-ETGSNMIVYSIPFLTGVNMGIEQFGELYKNPKVLGVKFTAGDFYLLERLKK [178]
P. multocida    HYYDSIIE-ATGNYMIVYSIPFLTGVNIGVEQFGELYKNPKVLGVKFTAGDFYLLERLKK [178]
C. botulinum    NYYNTIIE-ATNNNMIIYSIPFLTGVNITLNQFGELFKNEKIIGVKFTQGDFYLLERLRN [175]
E. coli         DHYRAIIDSADGLPMVVYNIPALSGVKLTLDQINTLVTLPGVGALKQTSGDLYQMEQIRR [179]
C. perfringens  HYYETIIN-SVDNKLIIYSIPFLTGVNMSIEQFAELFENDKIIGVKFTAADFYLLERMRK [175]
                
S. aureus       AFPDKLILSGFDEMLVQATISGVDGAIGSTYNVNGRRARKIFDLARQGQIQEAYQLQHDS [239]
G. haemolysans  RFPNKLIWSGFDEMLVQAAITGVDGAIGSTYNVNGQRSQEIFRLAKEGKVAEAYELQHEA [237]
H. influenzae   AYPNHLIWAGFDEMMLPAASLGVDGAIGSTFNVNGVRARQIFELTKAGKLKEALEIQHVT [238]
P. multocida    AYPNHLIWAGFDEMMLPAASLGVDGAIGSTFNVNGVRARQIFELTQAGKLKEALEIQHVT [238]
C. botulinum    EFPNKLIFSGFDEMLLPAVISGVDGAIGSTYNVNGKRAKEIFRLAKEGKVKEAYEIQHVT [235]
E. coli         EHPDLVLYNGYDEIFASGLLAGADGGIGSTYNIMGWRYQGIVKALKEGDIQTAQKLQTEC [239]
C. perfringens  AFPDKLIFAGFDEMMLPATVLGVDGAIGSTFNVNGVRARQIFEAAKKGDIETALEVQHVT [235]
                  
S. aureus       NDIIETVLSMGIYPTLKEILRHRGIDAG-LPKRPFKPFNEAHRQTLDQLIAKYDL--- [293]
G. haemolysans  NDVIEKVLELGLYQTLKEILKVKGIDAG-TCKKPMKSFDPAKLAEVEKLVKDYNL--- [291]
H. influenzae   NDLIEGILANGLYLTIKELLKLEGVDAG-YCREPMTSKATAEQVAKAKDLKAKFLS-- [293]
P. multocida    NDLIEGILANGLYLTIKELLKLDGVEAG-YCREPMTKELSSEKVAFAKELKAKYLS-- [293]
C. botulinum    NDLIEGILSNGLYQTIKEILKVKGVDAG-YCRQPMKRLTEG-KVKFAQELAKKFL--- [289]
E. coli         NKVIDLLIKTGVFRGLKTVLHYMDVVSVPLCRKPFGPVDEKYQPELKALAQQLMQERG [298]
C. perfringens  NDLITDILNNGLYQTIKLILQEQGVDAG-YCRQPMK-EATEEMIAKAKEINKKY---- [287]




arising from ammonium sulfate in the crystallisation conditions (Izard et al., 1994; 
Barbosa et al., 2000). Importantly, this prevented crystallographic analysis of N-
acetylneuraminate lyase in complex with substrates and/or substrate analogues (Izard et al., 
1994). Similarly, a sulfate ion was found residing in the active site of my ligand free 
structure of MRSA N-acetylneuraminate lyase. This was not unexpected as the 
crystallisation conditions contained 200 mM ammonium sulfate. This sulfate ion forms 
hydrogen bonds with the catalytically important residues Ser48, Ser49, Lys165 and Tyr137 
(Figure 2.16). This perhaps explains why co-crystallisation of MRSA N-acetylneuraminate 
lyase in complex with the sialic acid alditols was unsuccessful in these conditions. 
Figure 2.16. A sulfate ion in the active site of ligand free MRSA N-acetylneuraminate lyase. A stereo 
view of the sulfate ion that was modelled into electron density in the active site. The 2Fo-Fc electron density 
was contoured at a sigma level of 1 (blue), while the Fo-Fc was contoured at a sigma level of 3 (green) and -3 
(red). Hydrogen bonds are depicted as black dashes. 
2.2.9 A comparison of the S. aureus and MRSA N-
acetylneuraminate lyase structures 
The structure of S. aureus N-acetylneuraminate lyase (PDB entry 4ahp), which has a 100% 
sequence identity to MRSA N-acetylneuraminate lyase, was solved and published by 
Timms et al. (2013) at the same time that the crystallisation and preliminary X-ray 
diffraction analysis of my ligand free MRSA N-acetylneuraminate lyase was published 




of a higher resolution than the 2.10 Å structure of PDB entry 4ahp. More importantly, PDB 
entry 4ahp is missing amino acid residues Ala138 to Asn146, which forms a loop between 
the C-terminal end of β-strand e and α-helix E in my MRSA N-acetylneuraminate lyase 
structure (Figure 2.17). Timms et al. (2013) propose that this loop is missing from PDB 
entry 4ahp because ordering is only achieved when substrate is present in the active site, 
allowing the formation of a Schiff base, which repositions the catalytically important 
Tyr137 residue for catalysis. However, the presence of this loop in my structure of MRSA 
N-acetylneuraminate lyase suggests that ordering of this loop is unlikely to be involved in 
substrate binding. 
Figure 2.17. The structure of MRSA N-acetyleuraminate lyase and S. aureus N-acetylneuraminate 
lyase overlaid. The loop comprised of amino acid residues Ala138 to Asn146 missing from S. aureus N-
acetylneuraminate lyase (gray) is highlighted in blue in MRSA N-acetylneuraminate lyase (light purple).  
Furthermore, when these structures are aligned, they have an rmsd of 0.49 Å based on 1094 
pairs of atoms, indicating that they are highly similar. Despite this similarity, the overall 
shape of these structures is slightly different, with PDB entry 4ahp being longer along the 
axis of the tight dimer interface, and shorter along the axis of the weak dimer interface 
(Figure 2.18). It is well known in the literature that crystal environments can influence 
protein structure (Eyal et al., 2005). In alternate environments, a protein crystal will pack 
differently, which may result in local structural differences, rigid body motion of large 
structural units, or conformational changes in loops (Bertrand et al., 2000; Taylor et al., 




it is reasonable to assume that both the unresolved loop formed by residues Ala138 to 
Asn146 in PDB entry 4ahp and the difference in overall shape between the structures is an 
artefact of crystal packing in alternate environments. As was shown in Figure 2.8, this 
would also explain why the theoretical scattering profile of PDB entry 4ahp does not fit the 
experimental scattering of MRSA N-acetylneuraminate lyase in solution as closely as my 
structure. 
Figure 2.18. The difference in overall shape between the structures of MRSA N-acetylneuraminate 
lyase and S. aureus N-acetylneuraminate lyase. The crystal structure of S. aureus N-acetylneuraminate 
lyase (gray) is longer than MRSA N-acetylneuraminate lyase (light purple) along the axis of the intradimeric 





2.2.10 The structure of MRSA N-acetylneuraminate lyase in 
complex with a strong inhibitor 
As described in Section 2.2.4, the sialic acid alditols exhibited a Ki of 0.39 mM against 
MRSA N-acetylneuraminate lyase, making it a strong inhibitor. Thus, the structure of 
MRSA N-acetylneuraminate lyase in complex with this inhibitor was sought, as this type 
of data is important for further optimisation and the development of antibiotics. Because 
crystallographic analysis of N-acetylneuraminate lyase in complex with substrates and/or 
substrate analogues is difficult in crystallisation conditions that contain sulfate (Barbosa et 
al., 2000), co-crystallisation was performed in conditions that were without sulfate (Timms 
et al., 2013). Following refinement, electron density was observed in all four MRSA N-
acetylneuraminate lyase monomers in the asymmetric unit that could not be accounted for 
by the molecular replacement model, waters, or molecules present in the crystallisation 
conditions. 
The unresolved loop from residue Ala138 to Asn146 in PDB entry 4ahp is also unresolved 
for MRSA N-acetylneuraminate lyase in complex with sialic acid alditol. To ensure that 
this is not a result of model bias, the structure was also solved by molecular replacement 
with my ligand free structure of MRSA N-acetylneuraminate lyase as the molecular 
replacement model, where this loop is resolved. Following numerous rounds of refinement 
and attempts to build in these missing residues, no electron density appeared. This further 
suggests that the unresolved loop in PDB entry 4ahp is likely to be an artefact of crystal 
packing in different environments and not a feature of substrate binding. 
Although sialic acid alditol was synthesised as a racemic mixture, only the 2R-
diastereoisomer was successfully modelled and refined into the density within each 
monomer (Figure 2.19 A). Sialic acid alditol binds in the active site of MRSA N-
acetylneuraminate lyase, which is located in the centre of the (β/α)8-barrel, in a tight pocket 
located on the C-terminal end of the barrel (Figure 2.19 B). Importantly, this molecule has 
been refined into each monomer in a relatively similar conformation (Figure 2.19 C), 





Figure 2.19. Sialic acid alditol in complex with MRSA N-acetylneuraminate lyase. (A) Stereo view of 
active site omit maps with the 2R-diastereoisomer of sialic acid alditol (yellow) within all four monomers in 
the asymmetric unit. Sialic acid alditol is depicted in an open chain form. The omit map was generated by 
removing the ligand from all active sites followed by refinement. The 2Fo-Fc electron density was contoured 
at a sigma level of 1 (blue), while the Fo-Fc was contoured at a sigma level of 3 (green) and -3 (red). (B) Side 
view (left) and top view (right) of the MRSA N-acetylneuraminate lyase monomer with sialic acid alditol 
bound in the active site. The monomer is depicted as a surface representation and sialic acid alditol binds in a 




2.2.11 How inhibition is achieved by sialic acid alditol 
Analysis of the binding site for the 2R-diastereoisomer of sialic acid alditol in MRSA N-
acetylneuraminate lyase provides insight into how inhibition is achieved. This molecule 
contains a hydroxyl group at the C2 position as opposed to an aldehyde group, thus it 
should be incapable of Schiff base formation with Lys165. As anticipated, no covalent 
bond is formed between the C2 position of sialic acid alditol and Lys165 (Figure 2.20). 
Hydrogen bonds between Ser48 and Ser49 with the carboxylate moiety at position C1 of 
sialic acid alditol are formed just as they do in covalent complexes of E. coli N-
acetylneuraminate lyase and pyruvate (Lawrence et al., 1997). Additional hydrogen bond 
interactions between MRSA N-acetylneuraminate lyase and sialic acid alditol include the 
hydroxyl group at the C4 position with Gly189 and the hydroxyl group at the C6 position 
with Asp191 and Ser208; the latter of which also hydrogen bonds with the hydroxyl group 
at position C7 and the hydroxyl groups at position C7 and C9, which interact with Glu192. 
Importantly, all of these residues have been implicated in substrate/product binding for N-
acetylneuraminate lyase enzymes (Barbosa et al., 2000; Kruger et al., 2001; Huynh et al., 
2013; Daniels et al., 2014). In addition, Tyr252 hydrogen bonds with the carbonyl oxygen 
at position C5 of sialic acid alditol. The corresponding residue in E. coli N-
acetylneuraminate lyase (Phe252) lies in close proximity to the C5 carbonyl of 
substrate/product, but cannot form a hydrogen bond (Daniels et al., 2014). 
Figure 2.20. The sialic acid alditol binding site. Stereo view of the sialic acid alditol 2R-diastereoisomer 
binding site within MRSA N-acetylneuraminate lyase. Hydrogen bonds between the ligand and protein are 




The structure of H. influenzae N-acetylneuraminate lyase in complex with sialic acid 
alditol has been solved in the past. In this structure, it is also the 2R-diastereoisomer of 
sialic acid alditol that is bound in the active site. As depicted in Figure 2.21, sialic acid 
alditol is in a relatively similar conformation within both the MRSA and H. influenzae 
active sites. The hydroxyl groups at positions C7 and C8 have been refined in different 
orientations, however the active site residues implicated in binding sialic acid alditol are 
the same for both structures. Residue Tyr251 in H. influenzae N-acetylneuraminate lyase 
lies in close proximity, but does not interact, with the carbonyl oxygen at position C5 of 
sialic acid alditol like the corresponding residue Tyr252 in MRSA N-acetylneuraminate 
lyase, which adopts an alternate conformation. 
Figure 2.21. The sialic acid alditol binding site overlaid. A stereo view of the residues involved in 
binding the sialic acid alditol 2R-diastereoisomer in MRSA (green) and H. influenzae (purple) N-
acetylneuraminate lyase. Sialic acid alditol modelled into MRSA N-acetylneuraminate lyase is yellow and in 
H. influenzae N-acetylneuraminate lyase it is orange. 
As described, the Ki for a mixture of 2R- and 2S-diastereoisomers of sialic acid alditol with 
MRSA N-acetylneuraminate lyase is 0.39 mM, which is a magnitude better than the Ki of 
4.1 mM observed for the C. perfringens enzyme (Deijl & Vliegenthart, 1983). This 
increase in binding affinity against MRSA N-acetylneuraminate lyase suggests that 
species-specific inhibition is possible, which in this case may be attributed to altered 
binding interactions within the active site of respective enzymes and/or subtle differences 





This chapter reports a detailed investigation of the structure, function and inhibition of N-
acetylneuraminate lyase from MRSA. For the first time, solution studies confirmed that the 
enzyme is tetrameric in structure, consistent with N-acetylneuraminate lyase enzymes from 
other organisms. Kinetic analysis of MRSA N-acetylneuraminate lyase reports kinetic 
constants for the enzyme, which are consistent with the literature. A molecule known as 
sialic acid alditol, which has previously been demonstrated to inhibit the C. perfringens N-
acetylneuraminate lyase enzyme, was synthesised and kinetic analysis established that it is 
a much stronger inhibitor for MRSA N-acetylneuraminate lyase. 
Prior to this thesis, the structure of MRSA N-acetylneuraminate lyase had not been solved. 
However, the structure of S. aureus N-acetylneuraminate lyase was solved and published 
during the course of this study (PDB entry 4ahp) (Timms et al., 2013). Although this is not 
a methicillin-resistant strain of S. aureus, the enzyme has a 100% sequence identity to the 
construct studied in this chapter. Importantly, my structure of MRSA N-acetylneuraminate 
lyase is of a higher resolution than the published S. aureus structure and contains new 
information. Specifically, my structure resolves a loop that is disordered and missing from 
PDB entry 4ahp. 
To elucidate which residues are involved in binding sialic acid alditol in MRSA N-
acetylneuraminate lyase, the structure was also solved in complex with this inhibitor. A 
small difference in the binding of this inhibitor is observed between MRSA and H. 
influenzae N-acetylneuraminate lyase. Altered binding modes and/or differences in protein 
dynamics within the active site of N-acetylneuraminate lyase enzymes may account for the 
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The structure and mechanism of N-
acetylmannosamine-6-phosphate 2-
epimerase from methicillin-resistant 
Staphylococcus aureus  
Part of the work presented in this chapter has been published in: 
North, R. A., Kessans, S. A., Suzuki, H., Watson, A. J. A. Griffin, M. D. W., Fairbanks, A. 
J. & Dobson, R. C. J. (2014). Cloning, expression, purification, crystallisation and 
preliminary X-ray diffraction analysis of N-acetylmannosamine-6-phosphate 2-epimerase 
from methicillin resistant Staphylococcus aureus. Acta Crystallographica Section F, 
Structural Biology and Crystallisation Communications, 70, 643-649. 
3.1 Introduction 
3.1.1 Epimerase enzymes 
Chirality is a ubiquitous feature of proteins that allows enzymes their ability to catalyse 
reactions with an extremely high degree of stereoselectivity (Tanner, 2002). Epimerases 
are enzymes capable of catalysing selective inversions of stereochemistry in biological 
molecules that have multiple chiral centres. To catalyse an inversion of stereochemistry at 
a chiral centre, an epimerase must break a bond from one face and return it to the other 
face in a non-stereoselective manner (Allard et al., 2001; Tanner, 2002). Carbohydrate 
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molecules in particular have many chiral centres and almost every stereocentre is 
epimerised by at least one enzyme. Inversions of carbohydrate stereochemistry by 
epimerase enzymes can yield a diverse range of structures that cannot be generated in 
nature from non-carbohydrate precursors (Samuel & Tanner, 2002). 
3.1.2 Epimerase enzymes implicated in sialic acid utilisation 
To date, three different types of epimerase enzymes have been implicated in pathways that 
utilise sialic acid in both eukaryotes and prokaryotes; UDP-N-acetylglucosamine 2-
epimerase, N-acetylglucosamine 2-epimerase and N-acetylmannosamine-6-phosphate 2-
epimerase (Ferrero et al., 2007). In eukaryotes, UDP-N-acetylglucosamine 2-epimerase 
and N-acetylglucosamine 2-epimerase synthesise and degrade sialic acid, respectively 
(Hinderlich et al., 1997; Stasche et al., 1997; Luchansky et al., 2003). Interestingly, the N-
acetylglucosamine 2-epimerase that degrades sialic acid in eukaryotes, has also been 
identified in some photosynthetic cyanobacteria (Lee et al., 2007; Sola-Carvajal et al., 
2012). The mammalian UDP-N-acetylglucosamine 2-epimerase exists as a bifunctional 
enzyme that also possesses N-acetylmannosamine kinase activity. Thus, as the 
stereochemistry of UDP-N-acetylglucosamine is epimerised, the N-acetylmannosamine 
kinase portion of the enzyme phosphorylates N-acetylmannosamine into N-
acetylmannosamine-6-phosphate (Hinderlich et al., 1997; Stasche et al., 1997; Tanner, 
2005). 
In prokaryotes, an evolutionarily and mechanistically related UDP-N-acetylglucosamine 2-
epimerase is involved in the synthesis of sialic acid, but this enzyme is not bifunctional 
(Tanner, 2005). For the degradation of sialic acid, an N-acetylmannosamine-6-phosphate 
2-epimerase has been identified (Vann et al., 1997; Plumbridge & Vimr, 1999; Walters et 
al., 1999; Ringenberg et al., 2003; Murkin et al., 2004), which differs from the equivalent 
eukaryotic enzyme in that the substrate/product is not phosphorylated. The remainder of 
this chapter is focused on the N-acetylmannosamine-6-phosphate 2-epimerase enzyme, 
responsible for the inversion of stereochemistry at the C2 position of N-
acetylmannosamine-6-phosphate, yielding N-acetylglucosamine-6-phosphate (Figure 3.1). 
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Figure 3.1. The reaction catalysed by N-acetylmannosamine-6-phosphate 2-epimerase. The 
stereochemistry of N-acetylmannosamine-6-phosphate is inverted at the C2 position by N-
acetylmannosamine-6-phosphate 2-epimerase to yield N-acetylglucosamine-6-phosphate. 
3.1.3 The catalytic mechanism of N-acetylmannosamine-6-
phosphate 2-epimerase 
To date, several mechanistic strategies have been classified for carbohydrate epimerisation, 
including deprotonation/reprotonation, formation of a transient keto intermediate, carbon-
carbon bond cleavage, nucleotide elimination and mutarotation (Figure 3.2) (Allard et al., 
2001; Samuel & Tanner, 2002). Prior to this thesis, the reaction mechanism of N-
acetylmannosamine-6-phosphate 2-epimerase had not been elucidated. However, recent 
crystal structures and proton nuclear magnetic resonance spectroscopy (1H NMR) kinetic 
analysis of Clostridium perfringens N-acetylmannosamine-6-phosphate 2-epimerase have 
provided insight into the residues involved in substrate binding and the chemistry catalysed 
by this enzyme (Pelissier et al., 2014). They propose that epimerisation by N-
acetylmannosamine-6-phosphate 2-epimerase occurs via a deprotonation/reprotonation 
mechanism, which is the most commonly employed catalytic strategy of carbohydrate 

















Figure 3.2. Five possible reaction mechanisms classified for carbohydrate epimerases. (A) 
Deprotonation/reprotonation. (B) Formation of a transient keto intermediate. (C) Carbon-carbon bond 
cleavage. (D) Nucleotide elimination. (E) Mutarotation. In the deprotonation/reprotonation mechanism, the 
positive charge can be either a divalent metal ion or a positively charged amino acid residue. In the carbon-
carbon bond cleavage mechanism, the positive charge is a divalent metal ion. NAD+ and NADH respectively 
denote the oxidised and reduced form of nicotinamide adenine dinucleotide. NDP denotes nucleoside 
diphosphate [adapted from van Overtveldt et al. (2015)]. 
Deprotonation/reprotonation involves cleavage of a C-H bond at an “activated” stereogenic 
centre. Activated stereogenic centres are adjacent to a carbonyl group, such as an aldehyde, 
	 77 
ketone or carboxyl (Tanner, 2002; van Overtveldt et al., 2015). The presence of this group 
lowers the pKa of the stereogenic centre to less than 30, allowing the proton to be 
abstracted. Deprotonation forms a resonance-stabilised carbanion and then a non-
stereospecific reprotonation generates the epimer (Samuel & Tanner, 2002).  
For C. perfringens N-acetylmannosamine-6-phosphate 2-epimerase (Figure 3.3), it is 
proposed that a proton is abstracted from the C2 position of N-acetylmannosamine-6-
phosphate by Lys66, which acts as a Brønsted base (Pelissier et al., 2014). Importantly, the 
C2 position of N-acetylmannosamine-6-phosphate is adjacent to an aldehyde at the C1 
position, activating the stereogenic centre for deprotonation. Following abstraction of the 
proton, Pelissier et al. (2014) suggest that a negatively charged enolate intermediate is 
stabilised by Arg43, which forms a salt bridge with Asp126. Reprotonation by Lys66 then 
generates the C2 epimer, N-acetylglucosamine-6-phosphate, although this requires that the 
substrate will rotate in the active site to allow Lys66 to access the opposing face. There is 
no experimental evidence that this occurs. 
Figure 3.3. The proposed deprotonation/reprotonation catalytic mechanism of C. perfringens N-
acetylmannosamine-6-phosphate 2-epimerase. A proton is abstracted by Lys66 from an activated 
stereogenic centre at the C2 position of N-acetylmannosamine-6-phosphate. The negatively charged enolate 
intermediate is stabilised by Arg43, forming a salt bridge with Asp126. Reprotonation by Lys66 generates 
the epimer, N-acetylglucosamine-6-phosphate [adapted from Pelissier et al. (2014)]. 
3.1.4 Kinetic analysis of N-acetylmannosamine-6-phosphate 
2-epimerase 
The current method in the literature to assay N-acetylglucosamine-6-phosphate 2-
epimerase catalysis is by 1H NMR (Pelissier et al., 2014). However, this is a time and 
resource intensive procedure (Exnowitz et al., 2012). I developed a new multi-enzyme 
coupled assay to monitor N-acetylmannosamine-6-phosphate 2-epimerase activity (Section 
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3.2.4). This uses the next enzymes in the sialic acid degradation pathway, N-
acetylglucosamine-6-phosphate deacetylase and glucosamine-6-phosphate deaminase, 
along with phosphoglucoisomerase and glucose-6-phosphate dehydrogenase. 
Although enzyme reactions can be followed using a variety of techniques, the most 
convenient way to measure the conversion of substrate to product over time is by 
following the change in absorbance at a particular wavelength with a spectrophotometer. 
For this to be possible, the change in absorbance must be induced by a chromophore that is 
proportional to the amount of substrate/product (Cornish-Bowden, 2004). Often, however, 
neither the substrate nor product absorbs light at a wavelength compatible with this 
technique. In this case the reaction may be able to be coupled to another enzyme reaction, 
which can be monitored at a particular wavelength by following the change in absorbance 
over time. 
The reaction catalysed by N-acetylmannosamine-6-phosphate 2-epimerase involves the 
inversion of N-acetylmannosamine-6-phosphate and N-acetylglucosamine-6-phosphate 2-
epimerase, neither of which can be monitored spectrophotometrically. Pelissier et al. 
(2014) used 1H NMR to follow the conversion of N-acetylmannosamine-6-phosphate to N-
acetylglucosamine-6-phosphate 2-epimerase, which is the direction that the equilibrium 
lies (Ringenberg et al., 2003). Although it is not possible to directly follow the reaction 
catalysed by N-acetylmannosamine-6-phosphate 2-epimerase spectrophotometrically, it is 
possible to couple this reaction to other enzyme reactions until a change in absorbance can 
be achieved by catalysis. 
3.1.5 N-Acetylmannosamine-6-phosphate 2-epimerase is an 
antibiotic drug target 
As described in Chapter One, various studies have suggested that the sialic acid 
degradation pathway is a candidate for antibiotic drug development (Chang et al., 2004; 
Almagro-Moreno & Boyd, 2009; Jeong et al., 2009; Pezzicoli et al., 2012; Olson et al., 
2013). Deletion of the nanE gene coding for N-acetylmannosamine-6-phosphate 2-
epimerase renders Staphylococcus aureus (Olson et al., 2013), Escherichia coli and Vibrio 
cholerae (Almagro-Moreno & Boyd, 2009) incapable of growing on sialic acid as a sole 
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carbon source in vitro. Although there are a number of epimerase enzymes involved in 
sialic acid biosynthetic or degradation pathways throughout eukaryotes and prokaryotes 
(Section 3.1.3), bacterial N-acetylmannosamine-6-phosphate 2-epimerase is highly 
conserved among gram-positive and gram-negative bacteria (North et al., 2014), but does 
not display significant homology in the structure and catalytic mechanism to that of 
mammalian epimerases (Tanner, 2005; Pelissier et al., 2014). Thus, similar to N-
acetylneuraminate lyase (Chapter Two), N-acetylmannosamine-6-phosphate 2-epimerase 
can be considered as a potential target for the development of novel antibiotic drugs. 
3.1.6 Overview of this chapter 
This chapter will address the structure and catalytic mechanism of N-acetylmannosamine-
6-phosphate 2-epimerase from methicillin resistant S. aureus (MRSA), a pathogen that 
causes significant disease globally (McDonald et al., 1981; Boyce, 1992; Panlilio et al., 
1992; Grundmann et al., 2006; Chambers & Deleo, 2009). A specifically designed assay 
for kinetic analysis was developed for N-acetylmannosamine-6-phosphate 2-epimerase 
enzymes. The structure of MRSA N-acetylmannosamine-6-phosphate 2-epimerase was 
solved and in combination with a sequence analysis, residues that have potential to be 
involved in catalysis were identified and tested by kinetic analysis. Although structures and 
a proposed catalytic mechanism for C. perfringens N-acetylmannosamine-6-phosphate 2-
epimerase have been published during the course of this study, a critical analysis of these 
structures suggests that deprotonation/reprotonation by a conserved lysine residue is 
unlikely. Instead, I propose that catalysis occurs via the formation of a Schiff base or a 
proton displacement mechanism mediated by the substrate. Overall, this chapter presents a 
solution based characterisation of the wild type enzyme and a kinetic and structural 
analysis of the wild type and mutant enzymes. Because N-acetylmannosamine-6-phosphate 
2-epimerase is a potential target for the development of antibiotic drugs, this type of 




3.2 Results and discussion 
3.2.1 Cloning of N-acetylmannosamine-6-phosphate 2-
epimerase, N-acetylglucosamine-6-phosphate deacetylase and 
glucosamine-6-phosphate deaminase from MRSA 
The nanE gene encoding N-acetylmannosamine-6-phosphate 2-epimerase from MRSA 
USA300 (Appendix) was commercially supplied with SacI and HindIII restriction sites in 
a cloning plasmid designated pUC57-Kan. The nanE gene was excised from pUC57-Kan 
and sub cloned into the pET30ΔSE expression plasmid (Suzuki et al., 2014) to produce a 
construct named pET30ΔSE/nanE-His (Chapter Six, Sections 6.4.6-6.4.8). Initially, SacI 
and HindIII restriction sites were selected so that the overexpressed protein would contain 
an N-terminal 6 × Histidine tag (His-tag) located within pET30ΔSE that can be cleaved off 
with thrombin. However, the His-tag interfered with the purified protein and was deemed 
inappropriate for this construct (Section 3.2.2). To remove it, the polymerase chain 
reaction (PCR) was used to incorporate NdeI and HindIII restriction sites into the 5’ and 3’ 
ends of the nanE gene in pUC57-Kan (Chapter Six, Section 6.4.5). To do this, primer pair 
NanE-forward and NanE-reverse (Appendix) were used. The resulting PCR product was 
sub cloned into pCR2.1-TOPO (Chapter Six, Section 6.4.5) and then into pET30ΔSE to 
create pET30ΔSE/nanE (Chapter Six, Sections 6.4.6-6.4.8). Deoxyribonucleic acid (DNA) 
sequencing was used to confirm the identity of pET30ΔSE/nanE-His and 
pET30ΔSE/nanE. 
Mutated variants of the nanE gene encoding N-acetylmannosamine-6-phosphate 2-
epimerase from MRSA USA300 were commercially supplied in a pET30a(+) expression 
plasmid. Each variant contained a single amino acid change and was named according to 
the position of the mutation. The rationale behind each of these single amino acid 
substitutions is discussed in more detail later (Section 3.2.8). These mutants are referred to 
as Gln11Ala, Gln11Ser, Glu16Ala, Glu16His, Arg40Ala, Lys63Ala, Lys63Glu, 
Asp124Ala, Asp124Gln and Arg208Ala throughout this thesis. 
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Development of a multi-enzyme coupled assay for MRSA N-acetylmannosamine-6-
phosphate 2-epimerase (Section 3.2.4) required the two subsequent enzymes of the sialic 
acid degradation pathway (N-acetylglucosamine-6-phosphate deacetylase and 
glucosamine-6-phosphate deaminase). The nagA gene encoding N-acetylglucosamine-6-
phosphate deacetylase and the nagB gene encoding glucosamine-6-phosphate deaminase, 
both from MRSA USA300 (Appendix), were commercially supplied with NdeI and 
HindIII restriction sites in pUC57-Kan. The genes were excised from pUC57-Kan and sub 
cloned into pET30ΔSE to produce constructs named pET30ΔSE/nagA and 
pET30ΔSE/nagB, respectively (Chapter Six, Sections 6.4.6-6.4.8). DNA sequencing was 
used to confirm the identities of these constructs. 
3.2.2 Purification of N-acetylmannosamine-6-phosphate 2-
epimerase, N-acetylglucosamine-6-phosphate deacetylase and 
glucosamine-6-phosphate deaminase from MRSA 
All constructs to be overexpressed were transformed into E. coli BL21 (DE3) bacterial 
cells, cultured and overexpressed in Luria Bertani medium, harvested and lysed (Chapter 
Six, Sections 6.6.1-6.6.3). Utilisation of the SacI and HindIII restriction sites in the 
pET30ΔSE plasmid enabled the incorporation of a His-tag at the N-terminus of wild type 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase (pET30ΔSE/nanE-His). Following 
purification by immobilised metal affinity chromatography, cleavage of the His-tag with 
thrombin proved to be unsuccessful. This suggests that the His-tag may have been 
interacting with the protein in a way that made the thrombin cleavage site inaccessible for 
the protease. Thus, utilisation of a His-tag for purification of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase was not appropriate. 
The modified gene construct (pET30ΔSE/nanE) was expressed without a His-tag. Protein 
expressed from this construct was subjected to purification by anion exchange 
chromatography, hydrophobic interaction chromatography and size exclusion 
chromatography. The increasing purity of the wild type enzyme from each purification 
procedure is shown in Figure 3.4 A. The final purity was visually estimated to be at least 
95%, observed by the single band at 24.5 kilodalton (kDa) following size exclusion 
chromatography (Figure 3.4 A, lane 5). Following protein purification, the mass of MRSA 
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N-acetylmannosamine-6-phosphate 2-epimerase was confirmed by electrospray ionisation 
mass spectrometry. 
Figure 3.4. Purification of MRSA N-acetylmannosamine-6-phosphate 2-epimerase, MRSA N-
acetylglucosamine-6-phosphate deacetylase and MRSA glucosamine-6-phosphate deaminase. (A) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showing the increasing 
purity of wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase at each purification step. Lane 1, 
protein ladder (kDa); lane 2, crude; lane 3, pooled fractions from anion-exchange chromatography; lane 4, 
pooled fractions from hydrophobic interaction chromatography; lane 5, post-size-exclusion chromatography. 
(B) SDS-PAGE analysis showing the final purity of the mutant MRSA N-acetylmannosamine-6-phosphate 2-
epimerase enzymes, MRSA N-acetylglucosamine-6-phosphate deacetylase and MRSA glucosamine-6-
phosphate deaminase. Lane 1, protein ladder (kDa); lane 2, Gln11Ala; lane 3, Gln11Ser; lane 4, Glu16Ala; 
lane 5, Glu16His; lane 6, Arg40Ala; lane 7, Lys63Ala; lane 8, Lys63Glu; lane 9, Asp124Ala; lane 10, 
Asp124Gln; lane 11, Arg208Ala; lane 12, MRSA N-acetylglucosamine-6-phosphate deacetylase; lane 13, 
MRSA glucosamine-6-phosphate deaminase. 
The mutated variants of MRSA N-acetylmannosamine-6-phosphate 2-epimerase, the 
MRSA N-acetylglucosamine-6-phosphate deacetylase and the MRSA glucosamine-6-
phosphate deaminase were purified using anion exchange chromatography, hydrophobic 
interaction chromatography and size exclusion chromatography. The final purity of each 
enzyme was visually estimated to be at least 95%, observed by the single bands following 
size exclusion chromatography (Figure 3.4 B). The mutated variants of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase are all approximately 24.5 kDa in size 
(Figure 3.4 B, lanes 2 through to 11), whereas MRSA N-acetylglucosamine-6-phosphate 
deacetylase (Figure 3.4 B, lane 12) and MRSA glucosamine-6-phosphate deaminase 
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mutated variants of MRSA N-acetylmannosamine-6-phosphate 2-epimerase, the MRSA N-
acetylglucosamine-6-phosphate deacetylase and the MRSA glucosamine-6-phosphate 
deaminase was also verified by electrospray ionisation mass spectrometry. 
3.2.3 The solution structure of wild type MRSA N-
acetylmannosamine-6-phosphate 2-epimerase 
3.2.3.1. Quaternary structure as determined by analytical ultracentrifugation 
Sedimentation velocity experiments using analytical ultracentrifugation demonstrate that 
wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase is dimeric in solution. 
The continuous sedimentation coefficient distribution [c(s)] distribution resulted in a single 
symmetrical peak, confirming that wild type MRSA N-acetylmannosamine-6-phosphate 2-
epimerase is a single species in solution, with a sedimentation coefficient of 3.5 S (Figure 
3.5 A). This data was then fitted to a continuous mass distribution [c(M)] model to 
calculate the apparent molecular mass of the species (Figure 3.5 B). The apparent 
molecular mass was determined to be 49.2 kDa. Considering the theoretical monomeric 
mass of MRSA N-acetylmannosamine-6-phosphate 2-epimerase is 24.5 kDa, this is 
consistent with the theoretical dimeric mass of 49 kDa. The absorbance at 285 nm versus 
radial position of MRSA N-acetylmannosamine-6-phosphate 2-epimerase shows a single 
sedimenting boundary, consistent with the presence of a single species (Figure 3.5 C). The 
randomly distributed residuals and low root-mean-square deviation (rmsd) (0.0031) 







Figure 3.5. Sedimentation velocity analysis of wild type MRSA N-acetylmannosamine-6-phosphate 2-
epimerase using analytical ultracentrifugation. The experiment was conducted at 0.5 mg/mL (20.4 µM) of 
freshly purified protein in 20 mM 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris), pH 8.0, 150 mM 
sodium chloride. Data were collected at 285 nm, 50 000 rpm and 20 °C. SEDNTERP was used to calculate 
the partial-specific volume of MRSA N-acetylmannosamine-6-phosphate 2-epimerase (0.7412 g/ml), solvent 
density (1.0029 g/ml) and viscosity (0.0102 poise) (Laue et al., 1992). Data were fitted to a c(s) and c(M) 
model at a resolution of 300 and a confidence level of 0.95 using SEDFIT (Schuck, 2000). (A) The c(s) 
model plotted as a function of sedimentation coefficient. Data were fitted with an s value ranging between 1 
and 6 S. The fit resulted in a frictional ratio (f/f0) of 1.2928. (B) The c(M) model plotted as a function of 
molecular mass (kDa). Data were fitted with a minimum mass of 20 kDa and a maximum mass of 80 kDa. 
(C) Absorbance at 285 nm plotted as a function of radial position (cm). The raw data are represented as open 
symbols (o) and overlaid with the non-linear least squares best fit. The residuals for this fit are shown above. 
3.2.3.2 Small angle X-ray scattering analysis of the solution structure 
Small angle X-ray scattering (SAXS) data further verifies the dimeric solution structure of 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase. Guinier analysis was used to 
assess sample quality and the linearity of the plot confirms that the scattering is reliable 
(Figure 3.6 A). Scattering data are presented as an intensity plot (Figure 3.6 B) and a real 
space distance distribution function P(r) plot (Figure 3.6 C). The maximum dimension of 
the scattering particle (Dmax) was calculated by AUTOPOROD (Petoukhov & Svergun, 
2007) as 75.8 Å. The radius of gyration (Rg) determined by GNOM (Svergun, 1992) was 
calculated as 24.9 Å, in close agreement with the 23.5 Å Rg determined by Guinier 
analysis. The molecular mass extracted from the SAXS data is 40.4 kDa, which is slightly 
smaller than the 49 kDa theoretical dimeric mass and the 49.2 kDa apparent molecular 
mass derived from sedimentation velocity analysis. The low resolution of SAXS data 
would account for this discrepancy in size (Putnam et al., 2007). The P(r) distribution 
A B C
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shows a single peak with a positively skewed tail at long distances, indicative that MRSA 
N-acetylmannosamine-6-phosphate 2-epimerase acquires an elongated shape in solution. 
Figure 3.6. SAXS data for MRSA N-acetylmannosamine-6-phosphate 2-epimerase. (A) Guinier plot 
which is linear, determined using GNOM. (B) Experimental scattering data presented as an intensity plot. (C) 
P(r) plot determined using GNOM. 
To determine whether the structure in solution accurately reflects my crystal structure 
(Section 3.2.8), the experimental scattering data were compared with the theoretical 
scattering generated from the crystal structure using CRYSOL (Svergun et al., 1995). The 
theoretical scattering calculated for the crystal structure of MRSA N-acetylmannosamine-
6-phosphate 2-epimerase fits the experimental scattering data (χ2 = 0.56), confirming that 
the crystal structure is an accurate representation of the solution structure (Figure 3.7). 
Figure 3.7. Comparison of experimental and theoretical scattering data. The experimental scattering 
profile of MRSA N-acetylmannosamine-6-phosphate 2-epimerase (presented as open circles, o) overlaid with 
the theoretical scattering profile of the crystal structure in magenta. 
B CA
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3.2.4 Development of a multi-enzyme kinetic assay for N-
acetylmannosamine-6-phosphate 2-epimerase 
As described in Section 3.1.4, an efficient method to characterise the activity of N-
acetylmannosamine-6-phosphate 2-epimerase enzymes is lacking. Thus, I developed a 
multi-enzyme coupled assay to determine the kinetic properties of N-acetylmannosamine-
6-phosphate 2-epimerase in real time (Figure 3.8). This assay utilises the subsequent 
enzymes of the sialic acid degradation pathway, N-acetylglucosamine-6-phosphate 
deacetylase and glucosamine-6-phosphate deaminase, as well as phosphoglucoisomerase 
and glucose-6-phosphate dehydrogenase as coupling enzymes (Chapter Six, Section 6.9.2). 
Figure 3.8. The multi-enzyme coupled assay developed for N-acetylmannosamine-6-phosphate 2-
epimerase. As NADP+ is reduced into NADPH, the increase in absorbance at 340 nm is followed 























Briefly, the assay is initiated by the addition of substrate (N-acetylmannosamine-6-
phosphate), which is converted into N-acetylglucosamine-6-phosphate by N-
acetylmannosamine-6-phosphate 2-epimerase. N-Acetylglucosamine-6-phosphate 
deacetylase, glucosamine-6-phosphate deaminase, phosphoglucoisomerase and glucose-6-
phosphate dehydrogenase convert N-acetylglucosamine-6-phosphate into glucosamine-6-
phosphate, fructose-6-phosphate, glucose-6-phosphate and 6-phosphogluconate, 
respectively. As glucose-6-phosphate dehydrogenase turns over glucose-6-phosphate into 
6-phosphogluconate, nicotinamide adenine dinucleotide phosphate (NADP+) is 
simultaneously reduced to NADPH. Because NADP+ does not absorb at 340 nm and 
NADPH does, the increase in absorbance at this wavelength can be followed as the 
reaction is catalysed. The rate of this reaction will be proportional to the rate of catalysis 
by N-acetylmannosamine-6-phosphate 2-epimerase. 
Prior to kinetic analysis, the secondary structure of the wild type and mutant MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes was assessed to ensure that they 
were folded following purification (Section 3.2.4.1). In addition, the thermal stability of 
the wild type and the mutant MRSA N-acetylmannosamine-6-phosphate 2-epimerase 
enzymes, as well as the purified MRSA N-acetylglucosamine-6-phosphate deacetylase and 
MRSA glucosamine-6-phosphate deaminase coupling enzymes were evaluated (Section 
3.2.4.2). Understanding the thermal stability of these enzymes was necessary to determine 
a suitable temperature by which this multi-enzyme coupled assay could be conducted. 
Because this is a newly developed assay for kinetic analysis, various controls also had to 
be performed to ensure that the conditions of the experiment allowed for accurate and 
reproducible calculations to be made. Firstly, because multiple coupling enzymes were 
involved, it was important to ensure that none of these enzymes non-specifically acted 
upon the substrate, N-acetylmannosamine-6-phosphate (Section 3.2.4.3). In addition, it is 
important that all of the coupling enzymes were in excess so that they are not limiting the 
rate of the reaction being measured and the rate being measured is proportional to enzyme 
concentration (Section 3.2.4.4) (Cornish-Bowden, 2004). 
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3.2.4.1 Secondary structure of wild type and mutant MRSA N-acetylmannosamine-6-
phosphate 2-epimerase enzymes 
Circular dichroism (CD) spectroscopy was performed on the wild type and mutant MRSA 
N-acetylmannosamine-6-phosphate 2-epimerase enzymes to ensure that they were folded. 
In addition, this allowed for any differences in secondary structure between the enzymes to 
be assessed. The spectra recorded showed that the enzymes are folded (Figure 3.9). A 
broad minima is apparent between approximately 208 nm and 222 nm, which is 
characteristic of enzymes composed of both α-helices and β-strands. 
Figure 3.9. CD spectra of MRSA N-acetylmannosamine-6-phosphate 2-epimerase enzymes. CD 
spectroscopy was conducted at 0.1 mg/mL in 20 mM Tris, pH 8.0 for the wild type and mutant MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes. Mean residue ellipticity is plotted as a function of 
wavelength. Data are represented as open circles, with wild type MRSA N-acetylmannosamine-6-phosphate 
2-epimerase in black (o), Gln11Ala in blue (o), Gln11Ser in orange (o), Glu16Ala in purple (o), Glu16His in 
red (o), Arg40Ala in grey (o), Lys63Ala in magenta (o), Lys63Glu in lime green (o), Asp124Ala in cyan (o), 
Asp124Gln in pink (o) and Arg208Ala in dark green (o). 
Although the spectra recorded follow a similar trend, they do not overlay with one another. 
Thus, small differences in secondary structure are apparent between the wild type and 
mutant enzymes. The percentage of each secondary structure component present in each 
enzyme is shown in Table 3.1. The wild type enzyme appears to have a slightly higher 
percentage of α-helices and a slightly lower percentage of β-strands/turns compared to the 
mutant enzymes. The mutated variants contain single amino acid mutations within the 
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active site of MRSA N-acetylmannosamine-6-phosphate 2-epimerase. Although the exact 
location that the secondary structure is altered cannot be determined using CD 
spectroscopy, it is likely that these mutations are perturbing secondary structural elements 
at or near the active site of the enzyme. Crystal structures of the mutated variants would 
allow for changes in secondary structure to be probed, but this is beyond the scope of this 
thesis. 
Table 3.1. The percentage of each secondary structure component in the wild type and mutant 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase enzymes. Data was analysed using CDNN (Bohm 
et al., 1992). 
MRSA N-acetylmannosamine-
6-phosphate 2-epimerase 
α-Helix (%) β-Strand (%) β-Turn (%) Random coil (%) 
Wild type 37 15 16 32 
Gln11Ala 33 17 17 33 
Gln11Ser 32 18 17 33 
Glu16Ala 32 18 17 33 
Glu16His 30 19 17 34 
Arg40Ala 35 17 16 32 
Lys63Ala 35 17 16 32 
Lys63Glu 33 17 17 33 
Asp124Ala 33 18 17 32 
Asp124Gln 28 21 18 33 
Arg208Ala 33 18 17 32 
3.2.4.2 Thermal stability of the enzymes involved in the multi-enzyme coupled assay 
The thermal stability and structural integrity of the wild type and mutant MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes, as well as the purified MRSA N-
acetylglucosamine-6-phosphate deacetylase and MRSA glucosamine-6-phosphate 
deaminase coupling enzymes was determined using differential scanning fluorimetry 
(Table 3.2). It is clear that the mutant MRSA N-acetylmannosamine-6-phosphate 2-
epimerase enzymes have very similar melting temperatures to the wild type enzyme, 
suggesting that they are similarly folded into stable conformations. Moreover, the MRSA 
N-acetylglucosamine-6-phosphate deacetylase and the MRSA glucosamine-6-phosphate 
deaminase enzymes display a melting temperature of 47 °C and 43 °C, respectively. 
For the commercially purchased phosphoglucoisomerase from Saccharomyces cerevisiae 
and glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides, the literature 
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was consulted to ensure an appropriate temperature was selected for the assay that is also 
suitable for these coupling enzymes. Although the thermal stability has not been 
specifically measured, previous assays have shown that S. cerevisiae 
phosphoglucoisomerase is stable up to 60 °C (Maitra, 1971), whereas L. mesenteroides 
glucose-6-phosphate dehydrogenase is shown to be stable in assays conducted at room 
temperature (Vincent et al., 2005; Zhu et al., 2011). Taking this into consideration with the 
thermal stability of the wild type and mutated variants of MRSA N-acetylmannosamine-6-
phosphate 2-epimerase, the MRSA N-acetylglucosamine-6-phosphate deacetylase and the 
MRSA glucosamine-6-phosphate deaminase enzymes, a temperature of 25 °C was selected 
for kinetic analysis of MRSA N-acetylmannosamine-6-phosphate 2-epimerase. 
Table 3.2. Melting temperature of the wild type and mutant MRSA N-acetylmannosamine-6-
phosphate 2-epimerase enzymes, MRSA N-acetylglucosamine-6-phosphate deacetylase and MRSA 
glucosamine-6-phosphate deaminase. Differential scanning fluorimetry was conducted at 1 mg/mL in 20 
mM Tris, pH 8.0.  
Enzyme Melting temperature (°C) 





Gln11Ser 39.3 ± 0.3 
Glu16Ala 40.7 ± 0.3 
Glu16His 39.0 
Arg40Ala 41.3 ± 0.3 
Lys63Ala 43.0 
Lys63Glu 40.7 ± 0.3 
Asp124Ala 44.0 
Asp124Gln 38.7 ± 0.3 
Arg208Ala 42.0 
MRSA N-acetylglucosamine-6-phosphate deacetylase 47.0 
MRSA glucosamine-6-phosphate deaminase 43.0 
3.2.4.3 Ensuring that the coupling enzymes do not catalyse their reaction with N-
acetylmannosamine-6-phosphate 
A test was conducted to ensure that the coupling enzymes (MRSA N-acetylglucosamine-6-
phosphate deacetylase, MRSA glucosamine-6-phosphate deaminase, S. cerevisiae 
phosphoglucoisomerase and L. mesenteroides glucose-6-phosphate dehydrogenase) do not 
non-specifically catalyse their reaction with N-acetylmannosamine-6-phosphate, the 
substrate for N-acetylmannosamine-6-phosphate 2-epimerase. To do this, the baseline 
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absorbance of the assay mixture (100 mM Tris, pH 8.0, 5 mM magnesium chloride, 1 mM 
NADP+) with substrate, N-acetylmannosamine-6-phosphate, was recorded without any of 
the coupling enzymes (Figure 3.10). The coupling enzymes were sequentially added to the 
mixture in reverse order (glucose-6-phosphate dehydrogenase, phosphoglucoisomerase, 
glucosamine-6-phosphate deaminase and N-acetylglucosamine-6-phosphate deacetylase, 
respectively) to ensure that they were not turning over the substrate. 
Figure 3.10 The absorbance at 340 nm as each enzyme is sequentially added to the assay mixture. The 
assay mixture contains 100 mM Tris, pH 8.0, 5 mM magnesium chloride, 1 mM NADP+ and 5 mM of 
substrate (N-acetylmannosamine-6-phosphate 2-epimerase) for N-acetylmannosamine-6-phosphate 2-
epimerase. The baseline absorbance at 340 nm of the assay mixture does not increase (A). When the glucose-
6-phosphate dehydrogenase, phosphoglucoisomerase and glucosamine-6-phosphate deaminase coupling 
enzymes are added to the assay (B, C and D, respectively), the absorbance at 340 nm also does not increase. 
When the N-acetylglucosamine-6-phosphate deacetylase coupling enzyme is added to the assay, there is an 
increase in absorbance at 340 nm, which eventually flattens. When N-acetylmannosamine-6-phosphate 2-
epimerase (F) is added, the absorbance at 340 nm steeply increases. 
My control showed that as the coupling enzymes were sequentially added to the assay, the 
baseline absorbance did not change until N-acetylglucosamine-6-phosphate deacetylase 
was added, which was the final coupling enzyme to be tested. This means that a change in 
absorbance at 340 nm becomes apparent as glucose-6-phosphate dehydrogenase converts 
NADP+ into NADPH. Thus, N-acetylglucosamine-6-phosphate deacetylase is either 
conducting its reaction with N-acetylmannosamine-6-phosphate, or it is utilising it’s own 






Because the commercially purchased N-acetylmannosamine-6-phosphate is not completely 
pure (minimum purity 95%), there may be a small percentage of its epimer, N-
acetylglucosamine-6-phosphate present when made up in solution. Importantly, N-
acetylglucosamine-6-phosphate is the substrate for N-acetyglucosamine-6-phosphate 
deacetylase. As shown in Figure 3.10, the increase in absorbance at 340 nm associated 
with the addition of N-acetylglucosamine-6-phosphate deacetylase eventually flattens, 
implying that there is effectively no substrate left in the assay mixture for this enzyme. 
Then, when the N-acetylmannosamine-6-phosphate 2-epimerase enzyme is added to the 
assay mixture, the absorbance at 340 nm again increases. Thus, the N-acetylglucosamine-
6-phosphate deacetylase enzyme cannot be utilising N-acetylmannosamine-6-phosphate as 
a substrate and activity can be attributed to a small amount of N-acetylglucosamine-6-
phosphate being present in the commercially purchased N-acetylmannosamine-6-
phosphate. 
The presence of N-acetylglucosamine-6-phosphate in the commercially purchased N-
acetylmannosamine-6-phosphate means that if the amount of N-acetylmannosamine-6-
phosphate added to the assay is doubled, the amount of N-acetylglucosamine-6-phosphate 
also doubles. This combined with the absorbance range of the spectrophotometer, which is 
linear between approximately 0 and 1.2, defined an upper limit for the amount of N-
acetylmannosamine-6-phosphate that could be used. This upper limit was determined as 5 
mM N-acetylmannosamine-6-phosphate, by which kinetic analysis of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes could not be conducted above. 
3.2.4.4 Ensuring that the coupling enzymes are in excess and the rate of the reaction is 
proportional to MRSA N-acetylmannosamine-6-phosphate 2-epimerase concentration 
As described in Chapter Two, Section 2.2.3.1, it is important that all of the coupling 
enzymes are in excess so that they are not limiting the rate of the reaction being measured. 
In addition, the initial rate of the reaction that is being measured must be proportional to 
enzyme concentration (Cornish-Bowden, 2004). To test that the enzymes are in excess, the 
amount of each coupling enzyme initially added to the assay was sequentially doubled in 
reverse order (glucose-6-phosphate dehydrogenase, phosphoglucoisomerase, glucosamine-
6-phosphate deaminase and N-acetylglucosamine-6-phosphate deacetylase, respectively) to 
ensure that the rate of the reaction did not change. This control determined that 50 µg of N-
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acetylglucosamine-6-phosphate deacetylase, 100 µg of glucosamine-6-phosphate 
deaminase, 50 µg of phosphoglucoisomerase and 25 µg of glucose-6-phosphate 
dehydrogenase per assay could be used as excess. At these concentrations, the rate of the 
reaction did not change when the concentration of each coupling enzyme was doubled 
(Figure 3.11 A). To ensure that the initial rate of the reaction is proportional to the 
concentration of MRSA N-acetylmannosamine-6-phosphate 2-epimerase, a range of 
concentrations were analysed between 0.25 µg and 2 µg per assay. A final concentration of 
0.25 µg was selected for kinetic analysis of MRSA N-acetylmannosamine-6-phosphate 2-
epimerase, as this concentration was proportional to the initial rate of the reaction, depicted 
by the linearity of the initial velocity observed in Figure 3.11 B. 
Figure 3.11. Excess and concentration control for the multi-enzyme coupled assay developed for 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase. (A) The initial velocity of wild type MRSA N-
acetylmannosamine-6-phosphate 2-epimerase (baseline) with 50 µg of N-acetylglucosamine-6-phosphate 
deacetylase, 100 µg of glucosamine-6-phosphate deaminase, 50 µg of phosphoglucoisomerase and 25 µg of 
glucose-6-phosphate dehydrogenase. The amount of each enzyme was sequentially doubled in the order 
depicted in the graph. The mean is shown as a bar and the data is plotted as data points. (B) The initial 
velocity of wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase as a function of enzyme 















3.2.5 Michaelis-Menten kinetic analysis of wild type MRSA 
N-acetylmannosamine-6-phosphate 2-epimerase 
The initial rate of wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase with 
varying concentrations of N-acetylmannosamine-6-phosphate was measured and fitted to 
the Michaelis-Menten kinetic model, displaying a hyperbolic dependence of initial velocity 
on substrate concentration (Figure 3.12). For the wild type enzyme, the Michaelis-Menten 
constant (KM) value was found to be 0.7 ± 0.03 mM, the maximum velocity (Vmax) was 
calculated as 102 ± 1 µmol/min/mg and the catalytic turnover number (kcat) was 
determined to be 41.6 ± 0.6 s-1. 1H NMR kinetic analysis of N-acetylmannosamine-6-
phosphate 2-epimerase from C. perfringens revealed a KM value of 4.5 mM (Pelissier et 
al., 2014). Thus, the wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase 
enzyme has a much higher affinity for N-acetylmannosamine-6-phosphate than that of C. 
perfringens N-acetylmannosamine-6-phosphate 2-epimerase. 
Figure 3.12. Michaelis-Menten kinetic analysis of wild type MRSA N-acetylmannosamine-6-




3.2.6 Crystallisation of MRSA N-acetylmannosamine-6-
phosphate 2-epimerase 
To further investigate the solution structure of wild type MRSA N-acetylmannosamine-6-
phosphate 2-epimerase, crystallisation studies were conducted (Chapter 6, Section 6.7.1). 
The JCSG+ Suite produced crystals in several of the screen conditions. Condition E1 (1 M 
trisodium citrate, 0.1 M sodium cacodylate, pH 6.5) produced a cluster of crystals at 8 °C. 
These crystals were suitable for the collection of high resolution X-ray diffraction data to 
1.84 Å, without any optimisation required. 
3.2.7 Data processing and structure refinement of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase 
The data was processed in the space group P21212 and solved by molecular replacement 
using the monomer of MRSA N-acetylmannosamine-6-phosphate 2-epimerase (PDB entry 
1y0e) as the search model. The presence of two screw axes was verified by the presence of 
systematic absences in only two of the axes. Consistent with the solution structure, the 
asymmetric unit contains two monomers that correspond to a dimer. My construct differs 
by two amino acid residues to that of PDB entry 1y0e. Firstly, PDB entry 1y0e contains an 
extra alanine residue at position one, which precedes the methionine located at position 
one of the construct presented. Secondly, a valine residue located at position 220 of PDB 
entry 1y0e corresponds to an isoleucine residue located at position 219 of the construct 
presented. Following multiple rounds of structure refinement, the residual factor (Rfactor) 
and the free Rfactor (Rfree) were reduced to 16.9 and 19.8%, respectively. This model 
includes all residues except for the methionine at position one of each monomer, which 
was too disordered to model into the density at a sigma level of one. All relevant data 
collection and processing parameters as well as the structure and refinement statistics are 





Table 3.3. X-ray data collection and refinement statistics for wild type MRSA N-
acetylmannosamine-6-phosphate 2-epimerase. Statistical values for the highest resolution shells are given 
in parentheses. Each monomer within the asymmetric unit has a molecular weight of 49 090 Da. 
Statistics MRSA N-acetylmannosamine-6-phosphate 2-epimerase  
data collection statistics  
wavelength (Å) 0.95369 
number of images 360 
oscillations (°) 0.5 
space group P21212 
unit cell parameters (Å, °) a = 77.1, b = 173.7, c = 44.4, α = β = γ = 90 
resolution range (Å) 46.3-1.84 (1.88-1.84) 
observed reflections 189024 (9200) 
unique reflections 52704 (3125) 
mean I/σ(I) 10.8 (1.8) 
completeness (%) 99.8 (98.5) 
Rmerge† 0.082 (0.549) 
Rr.i.m.‡ 0.112 (0.738) 
Rp.i.m.§ 0.076 (0.490) 
wilson B value (Å2) 
molecules per asymmetric unit 
VM (Å3 Da-1) 





structure and refinement statistics  
Rfactor (%) 16.9 
Rfree (%) 19.8 





bonds (Å) 0.015 
angles (°) 1.524 




Ramachandran plot, residues (%)  
favoured region 96.8 
allowed region 2.74 
disallowed region 0.46 
Rmerge † = ∑hkl ∑i |Ii (hkl) - <I(hkl)>| / ∑hkl∑iIi (hkl). 
Rr.i.m ‡ = ∑hkl {N(hkl)/[N(hkl) - 1]}1/2 ∑i |Ii (hkl) – <I(hkl)>| / ∑hkl∑iIi (hkl). 
Rp.i.m.§ = ∑hkl [1/(N – 1)]1/2 ∑i |Ii (hkl) – <I(hkl)>| / ∑hkl∑iIi (hkl). 
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3.2.8 The structure of MRSA N-acetylmannosamine-6-
phosphate 2-epimerase 
Prior to the beginning of this thesis, crystal structures of N-acetylmannosamine-6-
phosphate 2-epimerase from MRSA (PDB entry 1y0e; Midwest Centre for Structural 
Genomics, unpublished work), Salmonella enterica (PDB entry 3igs; Centre for Structural 
Genomics of Infectious Diseases, unpublished work) and Streptococcus pyogenes (PDB 
entry 1yxy; Midwest Centre for Structural Genomics, unpublished work) had been solved 
and deposited in the PDB, but not yet published in the literature. Although the structure 
had already been solved for MRSA N-acetylmannosamine-6-phosphate 2-epimerase, a 
crystallisation protocol was developed for my construct in particular, which allowed for the 
structure to be solved. Having this protocol and a ligand free crystal structure available is 
important for studies directed at understanding how the chemistry is catalysed by these 
enzymes as well as for the development of inhibitors in the future. 
Consistent with the solution based structure, the crystal structure of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase is a dimer, consisting of two single domain 
triosephosphate isomerase barrels [(β/α)8-barrels] (Figure 3.14 A). Unlike any other known 
(β/α)8-barrel enzymes, dimerisation between monomers is enabled by exchanging the C-
terminal α-helix, which projects away from each barrel and packs against the β-sheet of the 
neighbouring monomer. This arrangement is highly similar to that observed for all 
structures solved to date of N-acetylmannosamine-6-phosphate 2-epimerase enzymes. The 
monomer of MRSA N-acetylmannosamine-6-phosphate 2-epimerase is shown in Figure 
3.14 B, with the consecutive β-strands labelled a through h and the α-helices labelled A 
through H. It is α-helix H that is exchanged to enable dimerisation between the monomers. 
As with all (β/α)8-barrel enzymes, the active site is located in the centre of the barrel at the 
C-terminal end of the β-strands (Wierenga, 2001). 
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Figure 3.14. The crystal structure of MRSA N-acetylmannosamine-6-phosphate 2-epimerase. (A) The 
dimeric structure of MRSA N-acetylmannosamine-6-phosphate 2-epimerase formed by exchanging an α-
helix between monomers. (B) The monomeric structure of MRSA N-acetylmannosamine-6-phosphate 2-
epimerase with the consecutive β-strands labelled a through h and the α-helices labelled A through H. 
Sequence analysis of N-acetylmannosamine-6-phoshate enzymes demonstrates a number 
of strictly conserved residues among gram positive bacterial species (Figure 3.15). Based 
on this conservation and considering the position of active sites within (β/α)8-barrel 
enzymes (Wierenga, 2001), my structure of MRSA N-acetylmannosamine-6-phosphate 
could be used to identify residues that may be important for catalysis (Figure 3.16). 
Specifically, residues Gln11, Glu16, Arg40, Lys63, Asp124 and Arg208 may have a role 
in catalysis, since they line the cleft at the C-terminal ends of the β-strands that is proposed 
to form the active site. To elucidate whether these residues are important for the chemistry 
catalysed by MRSA N-acetylmannosamine-6-phosphate 2-epimerase, they were mutated to 
an alanine, producing Gln11Ala, Glu16Ala, Arg40Ala, Lys63Ala, Asp124Ala and 
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Arg208Ala. In addition, Gln11 was also mutated into a serine, producing Gln11Ser; this is 
a more conservative amino acid substitution, changing the length of the side chain but 
retaining the ability to form hydrogen bonds. Glu16 was also mutated into a histidine, 
producing Glu16His, changing the charge of the amino acid side chain from negative to 
positive. Similarly, Lys63 was also mutated into a glutamate, producing Lys63Glu, also 
changing the charge of the amino acid side chain, but this time from positive to negative. 
Asp124 was mutated into a glutamine, producing Asp124Gln and changing the amino acid 
side chain from a negative charge to an uncharged functionality. As shown in Figure 3.16, 
Arg40 forms a salt bridge with Asp124 and removing the charge at this position will 
disturb the ability of these residues to form a salt bridge.  
Figure 3.15. Sequence alignment of N-acetylmannosamine-6-phosphate 2-epimerase from five gram 
positive species of bacteria. Conserved residues are highlighted in green, while those that may be involved 
in catalysis are highlighted in black. Species include S. aureus, Clostridium botulinum, C. perfringens, 
Streptococcus pneumoniae and S. pyogenes. Conserved residues are numbered according to S. aureus. The 
alignment was generated using ClustalW (Larkin et al., 2007) (http:// www.genome.jp/tools/clustalw/). 






































































S. aureus       ------------MLPHGLIVSCQALPDEPLHS--SFIMSKMALAAYEGGAVGIRANTKED [46]
C. botulinum    ---------MLKKIKGKLIVSCQALEDEPLHS--SFIMGRMALAAKMGGAVAIRAQSIED [49]
C. perfringens  ---------MLDVVKGNLIVSCQALSDEPLHS--SFIMGRMAIAAKQGGAAAIRAQGVND [49]
S. pneumoniae   -----METKKIKNLKGQIIVSCQALEGEPLYTPNGGVMPLLAKAAFQAGAKGIRANSVRD [55]
S. pyogenes     MPDKPTKEKLMEQLKGGIIVSCQALPGEPLYSETGGIMPLMAKAAQEAGAVGIRANSVRD [60]
         
S. aureus       ILAIKETVDLPVIGIVKRDYDHSDVFITATSKEVDELIESQCEVIALDATLQQRPK-ETL [105]
C. botulinum    INEIKKVTGLPVIGLVKRNYDDSDIYITPTKKEIDELLTTQCEIIALDATMRKRPNNEQL [109]
C. perfringens  INEIKEVTKLPIIGIIKRNYDDSEIYITPTMKEVDELLKTDCEMIALDATKRKRPNGENV [109]
S. pneumoniae   ISEIKEEVDLPIIGIIKRDYDGFEPFISATMKELDELVSEGVDILALDCTNRSRPGYDNI [115]
S. pyogenes     IKEIQAITDLPIIGIIKKDYPPQEPFITATMTEVDQLAALNIAVIAMDCTKRDRHDGLDI [120]
       
S. aureus       DELVSYIRTHAPNVEIMADIATVEEAKNAARLGFDYIGTTLHGYTSYTQGQLLYQNDFQF [165]
C. botulinum    KNLIDYIHENNK--LVMGDISTEAEGINAEILGVDCISTTLSGYTEYST--QGNSVDIQI [165]
C. perfringens  KDLVDAIHAKGR--LAMADISTLEEGIEAEKLGFDCVSTTLSGYTPYSK--QSNSVDFEL [165]
S. pneumoniae   TDFIHDIKVKYPNQLLMADISTFEEGKVAAESGVDFVGTTLSGYTPYSP--KKDNPDFEL [173]
S. pyogenes     ASFIRQVKEKYPNQLLMADISTFDEGLVAHQAGIDFVGTTLSGYTPYSR--QEAGPDVAL [178]
S. aureus       LKDVLQSVDAKVIAEGNVITPDMYKRVMDLGVHCSVVGGAITRPKEITKRFVQIMED--- [222]
C. botulinum    IKNLSSRLYIPVIGEGKISTPHDLQEVFKAGAYSAVVGGAITRPQLITEKFVKAINFEGR [225]
C. perfringens  LEELVKTVKIPVICEGRINTPEELKKALDLGAYSAVVGGAITRPQQITKRFTDIL----- [220]
S. pneumoniae   VERLVKELDVPVIAEGRISTPEQARKMLDLGAYAVVVGGAITRPLEIAKKFIEVV----- [228]
S. pyogenes     IEALCKAG-IAVIAEGKIHSPEEAKKINDLGVAGIVVGGAITRPKEIAERFIEALKS--- [234]
     
S. aureus       --- [222]
C. botulinum    YEL [228]
C. perfringens  --- [220]
S. pneumoniae   --- [228]
S. pyogenes     --- [234]
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Figure 3.16. Potential active site residues of MRSA N-acetylmannosamine-6-phosphate 2-epimerase. 
A stereo view of the MRSA N-acetylmannosamine-6-phosphate 2-epimerase monomer. The positions of the 
potential catalytic residues, Gln11, Glu16, Arg40, Lys63, Asp124 and Arg208 are shown. The bonds forming 
the salt bridge between Arg40 and Asp124 are indicated by black dashes. 
3.2.9 Michaelis-Menten kinetic analysis of mutant MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes 
Because enzyme kinetics in combination with mutagenesis can be used to test hypothetical 
catalytic mechanisms (Cornish-Bowden, 2004), kinetic analysis was used to assess 
whether the residues identified in Section 3.2.8 are important for catalysis in MRSA N-
acetylmannosamine-6-phosphate 2-epimerase. For each of the mutant MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes, initial rate data was collected 
using the multi-enzyme coupled assay that I developed and then fitted to the Michaelis-
Menten kinetic model. All kinetic parameters for the wild type and mutated variants of 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase can be found in Table 3.4. 
Because the kinetic assay could not be performed above 5 mM of N-acetylmannosamine-6-
phosphate, the kinetic parameters for the mutant N-acetylmannosamine-6-phosphate 2-
epimerase enzymes that displayed some activity carry significant error. However, it is 
likely that the catalytic activity of these mutants is exceptionally low compared to the wild 
type and the KM parameters are significantly higher than 5 mM. 
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Table 3.4. Kinetic parameters for wild type and mutated variants of MRSA N-acetylmannosamine-











Wild type 101.7 ± 1.4 41.6 ± 0.6 100 0.7 ± 0.03 
Gln11Ala 11.5 ± 2.1 4.7 ± 0.9 11.3 10.3 ± 2.6 
Gln11Ser 33.1 ± 20.1 13.5 ± 8.2 32.5 50.0 ± 32.9 
Glu16Ala 2.9 ± 0.1 1.2 ± 0.1 2.9 20.1 ± 0.7 
Glu16His 10.7 ± 9.6 4.4 ± 3.9 10.6 93 ± 87 
Arg40Ala NA - - - 
Lys63Ala NA - - - 
Lys63Glu NA - - - 
Asp124Ala NA - - - 
Asp124Gln NA - - - 
Arg208Ala 3.4 ± 1.8 1.4 ± 0.7 3.4 31.6 ± 19.0 
*NA denotes no activity 
The Arg40Ala, Lys63Ala, Lys63Glu, Asp124Ala and Asp124Gln mutated variants showed 
no detectable activity, even at enzyme concentrations at least 103 times more than that of 
the wild type MRSA N-acetylmannosamine-6-phosphate 2-epimerase. The Gln11Ala, 
Gln11Ser, Glu16Ala, Glu16His and Arg208 mutated variants displayed catalytic 
efficiencies that were significantly lower than the wild type MRSA N-acetylmannosamine-
6-phosphate 2-epimerase (Figure 3.17). Thus, Lys63 and the salt bridge formed between 
Arg40 and Asp124 are essential for the chemistry catalysed by MRSA N-
acetylmannosamine-6-phosphate 2-epimerase, while Gln11, Glu16 and Arg208 also 
participate in catalysis. Participation may involve substrate binding and/or binding to the 






Figure 3.17. Michaelis-Menten kinetic analysis of the mutant MRSA N-acetylmannosamine-6-
phosphate 2-epimerase enzymes. Data were fitted to the Michaelis-Menten equation. (A) Gln11Ala had an 
R2 value of 0.98. (B) Gln11Ser had an R2 value of 0.99. (C) Glu16Ala had an R2 value of 0.96. (D) Glu16His 
had an R2 value of 0.99. (E) Arg208Ala had an R2 value of 0.98. (F) The wild type (black) combined with 
the mutated variants. 
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3.2.10 The structure and proposed mechanism of C. 
perfringens N-acetylmannosamine-6-phosphate 2-epimerase 
A structural and 1H NMR kinetic analysis of wild type and mutated variants of C. 
perfringens N-acetylmannosamine-6-phosphate 2-epimerase was published during the 
course of this study (Pelissier et al., 2014). As described in Section 3.1.3, this analysis 
identified residues that are essential for catalysis by C. perfringens N-acetylmannosamine-
6-phosphate 2-epimerase. Of the residues identified in Section 3.2.8, Lys66, Arg43 and 
Asp126 of C. perfringens N-acetylmannosamine-6-phosphate 2-epimerase (equivalent to 
Lys63, Arg40 and Asp124 in MRSA N-acetylmannosamine-6-phosphate 2-epimerase) 
were determined to be crucial for the chemistry catalysed by this enzyme. In addition, 
Glu180 (also equivalent to Glu180 in MRSA N-acetylmannosamine-6-phosphate 2-
epimerase) was shown to participate in catalysis, but was not essential, as a Glu180Ala 
mutant displayed 1.9% activity relative to the wild type. 
The structures of C. perfringens N-acetylmanosamine-6-phosphate with bound product (N-
acetylglucosamine-6-phosphate) and a Lys66Ala mutant with unprocessed substrate (N-
acetylmannosamine-6-phosphate) demonstrate that Lys66 is ideally positioned relative to 
the C2 site of epimerisation. In addition, the guanidium group of Arg43, which forms a salt 
bridge with Asp126, is proposed to hydrogen bond with the O1 aldehyde of the substrate at 
position C1. As described in Section 3.1.3, Pelissier et al. (2014) propose that 
epimerisation occurs via a deprotonation/reprotonation mechanism, whereby the conserved 
lysine abstracts a proton from the C2 position of N-acetylmannosamine-6-phosphate and 
generates the epimer by reprotonation of the opposite face. To do this, the lysine is 
proposed to act as a Brønsted base on one stereoisomer and an acid catalyst on the other. 
3.2.11 Alternative catalytic mechanisms 
A critical analysis of the C. pefringens N-acetylmannosamine-6-phosphate 2-epimerase 
structures reveals that the proposed deprotonation/reprotonation is an unlikely catalytic 
mechanism. The active sites of my MRSA N-acetylmannosamine-6-phosphate 2-epimerase 
structure and the N-acetylmannosamine-6-phosphate and N-acetylglucosamine-6-
phosphate bound structures of C. perfringens N-acetylmannosamine-6-phosphate 2-
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epimerase are overlaid in Figure 3.18. Interestingly, the side chain orientations of all 
catalytically important residues are highly similar in each structure. Thus, the active site of 
N-acetylmannosamine-6-phosphate 2-epimerase enzymes is analogous between organisms 
and the presence of substrate or product does not affect the overall tertiary structure of the 
enzyme.  
As depicted in Figure 3.18, Lys63 (numbered according to MRSA N-acetylmannosamine-
6-phosphate 2-epimerase) is in a position where it could abstract a proton from the C2 
position of one stereoisomer, but it is not clear as to how it could reprotonate the opposite 
face to generate the epimer. For this to happen, Pelissier et al. (2014) suggest that 
following proton abstraction, the negatively charged intermediate must perform a 45 to 50° 
motion around the C2-C3 bond. In addition, the Gln11 side chain (equivalent to Gln14 in 
C. perfringens N-acetylmannosamine-6-phosphate 2-epimerase), adopts two alternate 
conformations in the C. perfringens N-acetylglucosamine-6-phosphate bound structure. In 
one of these conformations, there is room for the lysine to move, which would 
accommodate the aldehyde group of the intermediate following rotation of the C2-C3 
bond. If the lysine did move to this position, then Pelissier et al. (2014) propose that 
reprotonation on the opposite face could occur. However, no conformational rotamers of 
this lysine were identified in any structure, so this notion is contentious. 
Figure 3.18. Alignment of the active sites. A stereo view of the MRSA N-acetylmannosamine-6-phosphate 
2-epimerase (green), N-acetylglucosamine-6-phosphate bound C. perfringens N-acetylmannosamine-6-
phosphate 2-epimerase (blue) and N-acetylmannosamine-6-phosphate bound C. perfringens N-
acetylmannosamine-6-phosphate 2-epimerase (magenta) active sites reveal a conserved architecture. The 
bonds that could be formed with N-acetylmannosamine-6-phosphate (yellow) and N-acetylglucosamine-6-
phosphate (orange), as well as the salt bridge between Arg40 and Asp124 are indicated by black dashes. 
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Alternatively, I suggest that the catalytic mechanism of N-acetylmannosamine-6-phosphate 
2-epimerase enzymes may occur via the formation of a Schiff base or a proton 
displacement mechanism mediated by the substrate. For C. perfringens and MRSA N-
acetylmannosamine-6-phosphate 2-epimerase enzymes, the highly conserved and 
catalytically essential Lys63 residue is in a position where epimerisation via Schiff base 
formation is possible (Figure 3.19 A). This type of mechanism is already seen for N-
acetylneuraminate lyase (Chapter Two) (Lawrence et al., 1997). The presence of a Schiff 
base during catalysis by MRSA N-acetylmannosamine-6-phosphate 2-epimerase can be 
tested with sodium borohydride, which will reduce the Schiff base and inactivate the 
enzyme (Section 3.2.12). 
For a proton displacement mechanism mediated by the substrate (Figure 3.19 B), I propose 
that Lys63 deprotonates the C2 site and the substrate hydroxyl on the C5 position mediates 
reprotonation of the opposite face, which is ideally placed to do so and is activated by 
Glu180. Importantly, this does not require the substrate and the active site to reorient, 
which is consistent with the available crystallographic data. It is unclear whether the 
mechanism is concerted, or whether it involves an intermediate enolate form. But because 
the salt bridge formed between Arg40 and Asp124 is crucial for catalysis by both C. 
perfringens and MRSA N-acetylmannosamine-6-phosphate 2-epimerase, the formation of 
an enolate intermediate is highly likely. As shown in Figure 3.18, the guanidium of Arg40 
can hydrogen bond with the O1 of the aldehyde at the C1 position, which would be 
negatively charged in an enolate intermediate and thus stabilised by Arg40. We note that 
the structure of the substrate and product in the active site is ideally orientated for this 
mechanism and the Lys63 residues and the substrate C5 hydroxyl are perfectly placed to 






Figure 3.19.     Alternative catalytic strategies for N-acetylmannosamine-6-phosphate 2-epimerase. (A) 
Epimerisation may occur via the formation of a Schiff base with Lys63. (B) Epimerisation may occur via a 
proton displacement mechanism mediated by the substrate. 
3.2.12 Sodium borohydride reduction of wild type MRSA N-
acetylmannosamine-6-phosphate 2-epimerase 
The formation of a Schiff base during catalysis can be observed by enzyme inactivation in 
the presence of sodium borohydride and substrate. For N-acetylneuraminate enzymes and 
dihydrodipicolinate synthase enzymes, Schiff base formation between a highly conserved 
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lysine residue and pyruvate is reduced by sodium borohydride, resulting in complete 
inactivation of the enzyme (Mirwaldt et al., 1995; Lawrence et al., 1997). To test the 
hypothesis that the mechanistic strategy employed by MRSA N-acetylmannosamine-6-
phosphate 2-epimerase may involve the formation of a Schiff base, the enzyme was 
incubated in the presence of sodium borohydride and its substrate, N-acetylmannosamine-
6-phosphate (Chapter Six, Section 6.9.3). As a positive control, MRSA N-
acetylneuraminate lyase (Chapter Two) was also incubated in the presence of sodium 
borohydride and its substrate, sialic acid. To determine whether MRSA N-
acetylmannosamine-6-phosphate 2-epimerase and MRSA N-acetylneuraminate lyase were 
inactivated in the presence of sodium borohydride, their respective coupled enzyme assays 
were used to assess activity. As shown in Table 3.5, MRSA N-acetylmannosamine-6-
phosphate was not inactivated in the presence of sodium borohydride and substrate. But 
complete inactivation of MRSA N-acetylneuraminate lyase was seen in the presence of 
sodium borohydride and substrate. Thus, the mechanistic strategy of MRSA N-
acetylmannosamine-6-phosphate 2-epimerase is unlikely to involve the formation of a 
Schiff base. 
Table 3.5. Sodium borohydride reduction of MRSA N-acetylmannosamine-6-phosphate 2-epimerase 
and MRSA N-acetylneuraminate lyase. Enzymatic activity of these enzymes without sodium borohydride 
and following treatment with sodium borohydride in the presence of substrate.  
Enzyme condition Activity (%) 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase  100 
MRSA N-acetylmannosamine-6-phosphate 2-epimerase + sodium borohydride + substrate 97 
MRSA N-acetylneuraminate lyase 100 







This chapter investigates the structure and catalytic mechanism of N-acetylmannosamine-
6-phosphate 2-epimerase from MRSA. A new assay is developed that reports N-
acetylmannosamine-6-phosphate 2-epimerase activity in real time, which will be 
convenient and suitable for testing inhibitors, unlike the current NMR assay that is 
reported (Pelissier et al., 2014). The assay provides high quality rate data to determine 
kinetic constants for MRSA N-acetylmannosamine-6-phosphate 2-epimerase, which 
suggest that this enzyme has a much higher affinity for its substrate compared to C. 
perfringens N-acetylmannosmaine-6-phosphate 2-epimerase. 
Solution studies suggested that the enzyme is dimeric in its quaternary architecture, 
consistent with the crystal structure. Although there were some structures for N-
acetylmannosamine-6-phosphate 2-epimerase enzymes solved prior to this thesis, these 
were not published in the literature and no details were available regarding how these 
enzymes catalyse their chemistry. Using sequence analysis and my crystal structure, amino 
acids were identified that may be involved in catalysis. These residues were mutated and 
their participation in catalysis was assessed by kinetic experiments. During the course of 
this thesis, a structural analysis and an 1H NMR based kinetic analysis of C. perfringens N-
acetylmannosamine-6-phosphate 2-epimerase was published (Pelissier et al., 2014). From 
this data, the authors proposed that the catalytic mechanism employed by N-
acetylmannosamine-6-phosphate 2-epimerase enzymes involve deprotonation and 
reprotonation of the substrate by a catalytically essential lysine residue that acts both as a 
Brønsted base on one stereoisomer and an acid on the other. Although this type of 
mechanism is common mechanistic strategy for carbohydrate epimerases (Tanner, 2002), 
my critical analysis of their structures suggests that this mechanism is unlikely. For this to 
occur, the substrate and active site would have to reorient, for which there is no evidence.  
Alternatively, it is more likely that catalysis occurs via the formation of a Schiff base or a 
proton displacement mechanism mediated by the substrate. Both of which would utilise the 
catalytically essential lysine residue that is ideally positioned relative to the site of 
epimerisation on the substrate. The formation of a Schiff base was ruled out because 
treatment of the enzyme with sodium borohydride did not result in inactivation, which 
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would reduce a Schiff base. Instead, I propose that catalysis occurs via a proton 
displacement mechanism mediated by the substrate. In this mechanism, a proton is 
abstracted from the C2 site by the catalytically essential Lys63 residue and reprotonation 
of the opposite face is mediated by the substrate hydroxyl on the C5 position, which is 
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Towards a structural and functional 
understanding of bacterial sialic acid 
transporters 
The work presented in this chapter is collaborative with Dr Rosmarie Friemann’s group at 
the University of Gothenburg, Sweden. I visited the University of Gothenburg for a total of 
six months, three of which were funded by a fellowship from the European Molecular 
Biology Organisation (EMBO). I undertook the studies presented in this chapter with 
guidance from this group. Work that was independently completed by members of Dr 
Rosmarie Friemann’s group is mentioned here. Specifically, Elin Dunevall completed the 
cloning, overexpression trials and detergent screening for the Staphylococcus aureus and 
Proteus mirabilis sodium solute symporters for sialic acid transport. Together, we 
developed the purification protocol for the S. aureus transporter, which was later adapted 
by Elin for the P. mirabilis transporter. In collaboration with Professor Jeff Abramson’s 
group at the University of California, Los Angeles, Elin successfully crystallised the P. 
mirabilis transporter. At the Univeristy of Gothenburg, Elin Dunevall and Elin Claesson 
optimised these crystals and X-ray diffraction data was successfully collected. Together, 
we attempted to soak crystals with heavy metals, but this was unsuccessful. Instead, 
Weixiao Yuan Wahlgren, also from the University of Gothenburg, successfully obtained 
the phases by selenomethionine replacement and solved the structure. This structure is 





4.1.1 Sialic acid transporters 
Bacterial pathogens have evolved multiple mechanisms to transport sialic acid across the 
cytoplasmic membrane. These include an adenosine triphosphate (ATP) binding cassette 
transporter (ABC), a tripartite ATP independent periplasmic transporter (TRAP), a sugar 
proton symporter (NanT) and a sodium solute symporter (SSS). ABC transporters utilise 
the energy derived from ATP hydrolysis to drive the transport of a molecule across the 
membrane and are classed as primary transporters (Higgins, 1992). Conversely, TRAP, 
NanT and SSS transporters use an electrochemical gradient to facilitate transport and are 
classed as secondary transporters (Kelly & Thomas, 2001). This chapter is focused on the 
single component NanT and SSS sialic acid transporters. 
4.1.2 Sialic acid is transported using specific transporters 
A functional sialic acid transporter has proven to be essential for the uptake of sialic acid 
in a range of human bacterial pathogens, including Escherichia coli (Vimr & Troy, 1985), 
Haemophilus influenzae (Mulligan et al., 2012), S. aureus (Olson et al., 2013) and Vibrio 
cholerae (Severi et al., 2005). This means that without a specific sialic acid transporter, 
these organisms cannot acquire sialic acid from their surrounding environment. Moreover, 
inhibition of sialic acid transporters leads to non-virulence in animal models (Fuller et al., 
2000; Chang et al., 2004; Severi et al., 2007). Thus, developing novel molecules that target 
these transporters is a plausible mechanism for blocking pathogen colonisation.  
Whilst most bacterial pathogens possess only one type of sialic acid transporter, there are a 
few exceptions that are predicted to have two types from different families. For example, 
Photobacterium profundum has an SSS and a TRAP sialic acid transporter, Streptococcus 
pneumoniae has an SSS and a putative ABC sialic acid transporter and Salmonella enterica 
has an SSS and a NanT sialic acid transporter (Severi et al., 2010). It is not understood 
why these organisms produce more than one type of transporter, but it is possible that they 
import sialic acid derivatives that are known in biological contexts. 
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4.1.3 Sugar proton symporters for sialic acid transport 
The sugar proton symporter from E. coli, known as ‘NanT’, was the very first sialic acid 
transporter to be discovered (Vimr & Troy, 1985). NanT is a secondary transporter, 
meaning that it utilises an electrochemical gradient to facilitate the energetically 
unfavourable transport of sialic acid against its concentration gradient. NanT belongs to the 
major facilitator family and co-transports sialic acid and protons in the presence of a pH 
gradient (Martinez et al., 1995; Vimr et al., 2004; Severi et al., 2010; Mulligan et al., 
2012). Sodium, lithium or potassium ions play no part in sialic acid transport and have 
been demonstrated to have a slight inhibitory effect (Severi et al., 2010; Mulligan et al., 
2012). This may be a result of an increase in the ionic strength when these ions are present 
(Severi et al., 2010). The stoichiometry of protons required for the transport of sialic acid 
by NanT is yet to be confirmed. 
Most major facilitator superfamily transporters consist of 12 transmembrane helices, 
placing both the N- and the C-termini on the cytoplasmic side of the membrane (Huang et 
al., 2003). The transmembrane helices are split into two six-helix bundles that are 
connected by an extended central loop within the cytoplasm (Maiden et al., 1987). Based 
on deoxyribonucleic acid (DNA) sequence analysis, the E. coli NanT sialic acid transporter 
is predicted to consist of 14 transmembrane helices (Figure 4.1) (Martinez et al., 1995), as 
opposed to the usual 12 transmembrane helices found in the major facilitator superfamily 
(Huang et al., 2003). Twelve of the transmembrane helices that make up NanT contain 
residues that are conserved within the major facilitator superfamily (Vimr et al., 2004). 
However, two centrally located helices at position seven and eight (shaded black in Figure 
4.1) are neither observed nor conserved in other secondary transporters (Martinez et al., 
1995; Vimr et al., 2004). The amino acids comprising the seventh transmembrane helix are 
predicted to form an amphipathic helix, which may be important for the specificity of this 
protein towards sialic acid (Vimr et al., 2004). 
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Figure 4.1. A topological model of E. coli NanT. The white rectangles indicate the 12 transmembrane 
helices that are common within major facilitator superfamily members. The central black rectangles indicate 
those that are unique to E. coli NanT [adapted from Martinez et al. (1995)]. 
Unfortunately, our understanding of sugar proton symporters for sialic acid transport at a 
molecular level is limited to the E. coli NanT (Martinez et al., 1995). However, a number 
of crystal structures have been solved for other members of the major facilitator 
superfamily, the first of which includes the E. coli lactose permease sugar proton 
symporter (Abramson et al., 2003) and the glycerol-3-phosphate inorganic phosphate 
antiporter (Huang et al., 2003). The mechanism by which these transporters are proposed 
to move molecules across a membrane is described as the ‘rocker switch’ mechanism 
(Abramson et al., 2003; Huang et al., 2003). In this mechanism, the transporter alternates 
between an inward and outward facing conformation, where the substrate binding site is 
only accessible on one side of the membrane at any given time (Huang et al., 2003). 
4.1.4 Sodium solute symporters for sialic acid transport 
A more recently discovered type of sialic acid transporter, belonging to the SSS family of 
secondary transporters, was found in S. enterica (Severi et al., 2010). Orthologues of this 
transporter are encoded in the genome of a range of other clinically important human 
bacterial pathogens, including S. aureus, S. pneumoniae and Clostridium perfringens. 
Importantly, the genes encoding the SSS sialic acid transporters are widespread among 
both gram positive and gram negative species of bacteria, whereas other types of sialic acid 
transporters do not appear to be as widespread (Severi et al., 2010). In contrast to the NanT 
sialic acid transporters that utilise a proton gradient for symport, SSS transporters depend 
on a sodium gradient for the movement of sialic acid across the membrane (Wright et al., 





2004; Severi et al., 2010). It has long been established that cells maintain a low 
intracellular concentration of sodium ions by actively pumping them out of the cell. In 
combination with the negative potential of the membrane, this provides the driving force 
for the transport of solutes into the cell (Schultz & Curran, 1970; Faham et al., 2008).  
Currently, the only representative of the SSS family for which the crystal structure has 
been solved for is the sodium galactose transporter (SGLT) from Vibrio parahaemolyticus 
(Faham et al., 2008). The structure contains 14 transmembrane helices with an 
extracellular facing N- and C-termini. The transmembrane helices are arranged in an 
inward facing conformation made up of two inverted repeats, which each contain five 
transmembrane helices (Figure 4.2). Despite no sequence similarity, these 10 helices 
display a highly similar topology to the core structure of a sodium leucine symporter 
(LeuT) from Aquifex aeolicus, belonging to the neurotransmitter sodium symporter family 
(Yamashita et al., 2005). More recently, the crystal structure of a sodium hydantoin 
symporter (Mhp1) from Microbacterium liquefaciens (Weyand et al., 2008) and a sodium 
glycine betaine symporter (BetP) from Corynebacterium glutamicum (Ressl et al., 2009) 
have been shown to possess this same core architecture. These transporters belong to the 
nucleobase cation symport 1 family and the betaine/choline/carnitine transporter family, 
respectively. These transporters also do not share any sequence homology with one another 
or with the SSS family (Weyand et al., 2008; Abramson & Wright, 2009). Thus, this core 
domain of inverted topology represents a structural hallmark for many sodium driven 
transporters that is not based upon sequence (Yamashita et al., 2005; Weyand et al., 2008; 
Ressl et al., 2009). The additional non-conserved helices at the N- and C-termini of each 
respective structure may be important for function (Faham et al., 2008). 
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Figure 4.2. The topology derived from the structure of the sodium and galactose symporter from V. 
parahaemolyticus. The blue and red trapeziums represent the two inverted repeats made up of 
transmembrane helices 2 to 6 (blue) and 7 to 11 (red) [adapted from Faham et al. (2008)]. 
The stoichiometry of sodium ions required for transport by SSS transporters varies 
amongst family members. For some, two sodium ions are required for transport of their 
respective solute (Eskandari et al., 1997; Mackenzie et al., 1998), whereas others require 
only one sodium ion (Turk et al., 2000). Based on a comparison with the A. aeolicus LeuT 
structure (Yamashita et al., 2005), sequence analysis and mutational analysis, a putative 
sodium binding site was identified in the crystal structure of the V. parahaemolyticus 
SGLT. But unlike A. aeolicus LeuT, which possesses two sodium binding sites, a second 
site could not be detected in this symporter (Faham et al., 2008). 
4.1.5 A proposed mechanism of sodium and solute symport 
Similar to the mechanism described for the major facilitator superfamily transporters, 
sodium symporters also share an alternating access mechanism, where the transporter 
switches between an inward and an outward facing conformation for transport (Faham et 
al., 2008). Based on the observation that a common core structure is shared between V. 
parahaemolyticus SGLT, A. aeolicus LeuT, M. liquefaciens Mhp1 and C. glutamicum 
BetP and that the crystal structures reside in distinct conformations, a model for the 























Figure 4.3. The proposed mechanism of sodium and solute symport. In this model the starting 
conformation has no ligands bound (position 1). Following the binding of a sodium ion/ions from the 
extracellular side, an external gate (red) is opened so that the structure is in an outward facing and open 
conformation, with a pathway that leads to the substrate binding site (position 2). Upon substrate binding, the 
external gate closes causing the structure to be in an outward facing, but occluded conformation (position 3). 
The corresponding conversion from the outward to the inward facing occluded state occurs through an 
intermediate state, where the substrate is completely sequestered in the core of the transporter. The external 
pathway closes and there is no way that the substrate can exit (position 4). Once the inward facing 
conformation is formed, the internal pathway begins to open (position 5). Opening of the internal gate 
permits the sodium ion/ions and substrate to be released into the intracellular environment (position 6). The 
cycle is completed and the transporter returns to the starting conformation (position 1). It is important to note 
that the dwell time of ligands bound at any conformation is not known [adapted from Abramson and Wright 
(2009)]. 
The structure of M. liquefaciens Mhp1 has a sodium ion bound and is in an outward facing 
and open conformation (Weyand et al., 2008) (position 2, Figure 4.3). This provides 
evidence for a pathway that leads to the substrate binding site. The sodium and substrate 
bound structure of A. aeolicus LeuT is in an outward facing and occluded conformation, 
which suggests that upon substrate binding an external gate composed of hydrophobic 
residues is closed, which in turn occludes the substrate from the extracellular environment 
(Yamashita et al., 2005) (position 3, Figure 4.3). Yet, a pathway above the closed gate at 
the extracellular milieu remains intact. Next, it is proposed that the transporter will 
transition from an outward to an inward facing conformation through an intermediate state. 
This transition was discovered in the structure of C. glutamicum BetP (Ressl et al., 2009) 
(position 4, Figure 4.3). Finally, evidence for an inward facing and occluded conformation 
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al., 2008). Here, the substrate is bound in the centre of the core and occluded from the 
outside solutions by hydrophobic residues that form an intracellular gate. To date, there are 
no structures of an inward facing and open conformation devoid of substrate (position 6, 
Figure 4.3), so the nature of this transition cannot yet be inferred (Abramson & Wright, 
2009; Mulligan et al., 2011). 
4.1.6 Overview of this chapter 
To gain an understanding of how sialic acid is transported across the membrane of 
bacterial pathogens, this chapter explores three sialic acid transporter proteins, belonging 
to two distinct gene families. Data are presented for the NanT sialic acid transporter from 
Yersinia pestis and the SSS sialic acid transporters from S. aureus and P. mirabilis. 
Importantly, sialic acid transporters have proven to be essential for the survival of many 
harmful bacterial pathogens (Vimr & Troy, 1985; Chang et al., 2004; Severi et al., 2005; 
Severi et al., 2007; Mulligan et al., 2012; Olson et al., 2013). However, there are no 
structural data to explain how sialic acid transporters mediate transport across the 
membrane or how specificity is achieved. Thus, the overarching goal of this chapter is to 
gain structural data for these sialic acid transporters, which will underpin the design of 
future antibiotic drugs. 
This chapter presents the overexpression, solubilisation, purification and possible 
oligomeric states of these transporters; a significant step towards a structural and 
functional understanding of these difficult to work with proteins. In addition, a potential 
protein-protein interaction between the S. aureus SSS sialic acid transporter and N-
acetylneuraminate lyase is investigated. Excitingly, the P. mirabilis SSS sialic acid 
transporter was successfully crystallised and the structure was solved, which has provided 
insight into how this transporter mediates the movement of sialic acid across the 
membrane. Because sialic acid transporters are antibiotic drug targets, elucidating the 
structural basis for symport will greatly facilitate our understanding of the diseases caused 
by harmful bacterial pathogens and aid in the development of novel antibiotic drugs. 
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4.2 Results and discussion 
4.2.1 Cloning and overexpression of the Y. pestis NanT, S. 
aureus SSS and P. mirabilis SSS sialic acid transporters 
It is well recognised in the literature that the overexpression of membrane proteins is 
notoriously difficult (Gordon et al., 2008). When overexpressed in large quantities, the 
membrane protein will often become toxic to the overexpression host. This toxicity is most 
likely a result of saturating the membrane protein biogenesis/protein secretion machinery 
(Wagner et al., 2008; Schlegel et al., 2012). Tracking the production of folded and 
functional membrane protein throughout overexpression is difficult. Thus, the cloning and 
overexpression systems employed for such proteins need to be carefully thought out. A 
detailed account of the cloning and overexpression strategy used for the Y. pestis NanT, P. 
mirabilis SSS and S. aureus SSS sialic acid transporters is presented.  
The E. coli BL21(DE3) strain in combination with T7-ribonucleic acid (RNA) polymerase 
promoter (T7lac) based plasmids is the most commonly used platform to drive the 
overexpression of proteins (Schlegel et al., 2012). This is a bacteriophage T7-based 
pET/T7-RNA polymerase overexpression system, in which overexpression of the target 
protein is governed by T7-RNA polymerase. The isopropyl β-D-1-thiogalactopyranoside 
(IPTG) inducible lacUV5 promoter governs overexpression of this T7-RNA polymerase 
(Wanner et al., 1977). The rationale behind this system is that the more mRNA that is 
produced, the more protein that can be overexpressed (Schlegel et al., 2012).  
Recently, it has been shown that mutations in the lacUV5 promoter improve the 
overexpression of membrane proteins (Wagner et al., 2008). Because this promoter 
governs the overexpression of T7-RNA polymerase, which in turn governs the 
overexpression of a target protein, mutations in the lacUV5 promoter result in a 
simultaneous decrease in the production of T7-RNA polymerase and target protein. As a 
consequence, the risk of saturating the membrane protein biogenesis/protein secretion 
capacity upon overexpression is diminished (Schlegel et al., 2012). Thus, a modified strain 
of BL21(DE3), known as Lemo21(DE3), has been developed in which production of T7-
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RNA polymerase can be controlled by co-expression of its inhibitor, T7 lysozyme (Figure 
4.4). The gene encoding T7 lysozyme is located on a separate plasmid known as pLemo. 
The rhamnose (rhaBAD) promoter on this pLemo plasmid governs overexpression of T7 
lysozyme. This promoter is titratable, meaning that the amount of rhamnose that is added 
correlates with the amount of T7 lysozyme that is overexpressed (Giacalone et al., 2006). 
For instance, the more rhamnose that is added, the more T7 lysozyme that is overexpressed 
and the more T7-RNA polymerase that is inhibited, meaning that there is less T7-RNA 
polymerase available to induce the T7lac promoter for overexpression of the target protein 
and vice versa. As a consequence, Lemo21(DE3) is tunable and allows for conditions to be 
optimised for stable membrane protein overexpression (Schlegel et al., 2012).  
Figure 4.4. A schematic representation of Lemo21(DE3). The IPTG-inducible lacUV5 promoter 
governs overexpression of the chromosomally located gene that encodes T7-RNA polymerase. The gene 
encoding T7 lysozyme, an inhibitor of T7-RNA polymerase, is located on the pLemo plasmid. The titratable 
rhamnose promoter (rhaBAD) governs its overexpression. The gene encoding the target protein is located on 














Previously, it was shown that C-terminal green fluorescent protein (GFP) fusion tags could 
be used to monitor the overexpression of bacterial membrane proteins by measuring whole 
cell fluorescence (Drew et al., 2001). Membrane protein overexpression levels in the 
cytoplasmic membrane of E. coli can be estimated with a detection limit as low as 10 µg of 
protein per litre of bacterial culture (Drew et al., 2006; Hjelm et al., 2013). In addition, 
GFP fluorescence can also be detected by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), with a detection limit of less than 5 ng of GFP (Drew et al., 
2006). Importantly, the GFP is only fluorescent if the overexpressed protein is in a soluble 
form and correctly folded (Hjelm et al., 2013). Thus, this extremely stable GFP moiety can 
be easily visualised, allowing for both the amount and integrity of the target membrane 
protein to be monitored at any stage during the overexpression procedure. 
The gene encoding the Y. pestis NanT sialic acid transporter (Appendix) was commercially 
synthesised with XhoI and EcoRI restriction sites in the pMA-RQ cloning plasmid. The 
gene was excised from pMA-RQ and subcloned into the pWarf(−) expression plasmid to 
produce pWarf(−)NanT (Chapter Six, Section 6.4.6-6.4.8). Dr Rosmarie Friemann’s group 
supplied the genes encoding the S. aureus and P. mirabilis SSS sialic acid transporters 
(Appendix), also in the pWarf(−) expression plasmid. The pWarf(−) expression plasmid 
contains a C-terminal GFP fusion tag, allowing for the overexpression, detergent 
solubilisation and purification to be monitored through fluorescence (Drew et al., 2006; 
Hsieh et al., 2010). These constructs were transformed into E. coli Lemo21(DE3) bacterial 
cells and overexpression trials were performed in terrific broth (TB) medium (Chapter Six, 
Section 6.6.1). TB is an enriched medium that has been shown to achieve higher 
overexpression levels for membrane proteins (Hsieh et al., 2010). 
For overexpression of the Y. pestis NanT sialic acid transporter, a range of L-rhamnose 
concentrations (0-2000 µM) was tested, at various induction times and at either 25 or 30 
°C. In all conditions, the concentration of IPTG was kept constant, as this is not an 
important variable for overexpression in this system (Drew et al., 2006; Hsieh et al., 2010). 
Both whole cell fluorescence (Chapter Six, Section 6.6.4) and in-gel fluorescence by SDS-
PAGE (Chapter Six, Section 6.5.2) were utilised to analyse which overexpression 
condition is the most appropriate and to assess the integrity and quantification of 
overexpression. As shown in Figure 4.5 A, an overnight induction with 500 µM of L-
rhamnose had the highest whole cell fluorescence at both 25 and 30 °C. In addition, an 
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overnight induction with 250 µM L-rhamnose at 25 °C and 1000 µM L-rhamnose at 30 °C 
displayed the next highest whole cell fluorescence. All four of these overexpression 
conditions exhibited a relative fluorescent unit (RFU) above 15, which is the minimum 
overexpression criterion necessary for the isolation of a target protein in sufficient quantity 
for structural and functional studies (Hsieh et al., 2010). Although the NanT-GFP fusion 
fusion protein has a predicted molecular weight of 84.7 kDa, it appears at approximately 
50 kDa when subjected to in-gel fluorescence (Figure 4.5 B). This is often the case for 
membrane proteins when subjected to SDS-PAGE, but the reasons behind this 
phenomenon are not conclusively explained. It has been suggested that the binding of 
detergent molecules to the protein of interest may explain anomalous SDS-PAGE 
behaviour (Rath et al., 2009). The most intense fluorescent bands in Figure 4.5 B 
correspond to 500 µM of L-rhamnose at both 25 and 30 °C (lane 2 and lane 3, 
respectively), supporting the whole cell fluorescence data. Although a small amount of free 
GFP can be detected in the gel, the NanT-GFP fusion protein is present in adequate 
quantities for structural and functional studies. 
Figure 4.5. Whole cell fluorescence and in-gel fluorescence of the Y. pestis NanT sialic acid 
transporter in different overexpression conditions. (A) Whole cell fluorescence reported as RFU. The Y. 
pestis NanT sialic acid transporter was overexpressed at either 25 (magenta) or 30 °C (blue) overnight, 
across a range of L-rhamnose concentrations. The horizontal dashed line indicates 15 RFU, which is the 
minimum required for overexpression of a suitable amount of protein. (B) In-gel fluorescence of the Y. pestis 
NanT sialic acid transporter from the four best overexpression conditions determined by whole cell 
fluorescence. Lane 1, 250 µM L-rhamnose at 25 °C; lane 2, 500 µM L-rhamnose at 25 °C; lane 3, 500 µM L-
rhamnose at 30 °C; lane 4, 1000 µM L-rhamnose at 30 °C; lane 5, protein ladder (kDa). 
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From these results combined, the overexpression conditions selected for the Y. pestis NanT 
sialic acid transporter in Lemo21(DE3) bacterial cells consisted of an overnight induction 
with 500 µM of L-rhamnose, at a temperature of 25 °C. The conditions required for 
overexpression of the S. aureus SSS and P. mirabilis SSS sialic acid transporters were 
previously established as 100 µM and 250 µM of L-rhamnose, respectively. Culturing was 
also performed at a temperature of 25 °C and an overnight induction time. Following 
determination of the appropriate overexpression conditions, cells were cultured and protein 
was overexpressed at a larger scale. Cells were harvested and lysed (Chapter Six, Section 
6.6.2-6.6.3) and then the membranes were collected (Chapter Six, Section 6.6.5). 
4.2.2 Detergent screening of the Y. pestis NanT sialic acid 
transporter 
The development of membrane protein-GFP fusion methodology to monitor 
overexpression has been expanded to identify detergents that are suitable for both 
purification and crystallisation studies. Often, membrane protein crystallisation is only 
achieved in the presence of a detergent that maintains the protein in a monodisperse and 
stable state (Ostermeier & Michel, 1997), where the best detergent is usually one that 
mimics the proteins’ native membrane environment (Hsieh et al., 2010). Thus, successful 
crystallisation of a membrane protein is highly dependent upon the detergent that has been 
selected. Traditionally, detergent screening is a major obstacle for membrane protein 
crystallisation, as the methods require milligram quantities of already purified protein and 
are both time and resource intensive (Kawate & Gouaux, 2006; Hsieh et al., 2010). 
Fluorescence detection size exclusion chromatography (FSEC) has emerged as an efficient 
method for identifying an ideal detergent prior to extensive purification trials (Kawate & 
Gouaux, 2006). Because FSEC can exploit the unique fluorescence signal of GFP, crude 
samples can be subjected to this technique. This strategy involves solubilising the crude 
membrane collection with a variety of detergents and directly applying them to a size 
exclusion column equilibrated in a buffer containing the respective detergent (Chapter Six, 
Section 6.6.7). Here, the elution profile allows the monodispersity and stability of the 
membrane protein-GFP fusion to be monitored by fluorescence spectroscopy (Kawate & 
Gouaux, 2006; Hsieh et al., 2010). A monodisperse and stable protein will typically yield a 
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single and symmetrical peak, while a polydisperse and unstable protein will reveal multiple 
asymmetric peaks (Ricker & Sandoval, 1996; Kawate & Gouaux, 2006). 
Using FSEC, the Y. pestis NanT sialic acid transporter was subjected to a panel of six 
detergents, including n-dodecyl-N,N-dimethylamine-N-oxide (LDAO), n-octyl-β-D-
glucopyranoside (NG), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS), n-decyl-β-D-maltoside (DM), n-dodecyl-β-D-maltoside (DDM) and 2,2-
didecylpropane-1,3-bis-β-D-maltopyranoside (MNG), all of which are suitable for 
membrane protein structural and functional studies (Wiener, 2004; Prive, 2007; Chae et 
al., 2010). The Y. pestis NanT sialic acid transporter was unstable and formed aggregates 
in LDAO and NG complexes, identified by a single peak in the void volume of the FSEC 
profile. In CHAPS, the Y. pestis NanT sialic acid transporter did not form significant 
aggregates, but the elution profile was polydisperse (Figure 4.6 A). In DDM and MNG, the 
Y. pestis NanT sialic acid transporter displayed asymmetric and monodisperse peaks in the 
FSEC profile (Figure 4.6 B and C, respectively). However, there were no significant 
aggregates identified in the void volume of the column with this detergent. 
Figure 4.6. Detergent screening of the Y. pestis NanT sialic acid transporter using FSEC. NanT was 
solubilised in CHAPS (A), DDM (B) and MNG (C) and then subjected to analysis by FSEC. The traces in 
blue were obtained immediately after solubilisation, while the traces in magenta were obtained 48 h post 
solubilisation. The fluorescence traces were normalised between 0 and 1 for each detergent and time point. 
The void volume of the column is indicated with vertical dashes. 
To assess whether the Y. pestis NanT sialic acid transporter and detergent complexes with 
DDM, MNG and CHAPS were stable over time, the complexes were again evaluated by 
FSEC after 48 hours (Hsieh et al., 2010). After 48 hours, the FSEC profile of each of the Y. 
pestis NanT sialic acid transporter and detergent complexes remained similar. With 
CHAPS and DDM, the Y. pestis NanT sialic acid transporter showed a very small increase 
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in the amount of aggregate after 48 hours, depicted by a slight increase in the peak at the 
void volume of the column. In addition, a small amount of protein degradation was 
observed for the Y. pestis NanT sialic acid transporter with CHAPS, as indicated by an 
increase in the size of the second polydisperse peak seen in the chromatogram. The peak 
for the Y. pestis NanT sialic acid transporter with DDM shifted slightly after 48 hours, but 
overall, the protein and detergent complex remained stable and monodisperse over time. 
The Y. pestis NanT sialic acid transporter with MNG gave a similar elution profile after 48 
hours, meaning that this complex remained stable and monodisperse. In conclusion, both 
DDM and MNG are suitable detergents for the Y. pestis NanT sialic acid transporter, 
resulting in stable and monodisperse protein over time. DDM was selected for purification 
and additional experiments conducted with the Y. pestis NanT sialic acid transporter in this 
chapter. However, MNG should also be assessed for the purification and crystallisation of 
this protein. For the S. aureus and P. mirabilis SSS sialic acid transporters, DM and DDM 
were respectively selected as the best detergents. 
4.2.3 Purification of the Y. pestis NanT, S. aureus SSS and P. 
mirabilis SSS sialic acid transporters 
4.2.3.1  Immobilised metal affinity chromatography and protease cleavage 
A 6 × Histidine tag (His-tag) follows the C-terminal GFP fusion protein overexpressed 
with each transporter, meaning that each of these proteins could be subjected to 
immobilised metal affinity chromatography (IMAC) for purification (Chapter Six, Section 
6.6.8.3). Importantly, the fluorescence associated with the GFP fusion protein could be 
followed throughout each purification step. This allowed for the integrity and stability of 
the membrane protein to be monitored throughout purification trials. The purity and 
stability of each transporter following purification was assessed by SDS-PAGE and in-gel 
fluorescence. The purity of the Y. pestis NanT, S. aureus SSS and P. mirabilis SSS sialic 
acid transporters following purification by IMAC is depicted in Figure 4.7 A, B and C, 
respectively. For the S. aureus and P. mirabilis SSS sialic acid transporters, a band that is 
approximately double the size of the monomeric band is visualised by in-gel fluorescence; 
this may in fact be a higher oligomeric species. 
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Figure 4.7. SDS-PAGE and in-gel fluorescence analysis following IMAC. Fractions corresponding to 
elution of the Y. pestis NanT (A), S. aureus SSS (B) and P. mirabilis SSS (C) sialic acid transporters using 
IMAC. SDS-PAGE analysis is shown at the top, while the corresponding in-gel fluorescence analysis is 
shown at the bottom. The protein ladder (kDa) is located on the left of each SDS-PAGE gel. 
Because artificial fusion tags can sometimes have unfavourable effects in both structural 
and functional studies (Hsieh et al., 2010), the human rhinovirus 3C (HRV3C) protease 
cleavage site was engineered between the respective membrane protein and the C-terminal 
GFP fusion moiety with a His-tag. This allows for the GFP fusion moiety and His-tag to be 
removed. Following cleavage (Chapter Six, Section 6.6.8.5), the transporters were 
recovered by gravity flow chromatography (Chapter Six, Section 6.6.8.6), before being 
subjected to size exclusion chromatography. 
4.2.3.2 Size exclusion chromatography 
Size exclusion chromatography (Chapter Six, Section 6.6.8.7) was employed as the final 
purification step with overall yields presented in Table 4.1. Size exclusion chromatography 
of the Y. pestis NanT sialic acid transporter gave a 280 nm absorbance peak in the void 
volume of the column, indicating that considerable aggregation had occurred (Figure 4.8 
A). However, the peak corresponding to the elution of non-aggregated NanT is sharp and 
symmetrical in shape, suggesting that the non-aggregated sample is homogenous. 
Interestingly, the S. aureus SSS sialic acid transporter elutes across two distinct peaks, 
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Importantly, pooling the second peak corresponding to a smaller species (fractions at 11.5-
12.5 mL) and subjecting it to another round of size exclusion chromatography generates a 
similar profile. Consistent with IMAC, SDS-PAGE analysis displays a band that is 
approximately double the size of the monomeric band, providing further evidence for a 
higher oligomeric state. The P. mirabilis SSS sialic acid transporter elutes as a single peak, 
with a small shoulder at the beginning of elution making it slightly asymmetric (Figure 4.8 
C). Although not as distinctive as the double peak observed for the S. aureus SSS sialic 
acid transporter, SDS-PAGE analysis suggests that a higher oligomeric state might also be 
present for this transporter. The S. aureus SSS and P. mirabilis SSS sialic acid transporters 
do not display any significant aggregation. 
Table 4.1. Purification of each sialic acid transporter. The culture size, membrane yield and protein 








(mg/L of culture) 
Y. pestis NanT 4 7.3 0.8 0.2 
S. aureus SSS 3 5.1 1.9 0.6 
P. mirabilis SSS 12 20.7 10.6 0.9 
 
Figure 4.8. The purity of each sialic acid transporter determined by size exclusion chromatography 
and SDS-PAGE analysis. Chromatograms for size exclusion chromatography (top) and SDS-PAGE analysis 
(bottom) for the Y. pestis NanT (A), S. aureus SSS (B) and the P. mirabilis SSS (C) sialic acid transporters. 
For the S. aureus SSS sialic acid transporter, the red trace corresponds to re-injection of the second peak in 
black (fractions at 11.5-12.5 mL), which has been normalised to the original data. The areas of the 280 nm 
absorbance peaks that were analysed by SDS-PAGE are highlighted with an orange box. The protein ladder 
is located on the far left of each SDS-PAGE gel (kDa). 
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4.2.4 The oligomeric structure of the Y. pestis NanT, S. 
aureus SSS and P. mirabilis SSS sialic acid transporters 
Sedimentation velocity experiments by analytical ultracentrifugation were used to assess 
the oligomeric structure of the Y. pestis NanT, S. aureus SSS and the P. mirabilis SSS 
sialic acid transporters solvated in a detergent solution. Although challenging, this 
technique has been successful for membrane transporters in the past (Ebel, 2011). For the 
S. aureus SSS and P. mirabilis SSS sialic acid transporters, evidence for a higher 
oligomeric state was seen during purification; analytical ultracentrifugation can be used to 
further confirm this notion. A limitation of this work is that the detergent used for each 
protein is not accounted for in the density and viscosity calculations for the respective 
buffers. However, by fitting the data to a sedimentation coefficient distribution [c(s)] 
model, it is possible to qualitatively determine if the protein is a single species, or whether 
it self-associates in the detergent micelles. 
4.2.4.1 The solution structure of the Y. pestis NanT sialic acid transporter 
The c(s) distribution of the Y. pestis NanT sialic acid transporter shows a dominant single 
and symmetrical peak at a standardised sedimentation coefficient relative to water at 20 °C 
(s20,w) of 6.6, suggesting that the transporter is largely a single species in solution (Figure 
4.9 A). Importantly, most detergents do not absorb at 280 nm (Slotboom et al., 2008; Le 
Roy et al., 2015) and the peak seen corresponds to the protein. The distribution also shows 
evidence of contaminants from the purification, or aggregated protein, but this only 
represents 9% of the signal. SDS-PAGE analysis following size exclusion chromatography 
revealed that the sample is largely pure (Figure 4.8 A), but minor bands were still visible 
that could account for the presence of contaminants in the sample. However, considerable 
aggregation was also seen during size exclusion chromatography and it is more likely that 
the protein again began to aggregate during data collection in the analytical ultracentrifuge. 
The raw data and the fit generated by the c(s) model is plotted and the residuals are nearly 
randomly distributed around zero, indicating a good fit to the data (Figure 4.9 B) 
(Lebowitz et al., 2002). 
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Figure 4.9. Sedimentation velocity analysis of the Y. pestis NanT sialic acid transporter. The 
experiment was conducted at 0.5 mg/mL (8.9 µM) of freshly purified protein in 50 mM 2-amino-2-
hydroxymethyl-propane-1,3-diol (Tris), pH 8.0, 150 mM sodium chloride, 6% glycerol, 0.0174% DDM. 
Data were collected at 280 nm, 50 000 rpm and 4 °C. SEDNTERP was used to calculate the partial specific 
volume of the Y. pestis NanT sialic acid transporter (0.7505 g/ml), solvent density (1.0248 g/ml) and 
viscosity (0.0193 poise) (Laue et al., 1992). In these calculations, the detergent (DDM) was ignored. Data 
were fitted to a c(s) model at a resolution of 300 and a confidence level of 0.95 using SEDFIT (Schuck, 
2000). (A) The c(s) model plotted as a function of the s20,w. Data were fitted with an s value ranging 
between 1 and 10 S. (B) Absorbance at 280 nm plotted as a function of radial position (cm). The raw data are 
represented as open symbols (o) and overlaid with the non-linear least squares best fit. The residuals for this 
fit are shown above.  
4.2.4.2 The solution structure of the S. aureus SSS sialic acid transporter 
The c(s) distribution for S. aureus SSS sialic acid transporter resulted in two peaks with 
s20,w values of 6.4 and 8.8 S at 0.125 mg/mL (2.2 µM) (Figure 4.10 A). At 0.25 mg/mL 
(4.4 µM) these peaks were also observed as well as an additional peak at 11.4 S, 
suggesting that this transporter is forming a self-association in solution (Ebel, 2011; Le 
Roy et al., 2015). This data is consistent with the SDS-PAGE and in-gel fluorescence 
analysis following purification (Figures 4.7 and 4.8 B), where a species approximately 
twice the mass of the monomer is observed. Moreover, it is also consistent with the size 
exclusion chromatography data, which demonstrated that pooling and re-injecting the 
initial larger peak also gave rise to two peaks (Figure 4.8 B). In addition, because the size 
exclusion chromatography data resolved into these distinct peaks, the self-association may 
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have relatively slow rate constants for association (kon) and dissociation (koff). Although 
this analysis is only qualitative and the exact oligomeric structure cannot be determined, I 
propose that depending on the concentration, the S. aureus SSS sialic acid transporter is 
self-associating to form a monomer, dimer, trimer and so on in solution. The raw data and 
the fit generated by the c(s) model is plotted for the experiment conducted at 2.2 µM 
(Figure 4.10 B). The residuals are nearly randomly distributed around zero at both 
concentrations, indicating a good fit to the data (Figure 4.10 C) (Lebowitz et al., 2002). 
Figure 4.10. Sedimentation velocity analysis of the S. aureus SSS sialic acid transporter at two 
concentrations. The experiments were conducted at 2.2 µM (magenta) and 4.4 µM (blue) of freshly purified 
protein in 50 mM Tris, pH 8.0, 150 mM sodium chloride, 0.174% DM. Data were collected at 281 nm, 50 
000 rpm and 12 °C. SEDNTERP was used to calculate the partial specific volume of the S. aureus SSS sialic 
acid transporter (0.7568 g/ml), solvent density (1.0071 g/ml) and viscosity (0.0152 poise) (Laue et al., 1992). 
In these calculations, the detergent (DM) was ignored. Data were fitted to a c(s) model at a resolution of 300 
and a confidence level of 0.68 using SEDFIT (Schuck, 2000). (A) The c(s) model plotted as a function of the 
s20,w. Data were fitted with an s value ranging between 1 and 15 S. Data were normalised between 0 and 1. 
(B) Absorbance at 281 nm plotted as a function of radial position (cm) for the experiment conducted at 2.2 
µM. The raw data are represented as open symbols (o) and overlaid with the non-linear least squares best fit. 
(C) The residuals for the data collected at 2.2 µM are shown at the top and the residuals for the data collected 
at 4.4 µM fit are shown at the bottom.  
4.2.4.3 The solution structure of the P. mirabilis SSS sialic acid transporter 
Similar to the S. aureus SSS sialic acid transporter, the c(s) distribution for the P. mirabilis 
SSS sialic acid transporter resulted in two peaks with s20,w values of 7.5 and 10.6 (Figure 
4.11 A), suggesting that more than one oligomeric state is present in solution. I propose 
that the P. mirabilis SSS sialic acid transporter is self-associating to form a monomer and a 
dimer in solution. For this protein, multiple concentrations are yet to be tested to further 
confirm a self-association. Although SDS-PAGE and in-gel fluorescence analysis also 
B CA
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suggest that a higher oligomeric state is present (Figures 4.7 and 4.8 C), the size exclusion 
chromatography data (Figure 4.8 C) does not show two distinct peaks like the S. aureus 
SSS sialic acid transporter. This may suggest that if in a self-association, the kon and koff 
rates are fast for the P. mirabilis SSS sialic acid transporter. The raw data and the fit 
generated by the c(s) model is plotted and the residuals are nearly randomly distributed 
around zero, indicating a good fit to the data (Figure 4.11 B) (Lebowitz et al., 2002). 
Figure 4.11. Sedimentation velocity analysis of the P. mirabilis SSS sialic acid transporter. The 
experiment was conducted at 0.125 mg/mL (2.3 µM) of freshly purified protein in 50 mM Tris, pH 8.0, 150 
mM sodium chloride, 0.0174% DDM. Data were collected at 276 nm, 50 000 rpm and 12 °C. SEDNTERP 
was used to calculate the partial specific volume of the S. aureus SSS sialic acid transporter (0.7551 g/ml), 
solvent density (1.0071 g/ml) and viscosity (0.0127 poise) (Laue et al., 1992). In these calculations, the 
detergent (DDM) was ignored. Data were fitted to c(s) model at a resolution of 300 and a confidence level of 
0.68 using SEDFIT (Schuck, 2000). (A) The c(s) model plotted as a function of the s20,w. Data were fitted 
with an s value ranging between 1 and 15 S. (B) Absorbance at 276 nm plotted as a function of radial 
position (cm). The raw data are represented as open symbols (o) and overlaid with the non-linear least 
squares best fit. The residuals for this fit are also shown above. 
4.2.5 A potential protein-protein interaction 
It has long been established that proteins involved in the same metabolic pathway and 
more importantly the successive enzymes of a pathway, may be involved in protein-protein 
interactions with one another (Durek & Walther, 2008). Interestingly, the genes encoding 
the S. aureus SSS sialic acid transporter and N-acetylneuraminate lyase, the first and 
BA
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committed enzyme involved in the degradation of sialic acid, are co-transcribed. 
Moreover, as described in Chapter Two, N-acetylneuraminate lyase is tetrameric in 
structure and the four monomers associate by leaving a large pore in the central cavity of 
the tetramer, with the active sites oriented on the inward face of the pore. Thus, I 
hypothesised that a protein-protein interaction may occur between the SSS sialic acid 
transporter and N-acetylneuraminate lyase enzyme in S. aureus. To test this hypothesis, 
analytical ultracentrifugation was employed, which is a powerful tool for characterisation 
of protein-protein interactions (Rivas et al., 1999). Sedimentation velocity analysis was 
performed with the S. aureus SSS sialic acid transporter and methicillin-resistant S. aureus 
(MRSA) N-acetylneuraminate lyase (Chapter Two) separately and combined. The data 
were fitted to a c(s) distribution (Figure 4.12). 
Figure 4.12. Sedimentation velocity analysis of the P. mirabilis SSS sialic acid transporter and MRSA  
N-acetylneuraminate lyase, to assay a possible protein-protein interaction. The experiment was 
conducted at 0.5 mg/mL (8.8 µM) of the S. aureus SSS sialic acid transporter in one cell, 0.5 mg/mL (15.1 
µM) of MRSA N-acetylneuraminate lyase in a second cell and a combined final concentration of 0.5 mg/mL 
(11.9 µM) of both proteins in a third cell. Proteins were freshly purified in 50 mM Tris, pH 8.0, 150 mM 
sodium chloride, 0.0174% DM. Data were collected at 289 nm, 50 000 rpm and 12 °C. SEDNTERP was 
used to calculate the partial specific volume of the S. aureus SSS sialic acid transporter (0.7568 g/ml), 
MRSA N-acetylneuraminate lyase (0.7384 g/ml) and combined (0.7492 g/ml). SEDNTERP was also used to 
calculate the solvent density (1.0243 g/ml) and viscosity (0.0152 poise) (Laue et al., 1992). In these 
calculations, the detergent (DM) was ignored. (A) The c(s) model plotted as a function of the s20,w. Data 
were fitted with an s value ranging between 1 and 12 S. Data were normalised between 0 and 1. (B) The 
residuals for the MRSA N-acetylneuraminate lyase data (top), the S. aureus SSS sialic acid transporter data 
(middle) and the interaction data (bottom) are shown. 
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The c(s) distribution for the S. aureus SSS sialic acid transporter reveals two distinct peaks 
with s20,w values of 6.1 and 8.3. MRSA N-acetylneuraminate lyase reveals a dominant 
species with a s20,w of 7.5. In addition, a smaller peak with a s20,w value of 4.2 is apparent; 
this smaller peak is not seen for MRSA N-acetylneuraminate lyase in Chapter Two, 
Section 2.2.2.2, and could be a result of detergent destabilising the tetrameric structure. 
Excitingly, the c(s) distribution for both the S. aureus SSS sialic acid transporter and 
MRSA N-acetylneuraminate lyase combined reveals three peaks. Two with s20,w values of 
6.4 and 8.5, respectively, which are consistent with merged c(s) distributions that were 
observed for the proteins alone. A third peak is observed with a s20,w value of 11.9, which 
is not accounted for in the c(s) distributions of these proteins alone. This provides evidence 
for a protein-protein interaction between one of the S. aureus SSS sialic acid transporter 
species and MRSA N-acetylneuraminate lyase. I propose that this interaction would occur 
at the intracellular face of the membrane and allow for the immediate degradation of sialic 
acid upon entering the cell (Figure 4.13). 
Figure 4.13. The proposed protein-protein interaction between the S. aureus SSS sialic acid 
transporter and the N-acetylneuraminate lyase enzyme. Based on the observation that the genes encoding 
these two proteins are co-transcribed in S. aureus, the shape of N-acetylneuraminate lyase and the 







4.2.6 Crystallisation studies 
Crystallisation studies were performed using both vapour diffusion and lipidic cubic phase 
methods. For the Y. pestis NanT sialic acid transporter, no crystals were obtained in lipidic 
cubic phase, but unusual crystals were obtained in the MemGold™ vapour diffusion 
screen. These crystals took at least two weeks to form at 20 °C. Interestingly, they 
appeared spherical in shape and were birefringent; a result of fine needles growing in all 
directions from an initial nucleation event. Crystals from conditions D7 (100 mM 
potassium chloride, 100 mM Tris, pH 8.5, 39% v/v polyethylene glycol 400) and E4 (20 
mM Tris, pH 7.5; 22% v/v polyethylene glycol 500 monomethyl ether) diffracted to 
approximately 18 Å (Figure 4.14 A and B, respectively). These crystallisation conditions 
should be optimised in the future. In addition, because the Y. pestis NanT sialic acid 
transporter is also stable in MNG, purification and crystallisation with this detergent 
should also be tested. Unfortunately, no crystals were obtained for the S. aureus SSS sialic 
acid transporter in both vapour diffusion and lipidic cubic phase methods. Because 
crystallisation of a membrane protein is highly dependent upon the detergent that is being 
used (Hsieh et al., 2010), other detergents should be trialled.  
Figure 4.14. Crystals and X-ray diffraction of the Y. pestis NanT sialic acid transporter. (A) Crystals 
and diffraction from condition D7 of the MemGold™ screen. (B) Crystals and diffraction from condition E4 
of the MemGold™ screen. The black ring indicates diffraction to approximately 18 Å in both A and B. 
A B
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The P. mirabilis SSS sialic acid transporter was successfully crystallised using vapour 
diffusion methods. These crystals were optimised and an X-ray diffraction data set was 
collected to 2.1 Å. Molecular replacement was attempted with the only other structural 
representative of the SSS family, the V. parahaemolyticus sodium and galactose symporter 
(PDB entry 3dh4, 26% identity) (Faham et al., 2008), but the phases could not be obtained 
in this way. Instead, the phases were successfully obtained by selenomethionine 
replacement. An X-ray diffraction dataset was collected to 1.95 Å and the structure could 
then be solved. 
4.2.7 The structure of the P. mirabilis SSS sialic acid 
transporter 
The structure of the P. mirabilis SSS sialic acid transporter was solved in complex with 
sialic acid and sodium ions bound to the protein, which was added to the crystallisation 
conditions to stabilise the protein and to provide molecular information on ligand binding. 
The structure was solved in the space group C2 and the unit cell parameters are a =130.6, b 
= 98.1, c = 54.8, α = 90.0, β = 92.2, γ = 90.0.  The structure and refinement statistics are 
shown in Table 4.2.  
Table 4.2. Structure and refinement statistics for the P. mirabilis SSS sialic acid transporter. The 
structure was solved in the space group C2 and there is one monomer in the asymmetric unit. 
Statistics P. mirabilis SSS sialic acid transporter 
residual factor (Rfactor) (%) 20.1 
free Rfactor (Rfree) (%) 24.5 




root-mean-square deviation (rmsd)  
bonds (Å) 0.017 
angles (°) 1.082 




Ramachandran plot, residues (%)  
favoured region 97.25 
allowed region 2.33 
disallowed region 0.42 
	 140 
4.2.7.1 The crystal lattice demonstrates how oligomerisation may occur 
The asymmetric unit contains one monomer, which makes contacts with other monomers 
at three distinct interfaces in the crystal lattice. The monomers either side of the interfaces 
A and B are arranged in the opposite orientation to one another, whereas the monomers 
either side of interface C are arranged in the same orientation (Figure 4.15). As evidenced 
during purification and analytical ultracentrifugation, the P. mirabilis SSS sialic acid 
transporter may form a self-associated higher oligomer. Oligomerisation is likely to occur 
between monomers at interface C, which buries approximately 500 Å (approximately 3%) 
of the surface accessible area. Although the exact oligomeric structure of this transporter 
cannot be confirmed, this interface could enable dimerisation between monomers, or even 
higher order oligomeric structures. Moreover, whether such oligomers form in the cell 
membrane is unknown and it is possible that the oligomerisation seen in the solution based 
experiments are an artefact of the experimental conditions. 
Figure 4.15. Crystal packing of the P. mirabilis SSS sialic acid transporter. The monomer of the P. 
mirabilis SSS sialic acid transporter interacts with other monomers across three distinct interfaces. These 
interfaces are labelled A, B and C, respectively. A self-association may be enabled across interface C. 
If oligomerisation does occur, it is unclear what role it plays in the function of the P. 
mirabilis SSS sialic acid transporter. The interface is not extensive and it is largely made 
up of hydrophobic interactions, including contacts with a single DDM detergent molecule 
(Figure 4.16). Although this interface does not play a direct role in sialic acid or sodium 
ion interactions (Section 4.2.7.3), dimerisation may influence the positioning of the helices 
involved in these interactions and their ligand binding sites. 
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Figure 4.16. Oligomerisation of the P. mirabilis SSS sialic acid transporter. Dimerisation, or even higher 
order oligomers, may occur across interface C, which is made up of predominantly hydrophobic residues 
(grey sticks) and contacts with a DDM detergent molecule (yellow). 
4.2.7.2 The overall structural topology 
The structure contains 13 transmembrane helices (Tm1 to Tm13) with an N-terminus 
located in the periplasm and a C-terminus located in the cytoplasm. As depicted in Figure 
4.17 A, the structural core is formed from two inverted repeats of five transmembrane 
helices each (Tm2 to Tm6 and Tm7 to Tm11). This topological arrangement is similar to 
that of the V. parahaemolyticus SGLT (Faham et al., 2008), A. aeolicus LeuT (Yamashita 
et al., 2005), M. liquefaciens Mhp1 (Weyand et al., 2008) and C. glutamicum BetP (Ressl 
et al., 2009) sodium symporters, which do not share sequence similarities. The overall 
structure of the P. mirabilis SSS sialic acid transporter is composed of five transmembrane 
helices that contribute interactions for ligand selectivity (Tm2, Tm3, Tm4, Tm6 and Tm9) 
(Figure 4.17 B), while the remaining helices are probably important for stabilisation of the 
structure. Numerous transmembrane helices (Tm2, Tm3, Tm5, Tm7 and Tm11) display a 
break in the helical structure at positions that are within the membrane bilayer. It has 
previously been noted that discontinuous helices are often important for function and have 
mechanistic implications for a range of co-transporters (Faham et al., 2008). 
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Figure 4.17. The structure of the P. mirabilis SSS sialic acid transporter. (A) The topology of the 
transporter represents an inverted repeat made up of five transmembrane helices in each. The blue and red 
trapeziums represent the inverted topology of Tm2 to Tm6 and Tm7 to Tm11, respectively. The inverted 
repeats are related by an apparent two-fold symmetry around an axis through the centre of the membrane 
plane. A superposition of Tm2 to Tm6 (blue) with Tm7 to Tm11 (red) yields an r.m.s.d. of 6.6 Å for 75 Cα 
atoms. (B) A side-view of the transporter in the membrane plane is shown on the left. While the 
transmembrane helices involved in ligand binding are depicted in colour on the right. Sialic acid is shown as 






































































4.2.7.3 The sialic acid and sodium binding sites 
The sialic acid binding site in the P. mirabilis SSS sialic acid transporter forms side chain 
interactions with residues located on Tm2i, Tm2e, Tm3e and Tm4. Specifically, sialic acid 
forms hydrogen bonds with Thr58, Ser60, Thr63, Gln82 and Arg135 located on these 
central helices (Figure 4.18 A). Interestingly, the stoichiometry of sodium ions required for 
transport by SSS transporters varies amongst family members. For example, the structures 
of A. aeolicus LeuT (Yamashita et al., 2005) and C. glutamicum BetP (Ressl et al., 2009) 
elucidated two sodium binding sites for these transporters, whereas the structures of V. 
parahaemolyticus SGLT (Faham et al., 2008) and M. liquefaciens Mhp1 (Weyand et al., 
2008) possess only one sodium binding site. The P. mirabilis SSS sialic acid transporter 
structure comprises two sodium binding sites (Figure 4.18 B), one of which forms 
hydrogen bonds with Ala56, Leu59, Ala339, Ser342 and Ser343 and the other forms 
hydrogen bonds with Thr57, Asp182, Ser342, Ser345 and Ser346. Importantly, the 
residues involved in binding sialic acid and sodium ions are highly conserved with SSS 
sialic acid transporters from a range of other organisms (Figure 4.19). Thus, it is likely that 
SSS sialic acid transporters utilise two sodium ions for the transport of sialic acid across 
the membrane. 
Figure 4.18. The ligand binding sites of the P. mirabilis SSS sialic acid transporter. (A) Sialic acid 
(purple sticks) forms hydrogen bonds with Thr58, Thr63, Ser60, Gln82 and Arg135. (B) One sodium ion 
(blue spheres) forms hydrogen bonds with Ala56, Leu59, Ala339, Ser342 and Ser343 while the other forms 























Figure 4.19. Sequence alignment of SSS sialic acid transporters from five species of bacteria. Species 
include P. mirabilis, S. enterica, P. profundum, Vibrio fischeri and S. aureus. Strictly conserved residues are 
highlighted in magenta, conservation between residues with strongly similar properties are shown in blue and 
conservation between residues with weakly similar properties are shown in orange. Residues implicated in 
sialic acid and sodium binding in the P. mirabilis SSS sialic acid transporter are highlighted with a black box 
and numbered according to this transporter. 
P. mirabilis    MQLHDFGFINYAVLFGYLAAMLLVGVYFSKRQ-KTADDYFRGGGRVPGWAAGVSVFATTL [59]
S. enterica     MITHSFGIVNYLVLFGYLLAMMLVGVYFSRRQ-KTADDYFRGGGRVPGWAAGVSVFATTL [59]
P. profundum    MEMHAFGTLNYIVLLVYLTAVMLVGVYFAKRQ-KSVDDYFKAGGRIPGWAAGISVFATTL [59]
V. fischeri     MEAQSFGTLNYIALFAYLGAIMAVGVYFARRQ-KSADDYFKAGGRIPGWAAGFSVFATTL [59]
S. aureus       MKEVGFGTLNWVAVIIYLLAMLFIGVYFTKRASQSTNSFFTASGRLPSWVVGFSIYATTL [60]
                
P. mirabilis    SSITFMSIPAKAYTSDWTFIIGQYLAIAILPLVFYFYIPFFRKLKITSAYEYLEARFDVR [119]
S. enterica     SSITFMSIPAKAFTSDWTFIIGQYLAIAILPLVFYFYIPFFRKLKVTSAYEYLEARFDVR [119]
P. profundum    SSITFMSIPAKAYTGDWTFLIGQYVAILILPFVFLYYIPFFRKLNLTSAYEYLEKRFDVK [119]
V. fischeri     SSITFMSIPAKAYTSDWTFLIGQYVAIAILPIVFWFYIPFFRKLNLTSVYEYLERRFDVR [119]
S. aureus       SAITFMSTPEKAFLTDWSYIAGNIAIVAIIPLLIYFYVPFFKKLKVTSAYEYLEARFGPS [120]
                  
P. mirabilis    SRLFASLSFMLFHIGRVAIITYLTVLALRPFMGIDPVVLIVLISLLCIIYTWMGGIEGVI [179]
S. enterica     CRLFASMSFMLFHIGRIAIITFLTVLALRPFIAIDPVILVLLISVMCIIYTWMGGIEGVI [179]
P. profundum    MRLFASISFMLFHIGRVAIITYLTALALIPFVDINPLTIVFLIGVLCIVYTFMGGIEGVI [179]
V. fischeri     MRLFGSISFMLFHIGRIAIVTYLTALALMPFIDISPLMIVFLIGVLCIIYTFLGGIEGVI [179]
S. aureus       IRVIGSLLFVVYHLGRVAIVIYLPTLAITSVSDMNPYIVASLVGLLCILYTFLGGFEGVV [180]
                 
P. mirabilis    WTDVIQGLLLSGGAVLIFIMICFKVDGGISEIFTTTAQADKFFPTTQWRWSWTDSTIPVL [239]
S. enterica     WTDVIQGLLLSGSAILIFIVICLKVQGGIDEIFTVTQQADKFFPATQFHWSWTESTVPVL [239]
P. profundum    WTDVIQGIMLSLAAVLIFIVICFNVDGGVTEVFSMSAEADKYFPKEQFAWSWTEGTIPVL [239]
V. fischeri     WTDVIQGVMLSVAAILIFVVICFNVDGGIVEVFSMSNQADKYFPAEQFSWSWTDSTIPVL [239]
S. aureus       WSDFIQGVILLGGALVIIILGVMNIKGGFGTVFADAIEHKKLISADNWKLNTAAAAIPII [240]
                
P. mirabilis    MIGFLFANIQQFTASQDVVQRYIVTDSIKETKRTLITNAKLVAIIPIFFFAIGSALFVYY [299]
S. enterica     MIGFLFANIQQFTASQDVVQRYIVTDSIEETKKTLLTNAKLVAVIPVFFFAIGSALFVYY [299]
P. profundum    VIGFLFASLQQFTASQDVVQRYIVTDSIEETKKALITNAKLVAVIPIFFFAVGSALYAYY [299]
V. fischeri     MIGFFFASLQQFTASQDVVQRYIVTDNIDETKKALITNAKLVACVPIFFFAVGSALFAYY [299]
S. aureus       FLGNIFNNLYQYTASQDVVQRYQASDSLKETNKSLWTNGILALISAPLFYGMGTMLYSFY [300]
                
P. mirabilis    QQNPSLLPAGFNTGGILPLFIVTEMPIGIAGLIIAAIFAAAQSSISSSLNSISSCFNSDI [359]
S. enterica     QQHPQLLPAGFNTGGILPLFVVTEMPVGIAGLIIAAIFAAAQSSISSSLNSISSCFNSDI [359]
P. profundum    TQNPGLLPGDFNTGGILPFFVISEMPAGVAGLIIAAIFAASQSSISSSLNSISACFTSDI [359]
V. fischeri     TQNPELLPENFNTGGILPFYVISQMPVGVAGLIIAAIFAASQSSISSSLNSIAACFTSDI [359]
S. aureus       -AHEAVLPKGFNTSSVVPYFILTEMPPFVAGLLIAAIFAAAQSTISSSLNSISACISIDI [359]
                  
P. mirabilis    YTRLSKSSPSPEQKMKVAKLVIIVAGIFSSLAAIWLVLSDEAEIWDAFNSLIGLMGGPMT [419]
S. enterica     YQRLSHKKRTPENRMKIAKLVILVAGLISSAASVWLVMADESEIWDAFNSLIGLMGGPMT [419]
P. profundum    YHRLG-GETSPKKTMFVARSVIVVAGVFGVIASTYLIMSNESELWDAFNSLIGLMGGPMT [418]
V. fischeri     YEKVS-KNPTSEQKLRIGRTLTVVAGLLGVVASTYLIMSNESEIWDAFNSLLGLMGGPMT [418]
S. aureus       KQRFFGKGSE-RHEVNFARFIIIIAGIFGFGMSLYLIASNSNDLWDLFLFVTGLFGVPLA [418]
                         
P. mirabilis    GLFMLGIFVKRANAGSAVVGIIVSIIAVLAARYGSDLNFFFYGVIGSMSVVIAGTITAPL [479]
S. enterica     GLFMLGIFFKRANAGSAVLGIIISVITVLGARYATDLNFFFYGVIGSLSVVISGVIFAPL [479]
P. profundum    GLFMLGVFVKRANANSALAGVVASVIAILWVRAATDLNFFFYGVIGTLMVVFVGYITAPL [480]
V. fischeri     GLFMLGIFVRRANANSALLGVVASIATVLWVRSATDLNFFFYGVIGTLMVVIVGYLTAPM [480]
S. aureus       GVFAVGIFTKRTNTFGVICGLILGIIFAYVYNGVGKGNSPFYVSTISFTVAFVFAYILSF [480]
      
  
P. mirabilis    FAPAKQLSLDDSETSEN--------------- [496]
S. enterica     FAPAPPLTLDEKPEPKVTL------------- [498]
P. profundum    FKQNAVEDVNKSLIAQNS-------------- [496]
V. fischeri     FKNNLNSDEIDELSATKEKRSTTAEKA----- [505]
S. aureus       IVPSKHKKDITGLTIFEKDKPSTYISKTATKK [510]


















4.2.7.4 A novel outward facing and open conformation 
Importantly, our structure of the P. mirabilis SSS sialic acid transporter is in an outward 
facing and open conformation, with both sodium and sialic acid bound. The sialic acid sits 
within a cavity that is open on the periplasmic side, which can be seen at the top of the 
structure (Figure 4.20). The A. aeolicus LeuT sodium and leucine symporter is also in an 
outward facing conformation with both sodium and substrate bound (Yamashita et al., 
2005). However, this structure is in an occluded conformation and the substrate is 
sandwiched between residues that form an extracellular and intracellular gate.  
Figure 4.20. A surface representation of the P. mirabilis SSS sialic acid transporter. A view from the 
top of the P. mirabilis SSS sialic acid transporter (left) shows sialic acid (purple spheres) binding in a deep 
cavity that will be open and exposed on the extracellular side. The bottom of the transporter (right) is 
completely occluded so that the sialic acid will not be transported into the intracellular environment in this 
outward facing conformation. 
Based on the proposed mechanism of sodium and solute symport described in Section 
4.1.5, our outward facing and open conformation does not currently fit within this model. 
Elucidation of this novel conformation (Figure 4.21) suggests that substrate binding does 
not directly result in closure of the gate and it is mediated in some other way; which may 
be related to oligomerisation, given that the protein has been demonstrated to have variable 




Figure 4.21. A new proposed mechanism of sodium and solute transport. A novel conformation 
(position 2a) has been discovered in the P. mirabilis SSS sialic acid transporter structure. Here, the substrate 

















This chapter explored three sialic acid transporter proteins from two distinct gene families, 
with the aim of gathering structural data to elucidate how sialic acid is transported across 
the cytoplasmic membrane of bacterial pathogens. Because membrane proteins are 
notoriously difficult to work with, the Y. pestis NanT, S. aureus SSS and P. mirabilis SSS 
sialic acid transporters were explored in parallel. Following the development of a 
successful overexpression, solubilisation and purification protocol for these proteins, the 
oligomeric structure of these transporter proteins was investigated. The Y. pestis NanT 
sialic acid transporter is shown to be a single species in solution, while the S. aureus and P. 
mirabilis SSS sialic acid transporters are shown to form a self-association in solution. In 
addition, a possible protein-protein interaction was demonstrated for the S. aureus SSS 
sialic acid transporter and MRSA N-acetylneuraminate lyase enzyme. 
The structure of the P. mirabilis SSS sialic acid was solved collaboratively, which is the 
first known sialic acid transporter structure to be solved. The packing of the crystal lattice 
demonstrates a possible interface by which oligomerisation may occur. The structure was 
solved in complex with sialic acid and two sodium ions, providing insight into how this 
transporter mediates the movement of sialic acid across the membrane. In addition, the 
structure presents an outward facing and open conformation, a novel conformation among 
other sodium and solute symporters. These data present a significant step forward in the 
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Conclusions and future perspectives 
5.1 Overview 
Using enzymology and structural biology, this thesis explores the import and degradation 
of sialic acid in clinically important human bacterial pathogens. Bacterial pathogens that 
reside in heavily sialylated environments have evolved to degrade host-derived sialic acid 
as a nutrient source (Vimr et al., 2004; Almagro-Moreno & Boyd, 2009). First, this 
requires sialic acid to be imported into the bacterial cell across the cytoplasmic membrane. 
Two types of sialic acid transporters were investigated in this thesis, including the sugar 
cation symporter (NanT) from Yersinia pestis and the sodium solute symporters (SSS) 
from Staphylococcus aureus and Proteus mirabilis (Figure 5.1 A). Following the import of 
sialic acid, the catalytic degradation pathway is initiated. The first enzyme [N-
acetylneuraminate lyase (Figure 5.1 B)] and the third enzyme [N-acetylmannosamine-6-
phosphate 2-epimerase (Figure 5.1 C)] of this pathway from methicillin-resistant S. aureus 
(MRSA) were also explored. Given the importance of the import and degradation of sialic 
acid for the colonisation and persistence of bacterial pathogens, surprisingly little structural 
or functional data exists to explain how bacteria import and degrade sialic acids. This 
knowledge will inform inhibitor design and improve our understanding of this important, 
but poorly understood, metabolic pathway. 
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Figure 5.1. The aspects of sialic acid import and degradation investigated in this thesis. (A) Sialic acid 
import by the NanT and SSS sialic acid transporters. (B) N-acetylneuraminate lyase is the first enzyme of the 
sialic acid degradation pathway. (C) N-acetylmannosamine-6-phosphate 2-epimerase is the third enzyme of 
the sialic acid degradation pathway. 
5.1.1 The first reported structure of a sialic acid transporter 
Before sialic acid is degraded as a nutrient source, it must be transported across the 
cytoplasmic membrane and into the bacterial cell. Sialic acid is a negatively charged 
molecule that cannot diffuse freely through the membrane bilayer. A dedicated sialic acid 
transporter protein embedded within the cytoplasmic membrane is responsible for its 
import (Severi et al., 2007). In gram negative bacterial pathogens, such as Y. pestis and P. 
mirabilis, sialic acid must first cross the outer cell membrane into the periplasmic space 
before it can be imported into the bacterial cell. This process is not well understood, 
however, a sialic acid inducible porin has recently been implicated in the transport of sialic 






























2009). How this is achieved and the apparent processing of sialic acid in the periplasmic 
space represents an exciting avenue for future research. 
However, the biggest gap in the field is the paucity of structural or functional data that 
explains how sialic acid transporters mediate the movement of sialic acid across the 
cytoplasmic membrane, despite a number of groups addressing this issue around the world. 
The lack of progress is probably because membrane proteins are notoriously challenging to 
work with (Gordon et al., 2008). To address this, protocols to overexpress, solubilise and 
purify the Y. pestis NanT, S. aureus SSS and P. mirabilis SSS sialic acid transporters were 
developed. This is a significant step towards understanding the structure and function of 
these transporters. 
Following purification, solution studies demonstrate the oligomeric structure of these sialic 
acid transporters for the first time. Size exclusion chromatography and sedimentation 
velocity experiments using analytical ultracentrifugation demonstrate that the Y. pestis 
NanT sialic acid transporter exists as a single species in solution, whereas the S. aureus 
and P. mirabilis SSS sialic acid transporters appear to be in a self-association. Based on the 
sedimentation velocity data, it is likely that these transporters exist in a monomer-dimer 
equilibrium, although higher oligomeric structures were also observed for the S. aureus 
SSS sialic acid transporter. Nonetheless, these exciting results suggest that oligomerisation 
may be important for the SSS sialic acid transporters in nature. 
Excitingly, this thesis reports the structure of the P. mirabilis SSS sialic acid transporter, 
which is the first known sialic acid transporter structure to be solved. The structure was 
solved in complex with sialic acid and two sodium ions, providing insight into how this 
transporter mediates the movement of sialic acid across the membrane and the 
stoichiometry of sodium ions required for transport. Importantly, the structure was solved 
in an outward facing and open conformation, which is a novel conformation among other 
sodium symporters, that does not currently fit within the proposed mechanism of solute 
transport. This new conformation suggests that occlusion of the substrate is not a result of 
substrate binding and it may be mediated in some other way. Given that the SSS sialic acid 
transporters display variable oligomeric states, perhaps occlusion of the substrate is related 
to oligomerisation. 
	 156 
The Y. pestis NanT sialic acid transporter was successfully crystallised and X-ray 
diffraction data was collected to 18 Å. However, attempts to crystallise the S. aureus SSS 
sialic acid transporter were unsuccessful. Because the crystallisation of a membrane 
protein is highly dependent upon the detergent selected (Ostermeier & Michel, 1997; Hsieh 
et al., 2010), purification and crystallisation of these proteins with alternate detergents 
should be trialled in the future. 
5.1.2 Structure, function and inhibition of MRSA N-
acetylneuraminate lyase 
A detailed structural and functional investigation of MRSA N-acetylneuraminate lyase is 
reported. The kinetic constants reported here for MRSA N-acetylneuraminate lyase may be 
the first for this enzyme, given the ambiguity of a previous kinetic analysis of S. aureus N-
acetylneuraminate lyase (Timms et al., 2013; Daniels et al., 2014). The values obtained are 
consistent with the literature for other N-acetylneuraminate lyase enzymes. Despite there 
being a considerable amount of work already published for N-acetylneuraminate lyase 
enzymes, sedimentation velocity experiments demonstrate for the first time that MRSA N-
acetylneuraminate lyase is tetrameric in solution. This is consistent with other N-
acetylneuraminate lyase enzymes studied to date and it is also consistent with the crystal 
structure. 
A kinetic and structural analysis of MRSA N-acetylneuraminate lyase with a successful 
first generation inhibitor is presented and the mechanism of inhibition is elucidated for this 
enzyme. This molecule was demonstrated to be a strong inhibitor for MRSA N-
acetylneuraminate lyase, which is interesting since it has only been shown to be a moderate 
inhibitor of Clostridium perfringens N-acetylneuraminate lyase, suggesting that there is 
species-specific inhibition of MRSA N-acetylneuraminate lyase. Variable inhibition 
between N-acetylneuraminate lyase enzymes from different organisms may be a result of 
altered binding modes within respective active sites that is driven by protein dynamics. By 
comparing the inhibitor bound structure of MRSA N-acetylneuraminate lyase with a 
previously published structure of Haemophilus influenzae N-acetylneuraminate lyase, also 
in complex with this inhibitor (Barbosa et al., 2000), altered binding became apparent. 
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Currently, the only known regulation for the transporters and enzymes involved in sialic 
acid degradation is at the transcription level, by a DNA binding protein known as the 
nanRepressor. Surprisingly, N-acetylneuraminate lyase does not appear to be allosterically 
regulated, despite the related dihydrodipicolinate synthase enzymes being allosterically 
regulated by a downstream product, lysine (Blickling et al., 1997).  
Given that the concentration of free sialic acid in a cell is extremely low (Sillanaukee et 
al., 1999), the substrate binding affinities determined here and in the literature for N-
acetylneuraminate lyase enzymes are surprisingly low (3.2-4.1 mM). Thus, I suggest that 
N-acetylneuraminate lyase is regulated at the level of substrate concentration; that is, since 
the concentration of sialic acid is much lower relative to the Michaelis-Menten constant 
(KM), small changes in concentration will have a large effect on flux. 
My results suggest that MRSA N-acetylneuraminate lyase and the S. aureus SSS sialic acid 
transporter interact at the cytoplasmic membrane. It has long been established that proteins 
involved in the same metabolic pathway and more importantly the successive enzymes of 
the pathway, are often involved in protein-protein interactions with one another by forming 
either transient or permanent multi-enzyme complexes (Durek & Walther, 2008). 
Sedimentation velocity experiments provided evidence for the formation of a protein-
protein interaction between the S. aureus SSS sialic acid transporter and MRSA N-
acetylneuraminate lyase. If a protein-protein interaction does occur between a sialic acid 
transporter and N-acetylneuraminate lyase, the low substrate binding affinity may be an 
emergent property of this interaction. 
5.1.3 A novel mechanism for carbohydrate epimerase 
enzymes 
Currently, there is very little structural and functional information available for N-
acetylmannosamine-6-phosphate 2-epimerase enzymes. To address this, the structure and 
catalytic mechanism of N-aetylmannosamine-6-phosphate 2-epimerase from MRSA was 
investigated using structural biology and enzymology. A multi-enzyme coupled assay was 
developed that reports N-acetylmannosamine-6-phosphate 2-epimerase activity. Using this 
assay, the first kinetic constants were reported for MRSA N-acetylmannosamine-6-
	 158 
phosphate 2-epimerase. This enzyme was shown to have a considerably higher binding 
affinity for its substrate than the C. perfringens N-acetylmannosamine-6-phosphate 2-
epimerase, which was kinetically analysed by proton nuclear magnetic resonance 
spectroscopy (1H NMR). These types of assays are both time consuming and resource 
intensive (Exnowitz et al., 2012), whereas the multi-enzyme coupled assay presents a 
convenient method to assay activity in real time, which will be suitable for testing 
inhibitors in the future. 
For the first time, solution studies demonstrated that MRSA N-acetylmannosamine-6-
phosphate 2-epimerase is dimeric, which was confirmed by the crystal structure. Using the 
structure of MRSA N-acetylmannosamine-6-phosphate 2-epimerase in combination with 
sequence analysis, residues that may be important for catalysis were probed and their 
involvement in catalysis was assessed by mutagenesis and kinetic analysis. During the 
course of this thesis, it was proposed that N-acetylmannosamine-6-phosphate 2-epimerase 
enzymes catalyse their chemistry via a deprotonation/reprotonation mechanism (Pelissier 
et al., 2014). However, there was not sufficient experimental evidence to prove this notion.  
Instead, I propose that catalysis occurs via a proton displacement mechanism mediated by 
the substrate. Importantly, a role for the residues that were deemed catalytically essential 
by kinetic analysis can be predicted if catalysis does occur in this way. This type of 
mechanism appears to be a novel strategy for carbohydrate epimerase enzymes. The usual 
mechanisms employed by such epimerases include deprotonation/reprotonation, formation 
of a transient keto intermediate, carbon-carbon bond cleavage, nucleotide elimination and 
mutarotation (Allard et al., 2001; Samuel & Tanner, 2002). To confirm this hypothesis, 
crystallographic analyses of the wild type and mutant enzymes with substrate and 
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6.1 Experimental reagents 
6.1.1 Chemical reagents 
Sialic acid and N-acetylmannosamine-6-phosphate were purchased from Carbosynth. 
Chemicals used for media preparation were sourced from Invitrogen. All antibiotics were 
purchased from Sigma-Aldrich. Roche supplied cOmplete™, ethylenediaminetetraacetic 
acid (EDTA) free protease inhibitor tablets. 
6.1.2 Biological reagents 
Plasmids containing genes of interest were purchased from GenScript or GeneArt and 
oligonucleotides were ordered from Integrated DNA Technologies. Chemically competent 
Escherichia coli XL-1 Blue cells were obtained from Agilent Technologies. Chemically 
competent E. coli BL21(DE3) and Lemo21(DE3) cells were obtained from New England 
Biolabs. All restriction enzymes and Phusion® high fidelity deoxyribonucleic acid (DNA) 
polymerase were also obtained from New England Biolabs. TOPO TA® cloning kits and 
the PureLink® quick plasmid miniprep kits were purchased from Invitrogen. Agarose gel 
DNA extraction kits were supplied by Roche. Ligase was purchased from Takara. DNase I, 
Bovine serum albumin, glucose-6-phosphate dehydrogenase, lactate dehydrogenase and 
phosphoglucoisomerase were obtained from Sigma-Aldrich. Equipment required for 
sodium dodecyl sulfate polyacrylamide gel electrophoresis, including sample buffers, 
running buffers, precast gels and protein molecular weight markers were supplied by 
Thermofisher Scientific. Bioline supplied DNA markers and sample loading buffer. 
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SimplyBlue™ SafeStain was purchased from Invitrogen. SYPRO® Orange and SYBR® 
Safe DNA gel stain were also purchased from Invitrogen. Bradford dye reagent was 
supplied by BioRad. 
6.1.3 General materials 
All prepacked chromatography columns were purchased in various sizes from GE 
Healthcare. Nickel nitrilotriacetic acid (Ni-NTA) agarose resin and empty Poly-Prep® 
columns for gravity flow chromatography were obtained from Qiagen and BioRad, 
respectively. BioRad also supplied 96 well thick wall plates, while Sigma-Aldrich supplied 
Corning® 96 well clear bottom plates. Crystallisation screens that were used in-house and 
solutions used for cryo protection were purchased from Molecular Dimensions. Hampton 
Research supplied crystallisation plates and cryo loops. All solutions were made with 
Millipore purified water, which is referred to as MilliQ water throughout this thesis. 
Solutions that required filtering were passed through 0.22 µm syringe filters obtained from 
Millipore. Proteins were concentrated using appropriate molecular weight cut off spin 










6.2 General methods 
6.2.1 Bioinformatic analyses of nucleotide and amino acid 
sequences 
A variety of bioinformatic tools were employed throughout this study. For the 
determination of nucleotide and amino acid sequences, the basic local alignment search 
tool (BLAST) programs ‘BLASTn’ and ‘BLASTp’ were utilised respectively (Karlin & 
Altschul, 1990; Karlin & Altschul, 1993) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Multiple 
sequence alignments to investigate the similarity between nucleotide and amino acid 
sequences were conducted using the programs MUSCLE (Edgar, 2004), or ClustalW 
(Larkin et al., 2007) (http:// www.genome.jp/tools/clustalw/), with manual editing. 
6.2.2 Centrifugation 
All centrifugation was carried out using a Sorvall™ RC 6 Plus Centrifuge (Thermo 
Scientific), Eppendorf™ Centrifuge 5810 R (Thermo Fisher Scientific) or an Optima™ L-
90K Ultracentrifuge (Beckman Coulter). 
6.2.3 Measurement of molecular weight 
The masses of purified proteins were analysed on a MaXis 3G quadrople time of flight 
mass spectrometer, equipped with an electrospray ionisation source (Bruker Daltonics). 
Proteins to be measured were diluted to approximately 1 mg/mL with MilliQ water. 
6.2.4 pH measurement 
The pH of solutions was measured at room temperature using an Ultrabasic Benchtop pH 
meter (Denver Instrument). The pH was adjusted using 1 M or 10 M hydrochloric acid if 
the pH of the solution needed to be decreased, or 1 M or 10 M sodium hydroxide if the pH 
of the solution needed to be increased. 
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6.2.5 Sterilisation of media and equipment 
Media for bacterial cultures and the equipment to be used with it was autoclaved at 121 °C 
for 15 minutes. Solutions were prepared with MilliQ water. If the solution could not be 
autoclaved, it was filtered through a 0.22 µm syringe filter. Standard aseptic technique was 

















6.3.1 Bacterial strains 
Five bacterial strains of E. coli were routinely used in the research conducted for this 
thesis; these are described in Table 2.1. 
Table 2.1 Bacterial strains used throughout this thesis. The strain name and associated genotype is 
presented. 
E. coli strain Genotype 
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
Lemo21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS/pLemo(CamR) 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
pLemo = pACYC184-PrhaBAD-lysY 
XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
6.3.2 Antibiotics 
Antibiotic stock solutions were prepared at a 1 000 × concentration and sterilised through a 
0.22 µm syringe filter before storage at -20 °C. Antibiotics used for bacterial selection 
throughout this thesis are listed in Table  2.2. 
Table 2.2 Antibiotics used for bacterial selection. The stock concentration, working concentration and 
solvent used to dissolve the respective antibiotic are listed. 





ampicillin 100 100 MilliQ water 
kanamycin 50 50 MilliQ water 





6.3.3.1 Luria bertani medium 
Luria bertani (LB) base was purchased in a ready to use powdered form. For every 1 L of 
LB medium to be prepared, 20 g of LB base was added to MilliQ water. This was sterilised 
by autoclaving and then stored at room temperature. 
6.3.3.2 LB agar 
LB base and agar were mixed and prepared in MilliQ water. For every 1 L of LB agar 
prepared, 20 g of LB base, and 12 g of agar were added to MilliQ water. This was 
sterilised by autoclaving. Molten media was supplemented with the appropriate antibiotic, 
mixed by gentle swirling and poured into sterile petri dishes in either a laminar flow hood, 
or close to a flame. Plates were left to set in sterile conditions before being sealed with 
parafilm and stored at 4 °C for up to two weeks. 
6.3.3.3 Terrific broth medium 
Terrific broth (TB) medium was prepared by the addition of 12 g tryptone, 24 g yeast 
extract, 2.2 g monopotassium phosphate, 9.4 g dipotassium phosphate, and 4 mL glycerol 
to every 1 L of MilliQ water. The pH was adjusted to 7.2 with 10 M sodium hydroxide. TB 
medium was sterilised by autoclaving prior to being stored at room temperature. 
6.3.3.4 Super optimal broth with catabolite repression medium 
Super optimal broth with catabolite repression (SOC) medium was prepared by the 
addition of 20 g tryptone, 5 g yeast extract, 0.5 g sodium chloride, 2.5 mL 1 M potassium 
chloride, 10 mL 1 M magnesium chloride, 10 mL 1 M magnesium sulfate, and 20 mL 
glucose to every 1 L of MilliQ water. The pH was adjusted to 7.0 with 10 M sodium 
hydroxide. SOC medium was sterilised by autoclaving and then aliquoted into 1.7 mL 
eppendorf tubes in either a laminar flow hood, or close to a flame. SOC medium was 
stored at -20 °C. 
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6.3.4 Transformation of chemically competent bacterial cells 
All strains of chemically competent E. coli used in this thesis were commercially prepared, 
supplied and transformed according to manufacturer’s instructions. Briefly, competent 
cells were thawed on ice immediately prior to transformation. Approximately 100 ng of 
DNA was added to an aliquot of competent cells and incubated on ice for 20 minutes prior 
to a heat shock at 42 °C for 45 seconds. Cells were returned to ice for 5 minutes to cool. 
Subsequently, 400 µL of SOC media was added, and the cells were then incubated at 37 °C 
and 200 revolutions per minute (rpm) for 1 hour. Aliquots were plated onto antibiotic 
selective LB agar plates and incubated at 37 °C overnight. 
6.3.5 Bacterial culturing 
Starter cultures were prepared by inoculating a single bacterial colony in 5 mL of desired 
media with the appropriate antibiotic. These were incubated for 8 hours at 37 °C and 200 
rpm. Overnight cultures containing the appropriate media and antibiotic were inoculated 
with a 1/50 dilution of the starter culture. These were incubated at either 37 °C for soluble 
proteins, or 30 °C for membrane proteins, and 200 rpm overnight. Large scale cultures 
containing the appropriate media and antibiotic were further inoculated with a 1/50 
dilution of the overnight culture. These were incubated at 37 °C and 200 rpm until an 
appropriate optical density at 600 nm (OD600) was reached. Once reached, protein 
expression was induced and the cultures were incubated at a temperature appropriate for 
the respective construct and at 200 rpm overnight (Section 6.6.1). 
6.3.6 Preparation of glycerol stocks 
Bacterial strains were stored by harvesting an aliquot of overnight culture in a sterile 1.7 
mL eppendorf tube. Glycerol was added and combined to a final concentration of 15% 
(v/v). The tubes were snap frozen in liquid nitrogen and stored at -80 °C. 
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6.4 Molecular biology 
6.4.1 Plasmids 
The nanA gene encoding N-acetylneuraminate lyase from methicillin-resistant 
Staphylococcus aureus (MRSA) MRSA252 was previously amplified from genomic DNA 
and cloned into a pET11a expression vector. This construct was kindly supplied by 
Professor Matthew Perugini (University of Melbourne, Australia). The nanE, nagA and 
nagB genes respectively encoding N-acetylmannosamine-6-phosphate 2-epimerase, N-
acetylglucosamine-6-phosphate deacetylase and glucosamine-6-phosphate deaminase from 
MRSA USA300 were purchased from GenScript in the pUC57-Kan cloning vector and 
subsequently cloned into the pET30ΔSE expression vector (Suzuki et al., 2014). A more 
detailed description of this cloning is provided in Chapter Three, Section 3.2.1. Mutated 
variants of the nanE gene coding for single amino acid substitutions in N-
acetylmannosamine-6-phosphate 2-epimerase were also purchased from GenScript. These 
genes were supplied in the pET30a(+) expression vector. 
The gene encoding the sugar proton symporter (NanT) responsible for the transport of 
sialic acid from Yersinia pestis was purchased from GeneArt in the pMA-RQ cloning 
vector. This gene was then sub-cloned into the pWarf(−) expression vector (Hsieh et al., 
2010). A more detailed description of this cloning is provided in Chapter Four, Section 
4.2.1. The genes encoding the sodium solute symporters (SSS) responsible for the transport 
of sialic acid from S. aureus and Proteus mirabilis were previously sub-cloned into the 
pWarf(−) expression vector and kindly supplied by Dr Rosmarie Friemann (University of 
Gothenburg, Sweden). 
6.4.2 Plasmid extraction and isolation 
Plasmids were purified from 5 mL starter cultures of XL-1 Blue E. coli using a PureLink® 
Quick Plasmid Miniprep Kit. The concentration of purified plasmid was measured by 
absorption at 260 nm using a NanoDrop-1 000 spectrophotometer. The plasmid DNA was 
sequence verified by dideoxynucleotide sequencing (Section 6.4.3). 
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6.4.3 Dideoxynucleotide sequencing 
Canterbury Sequencing and Genotyping at the University of Canterbury provided 
dideoxynucleotide sequencing. Approximately 300 ng of purified double stranded plasmid 
and 3.2 µM of the relevant primer were supplied for each sequencing reaction to be carried 
out by a 3130xl Genetic Analyser and BigDye Terminator v3.1 (Applied Biosystems). 
6.4.4 Primers 
Oligonucleotide primer sequences were designed so that the TM of each primer pair were 
within 2 °C of each other, the GC content was higher than 40% and the formation of 
secondary structure elements could be avoided. Primers were adjusted to 100 µM per tube 
by resuspending dessicated pellets in sterile MilliQ water and then diluted to a working 
stock of 10 µM with sterile MilliQ water. Primer solutions were stored at -20 °C. 
6.4.5 Polymerase chain reaction 
The polymerase chain reaction (PCR) was performed using Platinum® taq high fidelity 
DNA polymerase, according to the supplied manual. Briefly, the reaction mixture was 
composed of 1 × high fidelity PCR buffer, 0.2 mM deoxynucleotide triphosphates 
(dNTP’s), 2 mM magnesium sulfate, 0.2 µM forward primer, 0.2 µM reverse primer, 200 
ng template DNA and 1 U of Platinum® taq high fidelity DNA polymerase made up to a 
total volume of 50 µL with sterile MilliQ water. PCR was performed according to the 
cycling conditions in Table 2.3. The thermal melting temperature (TM) reflects the lower 
temperature of the two PCR primers. Resulting PCR products were sub-cloned according 
to manufacturer’s instructions into pCR®2.1-TOPO using a TOPO® TA cloning kit and 




Table 2.3 PCR cycling reaction. The temperature, time, and number of cycles used in a PCR cycling 
reaction. 
Temperature (°C) Time Cycles 
94 2 minutes 1 
94 15 seconds  
30 TM − 5 30 seconds 
68 1 minute per kilobase 
4 as required 1 
6.4.6 Restriction digestion 
To obtain either a gene of interest, or an empty plasmid for subsequent cloning, restriction 
digests were performed to cut plasmids at particular recognition sites. Restriction digests 
were performed according to the manufacturer’s instructions. Components of a typical 
restriction digestion are listed in Table 2.4. Reactions were incubated at 37 °C for 3 hours 
and then analysed by agarose gel electrophoresis (Section 6.4.7). 
Table 2.4 Restriction enzyme digest reaction. Components are listed for a reaction volume of 50 µL. 
Reagent Volume (µL) 
10 × reaction buffer 5 
plasmid DNA ~2 000 ng DNA 
restriction enzyme 1 1 
restriction enzyme 2 1 
MilliQ Water total volume 50 
6.4.7 Agarose gel electrophoresis for DNA preparation 
Following PCR and/or restriction digestion, the DNA fragments were mapped on a 1% 
(w/v) agarose gel (Section 6.5.1). The gel was loaded with digested DNA in loading buffer 
alongside a DNA ladder, and then electrophoresis was conducted for 40 minutes at 120 
volts. DNA fragments were visualised on an ultraviolet (UV) light box and either the 
digested gene of interest, or digested and empty plasmid, was carefully excised from the 
gel. DNA was purified from the gel using an agarose gel DNA extraction kit. The 
concentration of purified DNA was measured by absorption at 260 nm using a NanoDrop-
1 000 spectrophotometer. 
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6.4.8 Ligation reactions 
Following purification of the relevant plasmid and gene of interest, a ligation reaction was 
carried out. Components of a typical ligation reaction are listed in Table 2.5. Reactions 
were incubated at room temperature for 50 minutes and then transformed into XL-1 Blue 
competent cells. Positive transformants were identified via antibiotic resistance prior to 
plasmid purification and sequence verification using dideoxynucleotide sequencing. 
Following verification, the resulting recombinant plasmid was transformed into an 
appropriate cell line of E. coli for protein expression. 
Table 2.5 Ligation reaction. Components for a reaction volume of 5 µL. 
Reagent Volume (µL) 
plasmid DNA ~100 ng  
insert DNA ~200 ng 
ligase 2 









6.5.1 Agarose gel electrophoresis 
DNA fragments were separated using agarose gel electrophoresis. Agarose gels were 
prepared by dissolving 1% (w/v) agarose in 1 × 2-Amino-2-hydroxymethyl-propane-1,3-
diol (Tris)-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM glacial acetic acid and 1 mM 
EDTA). Once the solution reached approximately 50 °C, SYBR® Safe DNA Gel Stain 
was added to a final concentration of 1 × and the gel was poured and left to set. DNA 
samples were combined with 6 × DNA gel loading dye to a final concentration of 1 × and 
loaded into the gel alongside HyperLadder™ 1 kb. Gels were electrophoresed in 1 × TAE 
buffer at 120 volts for 40 minutes. Bands were visualised by UV transillumination. 
6.5.2 Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to separate 
proteins was performed using either Novex® 4-12% tris glycine 1.0 mM or Novex® 4-
12% bis tris 1.0 mM precast protein gels with 1 × Novex® tris glycine SDS or 1 × 
Novex® 2-(N-morpholino)ethanesulfonic acid SDS buffer, respectively. Electrophoresis 
was performed at room temperature using a XCell SureLock® apparatus for 35 minutes at 
200 volts for bis tris gels, or 1.5 hours and 125 volts for tris glycine gels. Samples to be 
electrophoresed on a bis tris gel were resuspended in NuPAGE® lithium dodecyl sulfate 
sample buffer and NuPAGE® sample reducing agent. Samples to be electrophoresed on a 
tris glycine gel were resuspended in 1 × Novex ® tris glycine SDS sample buffer. Samples 
were electrophoresed alongside Novex® sharp prestained protein standards. If in-gel 
fluorescence needed to be assessed (Drew et al., 2006; Hjelm et al., 2013), then samples 
were electrophoresed alongside a BenchMark™ fluorescent protein standard. Following 
electrophoresis, gels were stained using SimplyBlue™ SafeStain. Images of the gels were 
captured using a CHEMI GENIUS2 bio-imaging system (Syngene). Chemiluminescence 
imaging was used to detect in-gel fluorescence. 
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6.6 Protein biochemistry 
6.6.1 Recombinant protein expression 
Cultures for protein expression were routinely grown to an appropriate OD600 of 0.4 – 0.6 
for LB medium and 1.7 – 1.9 for TB medium. Once these OD600 levels were achieved, 
cultures were cooled to an appropriate temperature for expression of the relevant construct. 
Induction was achieved by the addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
to a final concentration of 0.4 mM for the expression of membrane proteins, or 1 mM for 
the expression of soluble proteins. 
6.6.2 Harvesting of cells 
Following protein expression, large scale cultures were harvested by centrifugation at 6250 
g, for 20 minutes, at 4 °C. Cell pellets were washed in ice cold 1 × phosphate buffered 
saline (PBS) solution and the centrifugation step was repeated. Cell pellets were then snap 
frozen in liquid nitrogen and stored at -80 °C. 
6.6.3 Cell lysis 
All cell lysis and purification was performed either on ice or at 4 °C. Cell pellets were 
thawed and resuspended in approximately 3 mL/g of cell pellet in 1 × PBS solution, or the 
first buffer to be used in purification. Proteolytic activity was inhibited by the addition of 1 
cOmplete™, EDTA free protease inhibitor tablet per 50 mL of cell resuspension. In 
addition, lysozyme was added to the cell resuspension at a final concentration of 0.5 
mg/mL and incubated on ice for 30 minutes. Subsequently, 5 µg/mL of DNaseI and 2 mM 
magnesium chloride were added to the cell resuspension and incubated on ice for a further 
15 minutes. Cells were lysed by sonication on ice using a UP200S Ultrasonic Processor 
(Hielscher) at 70% amplitude, 0.5 seconds on, 0.5 seconds off, for 10 minutes. Any 
unbroken cells and cell debris were removed by centrifugation at 24 000 g, for 25 minutes, 
at 4 °C. Supernatant was collected and stored at 4 °C. 
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6.6.4 Whole cell fluorescence 
Following protein expression trials, the OD600 of the cell culture was measured and 5 mL 
of culture was harvested. Cell pellets were resuspended in PBS buffer and 200 µL was 
transferred to a Corning® 96 well, clear bottom plate for the measurement of fluorescence 
from a green fluorescent protein (GFP) fusion tag with excitation at λ = 485 nm and 
emission at λ = 512 nm (Drew et al., 2001; Drew et al., 2006; Hjelm et al., 2013). All 
fluorescence data was processed as described in Hsieh et al. (2010). The fluorescent values 
(F) were normalised (FN) against the OD600 measurement (Equation 6.1). Furthermore, the 
fluorescence values were reported as relative fluorescent units (RFU); where the 
normalised fluorescence (FN1) is divided by the normalised fluorescence of non-induced 
cells (FN2) that contain the same plasmid (Equation 6.2). 




Equation 6.2. RFU = FN1
FN2
 
6.6.5 Harvesting of membranes 
For the membrane proteins expressed and studied in this thesis, the membrane fraction was 
harvested following cell lysis. The supernatant collected in Section 6.6.3 was centrifuged a 
second time at 24 000 g, for 25 minutes, at 4 °C to clear the supernatant from any residual 
cells and cell debris. Membranes were separated from the supernatant by 
ultracentrifugation at 200 000 g, for 1.5 hours, at 4 °C, using a Ti45 rotor. The supernatant 
was discarded and the membranes were washed in membrane resuspension buffer (1 × 
PBS, 5 mM dithiothreitol, 6% glycerol and 0.1 µM phenylmethylsulfonyl fluoride). 
Ultracentrifugation was repeated at 200 000 g, for 1 hour, at 4 °C. The membrane pellet 




6.6.6 Membrane protein solubilisation 
The membrane pellet was slowly thawed on ice and 5 mL of membrane resuspension 
buffer was added for every 1 g of membranes. Once thawed, an appropriate detergent 
(Section 6.6.7) was added to a final concentration of 2% (w/v). Solubilisation was carried 
out for 2 hours, at 4 °C, with gentle agitation. The membranes that had not been solubilised 
were pelleted by centrifugation at 24 000 g, for 1 hour, at 4 °C. The supernatant was 
carefully separated from the pellet and kept at 4 °C. 
6.6.7 Detergent screening 
Fluorescence detection size exclusion chromatography (FSEC) was used as an efficient 
method to identify ideal detergents. Approximately 100 mg of membrane pellets were 
solubilised in a range of detergents. Following centrifugation, 250 µL of the supernatant 
was immediately applied to a Superose 6 10/150 column that was pre-equilibrated in 
membrane resuspension buffer containing the respective detergent at a concentration above 
the critical micelle concentration. Because FSEC can exploit the unique fluorescence 
signal of GFP, the eluate was monitored by GFP emission at 512 nm (Drew et al., 2006; 
Hsieh et al., 2010). FSEC was repeated after 48 hours with a further 250 µL of the 
supernatant that was kept at 4 °C. 
6.6.8 Protein purification 
Various chromatographic techniques were performed in this work using ÄKTA protein 
purification systems and gravity flow purification methods. All protein purification 
procedures were conducted at 4 °C. Prior to any procedure, the columns as well as the 
resin used for gravity flow techniques were pre-equilibrated with at least three column 
volumes of the initial purification buffer. Depending on the type of protein being purified 
and the purification step being utilised, the cell free supernatant, solubilised membrane 
fraction, or partially purified protein was loaded on to the appropriate column. To remove 
any unbound protein, the column was then washed with an additional three column 
volumes of the initial purification buffer until stable baselines at 280 nm were achieved.  
	 176 
For immobilised metal affinity chromatography (IMAC), anion exchange chromatography 
and hydrophobic interaction chromatography, the protein was eluted with either an 
increasing or a step wise gradient of a second comparable buffer containing a much higher 
concentration of imidazole, or sodium chloride, or a reduced concentration of ammonium 
sulfate, respectively. The eluate was fractionated and collected in 96 well plates. Following 
these procedures, fractions were conservatively selected and pooled with respect to their 
purity, as determined by SDS-PAGE. After the final purification step, all proteins were 
aliquoted into ice cold 1.7 mL eppendorf tubes and snap frozen in liquid nitrogen for long 
term storage at -80 °C. 
6.6.8.1 Anion exchange chromatography 
Anion exchange chromatography was employed as the first purification step for the 
purification of MRSA N-acetylneuraminate lyase, N-acetylmannosamine-6-phosphate 2-
epimerase, N-acetylglucosamine-6-phosphate deacetylase and glucosamine-6-phosphate 
deaminase. The components of each buffer used for anion exchange chromatography are 
described in Table 2.6. The cell free supernatant was applied to a 20 mL anion exchange 
column containing positively charged Q sepharose resin, which had been pre-equilibrated 
with anion exchange buffer A. Once the cell free supernatant was loaded onto the column, 
it was washed with three column volumes of anion exchange buffer A. Bound proteins 
were eluted with a continuous gradient of anion exchange buffer B, up to 100% over three 
column volumes. Eluate was collected in fractions and peaks in the 280 nm absorbance 
trace were analysed for the protein of interest by SDS-PAGE before being pooled. 
Table 2.6. Anion exchange chromatography buffers. Components of each buffer are listed. 
Buffer Components 
anion exchange buffer A 20 mM Tris, pH 8.0 
anion exchange buffer B 20 mM Tris, pH 8.0; 1 M sodium chloride 
6.6.8.2 Hydrophobic interaction chromatography 
Hydrophobic interaction chromatography was implemented as a second purification step 
for any proteins that were subjected to anion exchange chromatography as an initial 
purification step. This includes MRSA N-acetylneuraminate lyase, N-acetylmannosamine-
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6-phosphate 2-epimerase, N-acetylglucosamine-6-phosphate deacetylase and glucosamine-
6-phosphate deaminase. The components of each buffer used for hydrophobic interaction 
chromatography are described in Table 2.7. To a final concentration of 1 M, ammonium 
sulfate was added to the partially purified protein pooled from the anion exchange 
chromatography step. The protein was then applied to a phenyl sepharose 20 mL column 
pre-equilibrated with hydrophobic interaction buffer A, and washed with a further three 
column volumes of this buffer. Bound proteins were eluted with a continuous gradient of 
hydrophobic interaction buffer B, up to 100% over three column volumes. Fractions 
corresponding to any 280 nm absorbance peaks were analysed by SDS-PAGE for the 
protein of interest prior to being pooled. All proteins purified by anion exchange and 
hydrophobic interaction chromatographies were next subjected to size exclusion 
chromatography as the final purification step (Section 6.6.8.7). 
Table 2.7. Hydrophobic interaction chromatography buffers. Components of each buffer are listed. 
Buffer Components 
hydrophobic interaction buffer A 20 mM Tris, pH 8.0; 1 M ammonium sulfate 
hydrophobic interaction buffer B 20 mM Tris, pH 8.0 
6.6.8.3 Immobilised metal affinity chromatography 
IMAC was employed as the first purification step for the sialic acid transporter proteins 
studied in this thesis (Y. pestis NanT, P. mirabilis SSS, and S. aureus SSS). This type of 
chromatography was achieved using a His Trap 5 mL column, pre-equilibrated with Buffer 
A for each selected protein (Table 2.8). The solubilised membrane fraction was applied to 
the column. The column was then washed with a further five column volumes of the initial 
buffer used for pre-equilibration. Depending on the protein, elution from the column was 
conducted using either an increasing or step wise gradient of an elution buffer B made up 
of the same components as the initial buffer, but with a higher concentration of imidazole 
(Table 2.10). For the P. mirabilis SSS sialic acid transporter, the column was washed for 
ten column volumes with 5% of the P. mirabilis SSS buffer B before a continuous gradient 
of elution buffer up to 100% was initiated over twenty column volumes. For the Y. pestis 
NanT and S. aureus SSS sialic acid transporters, elution was conducted via a step wise 
gradient using the Y. pestis NanT and S. aureus SSS buffer B, respectively. This involved 
washing the column with 10% of the relevant elution buffer over ten column volumes, then 
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increasing the concentration of elution buffer to 50% over twenty column volumes. 
Fractions corresponding to any 280 nm absorbance peaks were analysed by SDS-PAGE 
for the protein of interest prior to being pooled.  
Table 2.8. IMAC buffers. Buffer components are listed for each protein subjected to IMAC throughout 
this thesis. Buffer A refers to the initial buffer used for pre-equilibration of the column. Buffer B refers to the 
elution buffer for each respective protein. 
Buffer Components 
Y. pestis NanT buffer A 
 
 
Y. pestis NanT buffer B 
 
 
P. mirabilis SSS buffer A 
70 mM Tris, pH 8.0; 150 mM sodium chloride; 20 mM 
imidazole; 6% glycerol; 5 mM β-mercaptoethanol; 0.0174% n-
dodecyl-β-D-maltopyranoside 
70 mM Tris, pH 8.0; 150 mM sodium chloride; 500 mM 
Imidazole; 6% Glycerol; 5 mM β-mercaptoethanol; 0.0174% n-
dodecyl-β-D-maltopyranoside  
70 mM Tris, pH 8.0; 150 mM sodium chloride; 20 mM 
imidazole; 6% glycerol; 5 mM β-mercaptoethanol; 0.0174% n-
dodecyl-β-D-maltopyranoside 
P. mirabilis SSS buffer B 70 mM Tris, pH 8.0; 150 mM sodium chloride; 500 mM 
imidazole; 6% glycerol; 5 mM β-mercaptoethanol; 0.0174% n-
dodecyl-β-D-maltopyranoside 
S. aureus SSS buffer A 70 mM Tris, pH 8.0; 150 mM sodium chloride; 20 mM 
imidazole; 6% glycerol; 5 mM β-mercaptoethanol; 0.174% n-
decyl-β-D-maltopyranoside 
S. aureus SSS buffer B 
 
 
70 mM Tris, pH 8.0; 150 mM sodium chloride; 500 mM 
imidazole; 6 % glycerol; 5 mM β-mercaptoethanol; 0.174 % n-
decyl-β-D-maltopyranoside 
6.6.8.4 Buffer exchange 
Following purification by IMAC, the protein was exchanged into a buffer devoid of any 
imidazole. Usually, this is the same buffer that will be used for size exclusion 
chromatography (Section 6.6.8.7). In order to exchange the buffer, proteins were 
concentrated using an appropriate molecular weight cut off spin concentrator and diluted 
into the new buffer multiple times.  
6.6.8.5 Human rhinovirus 3C protease cleavage 
Following buffer exchange, the Y. pestis NanT, P. mirabilis SSS and S. aureus SSS sialic 
acid transporters required a C-terminal GFP fusion protein and a 6 × Histidine tag to be 
cleaved off by the human rhinovirus 3C (HRV3C) protease (Hsieh et al., 2010). At a 1 to 
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12.5 ratio of HRV3C to the protein of interest, cleavage was conducted for 20 hours, at 4 
°C, and with gentle agitation. Following cleavage, gravity flow chromatography (Section 
6.6.8.6) was conducted prior to size exclusion chromatography (section 6.6.8.7). 
6.6.8.6 Gravity flow chromatography 
Gravity flow chromatography was used to separate the cleaved protein from both the tag 
and any protein that failed to cleave. Gravity flow chromatography was carried out using 
Poly Prep® columns with Ni-NTA agarose resin pre-equilibrated with the same buffer that 
the protein was exchanged into for cleavage. Cleaved protein was incubated with the pre-
equilibrated resin for 1 hour, at 4 °C and with gentle agitation. The protein and resin 
combination was then loaded into a gravity flow column. The flow through containing the 
cleaved protein of interest was collected in 1 mL aliquots. The resin was washed with a 
further three column volumes of buffer to remove any residual cleaved protein. 
6.6.8.7 Size exclusion chromatography 
Size exclusion chromatography was employed as a final polishing step for all purification 
procedures described above. Either a HiLoad Superdex 200 16/60 120 mL or Superdex 
200 Increase 10/300 GL 24 mL column was employed for size exclusion chromatography. 
All buffers used for size exclusion chromatography throughout this thesis are listed in 
Table 2.9. For MRSA N-acetylneuraminate lyase, N-acetylmannosamine-6-phosphate 2-
epimerase, N-acetylglucosamine-6-phosphate deacetylase and glucosamine-6-phosphate 
deaminase, size exclusion buffer A was selected as the final purification buffer. For the Y. 
pestis NanT, P. mirabilis SSS and S. aureus SSS sialic acid transporters, the buffers varied 
depending on the detergent required for each respective protein. Prior to being applied to 
the column, pooled protein from the previous purification step was concentrated to 
approximately 1% of the column volume. Eluted fractions corresponding to the 280 nm 





Table 2.9. Size-exclusion chromatography buffers. Components of each buffer are listed. 
Buffer Components 
size-exclusion buffer A 20 mM Tris, pH 8.0 
Y. pestis NanT size exclusion buffer A 50 mM Tris, pH 8.0; 150 mM sodium chloride; 0.174% n-
dodecyl-β-D-maltopyranoside  
P. mirabilis SSS size exclusion buffer A 50 mM Tris, pH 8.0; 150 mM sodium chloride; 0.0174% n-
dodecyl-β-D-maltopyranoside 
S. aureus SSS size exclusion buffer A 50 mM Tris, pH 8.0; 150 mM sodium chloride; 0.174% n-decyl-
β-D-maltopyranoside 
6.6.9 Protein quantitation 
6.6.9.1 The Bradford protein assay to determine protein concentration 
The concentration of protein was measured using the Bradford protein assay (Bradford, 
1976). Bradford dye reagent was prepared by diluting one part of the concentrate with four 
parts of MilliQ water. Protein concentrations were obtained from a calibration curve 
generated in parallel. To construct this calibration curve, bovine serum albumin was 
serially diluted from 0.5 mg/mL to 0.016 mg/mL in the same buffer that the protein sample 
was in. Protein samples were diluted in accordance to the midpoint of the calibration curve 
and prepared in triplicate with 200 µL of the diluted bradford dye reagent and 10 µL of 
protein. The solution was mixed thoroughly and incubated at room temperature for exactly 
5 minutes before measurement of the absorbance at 595 nm. Measurements were taken 
against a blank consisting of 200 µL bradford dye reagent and 10 µL of buffer. 
6.6.9.2 NanoDrop spectrophotometry 
Alternatively, protein concentration was measured by UV absorbance at 280 nm using a 
NanoDrop-1 000 spectrophotometer. The extinction coefficient for each protein being 
measured was calculated using ExPASy’s ProtParam tool 
(http://web.expasy.org/protparam/). The Beer Lambert law was used to convert the 
absorbance into concentration. 
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6.7 X-ray crystallography 
6.7.1 Crystallisation 
Crystallisation studies were performed using freshly purified preparations of protein, 
concentrated to 10-20 mg/mL with an appropriate molecular weight cut off spin 
concentrator. Initial protein crystallisation trials were either performed in-house, or at the 
Collaborative Crystallisation Centre (C3; http://www.csiro.au/c3/) node of the 
Commonwealth Scientific and Industrial Research Organisation. All trays were inspected 
every two to three days for crystal growth. 
Initial crystallisation trials for MRSA N-acetylneuraminate lyase and N-
acetylmannosamine-6-phosphate 2-epimerase were performed at C3 using the PACT Suite 
and the JCSG+ Suite crystal screens (Newman et al., 2005; Newman et al., 2008). These 
trials were conducted using the sitting drop vapour diffusion method, at 8 °C and 20 °C, 
with droplets consisting of 150 nL protein solution and 150 nL reservoir solution. In-house 
optimisation of the initial hits were performed using the hanging drop vapour diffusion 
method in 24-well Linbro plates, with siliconised cover slips at 8 °C and 20 °C. Hits were 
first optimised by varying the amounts of protein and reservoir solution; for example, 1.7-
2.2 µL of reservoir solution with either 2.0 µL or 2.5 µL of protein solution was 
equilibrated against 1 mL of reservoir solution. The crystallisation conditions that resulted 
in diffraction of MRSA N-acetylneuraminate lyase and MRSA N-acetylmannosamine-6-
phosphate 2-epimerase are described in Chapter Two and Chapter Three, respectively.  
Crystallisation trials for the Y. pestis NanT and S. aureus SSS sialic acid transporters were 
conducted at 20 °C using both vapour diffusion and lipidic cubic phase methods either in-
house or at C3. Screens used in-house for vapour diffusion studies included MemGold™, 
MemGold2™, MemStart™, MemSys™, and The PGA Screen™.  The droplets consisted 
of 200 nL protein solution and 200 nL reservoir solution. All lipidic cubic phase 
crystallisation was attempted using screens prepared at C3, including the SG1 (Shotgun) 
Screen, the PACT Suite, Cubic, MemFac, MemGold, and MemGold2. Conditions that the 
Y. pestis NanT sialic acid transporter produced crystals in are described in Chapter Four. 
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6.7.2 Data collection, processing and structure refinement 
6.7.2.1 Data collection 
For X-ray data collection, crystals were mounted onto cryo loops of an appropriate size for 
the crystal of interest, briefly soaked in cryo protectant solution, and flash cooled in liquid 
nitrogen. Crystals that had been flash cooled were mounted onto the beamline in a cold 
nitrogen stream at -173 °C. Diffraction data was collected on the MX1 and MX2 beamlines 
at the Australian Synchrotron. 
6.7.2.2 Data processing 
Indexing and integration of the data were performed using the program iMOSFLM (Battye 
et al., 2011) or XDSME (Kabsch, 2010). The space group was verified by running 
POINTLESS (Evans, 2006) from the CCP4 program suite (Winn et al., 2011). If required, 
the data was reprocessed in a new space group. Scaling and data reduction were then 
performed using SCALA (Evans, 2006) or AIMLESS (Evans, 2006; Evans, 2011), also from 
CCP4. The resulting intensity data were analysed using PHENIX XTRIAGE and the 
PHENIX REFLECTION FILE EDITOR (Adams et al., 2010) was used to generate a new 
Rfree set in thin resolution shells. The output allowed the true resolution of the data, the 
signal to noise ratio, multiplicity, completeness, and bad sections of data to be assessed. 
An estimate of the number of molecules in the asymmetric unit was obtained using the 
MATTHEWS COEFFICIENT program (Matthews, 1968; Kantardjieff & Rupp, 2003) from 
the CCP4 suite.  
6.7.2.3 Model building and structure refinement 
If required, the coordinate file of the search model was prepared using CHAINSAW (Stein, 
2008) from the CCP4 Suite, which uses a sequence alignment of the search model protein 
and the target protein to edit the coordinate file. Molecular replacement was used to 
estimate the phases from a search model using the program PHASER (McCoy et al., 2007), 
also from CCP4. Structure refinement was initially performed using REFMAC (Murshudov 
et al., 2011) in CCP4 and continued thereafter in PHENIX REFINE (Adams et al., 2010). 
The first time that refinement was conducted in PHENIX REFINE, simulated annealing 
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was performed to eliminate model bias. Iterative improvement of both the map and the 
model was performed using alternate cycles of refinement and residue-by-residue analysis 
in COOT (Emsley & Cowtan, 2004). In COOT, manual repositioning of some residues to 
better fit the electron density was performed. Water molecules were added using the ‘add 
waters’ function in COOT, and manually assessed for fit to the observed spherical electron 
density. Ligands were added via COOT and modelled into the observed electron density 
map manually. Coordinate and restraint files for ligands not in the COOT library were 
generated via SKETCHER in the CCP4 suite. Following each cycle of refinement, the 
output was monitored for a decrease in both the residual factor (Rfactor) and the free Rfactor 














6.8 Biophysical techniques 
6.8.1 Circular dichroism spectroscopy 
A Jasco J815 circular dichroism (CD) spectrophotometer was used to record the CD 
spectra of purified proteins. Wavelength scans between 180 nm and 260 nm were 
performed on protein samples in an appropriate buffer. Data were collected in a 2 mm path 
length quartz cuvette, at 20 °C, and in 0.5 nm increments. Buffer data was subtracted from 
sample data, and data exceeding a voltage of 600 was removed. Data was converted to 
mean residue ellipticity by multiplying by the conversion factor (Equations 6.3 and 6.4). 
Resulting data was analysed using the CDNN software package (Bohm et al., 1992). 
Equation 6.3. mean residue concentration = number of amino acids in protein
molecular weight g/mol  × sample  (mg/mL) 
Equation 6.4  conversion factor = 1
mean residue concentration × path length (mm)
 
6.8.2 Differential scanning fluorimetry 
Differential scanning fluorimetry was performed with an iQ™5 Multicolour Real Time 
PCR Detection System (BioRad). Samples consisted of 20 µL 1 × SYPRO® Orange and 
80 µL of the relevant protein at 1 mg/mL. Samples were prepared and measured in 
triplicate in 96 well thick wall plates. Fluorescence was measured for 10 seconds in 0.5 °C 
increments from 20 °C to 100 °C. 
6.8.3 Analytical ultracentrifugation 
Sedimentation velocity experiments using analytical ultracentrifugation were performed in 
an XL-I Analytical Ultracentrifuge (Beckman Coulter). Depending on the protein, the 
absorbance optical system was employed at wavelengths in the range of 280 to 285 nm. 
Initial scans were performed at 3 000 rpm to determine the optimal radial settings and 
wavelength. For these experiments, 400 µL of reference and 380 µL of sample solutions 
were loaded into 12 mm double sector cells with quartz or sapphire windows, and then 
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mounted in an An-60 Ti four or eight hole rotor. Proteins were centrifuged at a rotor speed 
of 50 000 rpm at either 12 °C or 20 °C. Radial absorbance data were collected at a single 
wavelength without averaging, using a 0.003 cm step size for a total of 80 to 120 scans. 
Solvent density, solvent viscosity and estimates of the partial specific volume for proteins 
were computed using the program SEDNTERP (Laue et al., 1992). Data were fitted to a 
continuous size distribution [c(s)] model using the program SEDFIT (Schuck, 2000). This 
data was then fitted to a continuous mass distribution [c(M)] in SEDFIT to calculate the 
apparent molecular mass of the species observed in the [c(s)] distribution. 
6.8.4 Small angle X-ray scattering 
6.8.4.1 Small angle X-ray scattering measurements 
Small angle X-ray scattering (SAXS) data were collected on the SAXS/WAXS beamline, 
equipped with a Pilatus 1M detector (170 mm × 170 mm, effective pixel size, 172 × 172 
µm) at the Australian Synchrotron. The wavelength of the X-rays was 1.0332 Å. A sample 
detector distance of 1600 mm was used, providing a q range of 0.006-0.4 Å-1  (where q is 
the magnitude of the scattering vector, which is related to the scattering angle (2θ) and the 
wavelength (λ) as follows: q = (4π/λ)sinθ). For all proteins analysed, 50 µL of sample at 
approximately 10 mg/mL was subjected to size exclusion chromatography on a Superdex 
200 5/150 GL column, pre-equilibrated with an appropriate buffer. Data were collected 
using a 1.5 mm glass capillary, at 20 °C, and at 2 second intervals. Two dimensional 
intensity plots were radially averaged, normalised to sample transmission, and background 
subtracted using Scatterbrain software (Australian Synchrotron). 
6.8.4.2 Small angle X-ray scattering data analysis 
All subsequent SAXS analyses were performed using the ATSAS software package 
(version 2.3) (Konarev et al., 2006). Guinier plots were analysed using PRIMUS (Konarev 
et al., 2003) to assess data quality. Indirect fourier transform of the data was performed 
using GNOM (Svergun, 1992) to generate the P(r) distribution. Theoretical scattering 
curves were generated from atomic coordinates and compared with experimental scattering 
curves using CRYSOL (Svergun et al., 1995). 
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6.9 Enzyme kinetics 
6.9.1 Coupled assay for N-acetylneuraminate lyase 
Kinetic analysis of MRSA N-acetylneuraminate lyase was performed using a lactate 
dehydrogenase coupled assay, as described elsewhere (Devenish & Gerrard, 2009; Timms 
et al., 2013). The coupled enzyme reaction is illustrated in Figure 6.1. Appropriate controls 
were performed to ensure that enzyme concentration was proportional to rate, lactate 
dehydrogenase was in excess, and the temperature selected to run the desired assays were 
suitable. Controls were performed with 20 mM of the substrate, sialic acid, which was at 
least 5 × the Michaelis-Menten constant (KM). The reaction was followed by measuring the 
consumption of reduced nicotinamide adenine dinucleotide (NADH) by measurement of 
absorbance at 340 nm as a function of time using the Cary 100 Bio UV/Vis 
spectrophotometer (Agilent Technologies). Enzyme assays were performed in duplicate or 
triplicate and initial velocities were reproducible within 10% error. 
Figure 6.1. The lactate dehydrogenase coupled assay for N-acetylneuraminate lyase. As N-
acetylneuraminate lyase converts sialic acid into N-acetylmannosamine and pyruvate, lactate dehydrogenase 
converts pyruvate into lactate while simultaneously reducing NADH to NAD+. 
6.9.1.1 Steady state kinetic analysis of MRSA N-acetylneuraminate lyase 
Steady state kinetic analysis of MRSA N-acetylneuraminate lyase was performed at 30 °C. 
Reaction mixtures were allowed to equilibrate to 30 °C in the instrument for 10 minutes 
prior to initiation by addition of 20 µL MRSA N-acetylneuraminate lyase. Standard 












pH 7.6, 0.15 mM NADH, 100 µg LDH, and 0.16 to 40 mM of the substrate [S], sialic acid. 
Initial rate (V0) data were analysed using OriginPro (version 8.5.1) and fitted to the 
Michaelis-Menten model (Equation 6.5) to determine the relevant kinetic constants, 
including the KM, maximum velocity (Vmax), and the catalytic turnover number (kcat). 




6.9.1.2 Inhibition studies of MRSA N-acetylneuraminate lyase 
To evaluate kinetic inhibition of MRSA N-acetylneuraminate lyase by the sialic acid 
alditols, the concentration of the substrate (sialic acid) and a sialic acid alditol mixture 
were varied against one another. The inhibitor constant (Ki) was determined with 0.16 to 
20 mM sialic acid against 0 to 5 mM of the sialic acid alditol mixture. These assays were 
performed at a physiologically relevant temperature of 37 °C. Initial rate data were 
analysed using OriginPro and data were fitted to the competitive inhibition model 
(Equation 6.6), non-competitive inhibition model (Equation 6.7), un-competitive inhibition 
model (Equation 6.8) and the mixed inhibition model (Equation 6.9). The inhibitor 
constant for a competitive inhibitor, non-competitive inhibitor, and un-competitive 
inhibitor is denoted Kic, Kinc, and Kiuc, respectively. The best fit was determined through 
consideration of R2 values and % residuals. 
Equation 6.6. V0 = 
Vmax [S]





Equation 6.7. V0 = 
Vmax [S]





Equation 6.8. V0 = 
Vmax [S]





Equation 6.9. V0 = 
Vmax [S]
(1 + [I]Kic







6.9.2 Multi-enzyme coupled assay for N-acetylmannosamine-
6-phosphate 2-epimerase  
A new enzyme assay was developed to probe N-acetylmannosamine-6-phosphate 2-
epimerase function. Kinetic analysis of MRSA N-acetylmannosamine-6-phosphate 2-
epimerase was performed using a multi-enzyme coupled assay; including N-
acetylglucosamine-6-phosphate deacetylase and glucosamine-6-phosphate deaminase, the 
subsequent enzymes of the sialic acid degradation pathway, as well as a 
phosphoglucoisomerase and glucose-6-phosphate dehydrogenase (Figure 6.2). Briefly, the 
coupling enzymes work sequentially until glucose-6-phosphate dehydrogenase produces 6-
phosphogluconate while simultaneously reducing NADP+ into NADPH. This assay was 
extended and adapted from the coupled assay described for glucosamine-6-phosphate 
deaminase (Vincent et al., 2005). Appropriate controls were performed to ensure that 
enzyme concentration was proportional to rate and all of the coupling enzymes were in 
excess. The reaction was followed by measurement of absorbance at 340 nm as a function 
of time using the Cary 100 Bio UV/Vis spectrophotometer. Enzyme assays were 
performed in duplicate and initial velocities were reproducible within 10% error. 
6.9.2.1 Steady state kinetic analysis of MRSA N-acetylmannosamine-6-phosphate 2-
epimerase 
Steady state kinetic analysis of MRSA N-acetylmannosamine-6-phosphate 2-epimerase 
was performed at 25 °C. Reaction mixtures were allowed to equilibrate to 25 °C in the 
instrument for 10 minutes prior to initiation by addition of 20 µL N-acetylmannosamine-6-
phosphate 2-epimerase. Standard reaction mixtures were made up to 1 mL and contained 
100 mM Tris, pH 8.0, 50 µg N-acetylglucosamine-6-phosphate deacetylase, 100 µg 
glucosamine-6-phosphate deaminase, 50 µg phosphoglucoisomerase and 25 µg glucose-6-
phosphate dehydrogenase and an appropriate amount of the substrate, N-
acetylmannosamine-6-phosphate. The kinetic constants, KM, Vmax, and kcat were determined 
with 0.16 to 5 mM N-acetylmannosamine-6-phosphate for the wild type enzyme and 1 to 5 
mM N-acetylmannosamine-6-phosphate for mutated variants of this enzyme. Initial rate 
data were analysed using OriginPro and fitted to the Michaelis-Menten model to determine 
the relevant kinetic constants. 
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Figure 6.2. The multi-enzyme coupled assay for N-acetylmannosamine-6-phosphate 2-epimerase. As 
N-acetylmannosamine-6-phosphate 2-epimerase converts N-acetylmannosamine-6-phosphate into N-
acetylglucosamine-6-phosphate, N-acetylglucosamine-6-phosphate deacetylase converts this into 
glucosamine-6-phosphate. This is then converted into fructose-6-phosphate by glucosamine-6-phosphate 
deaminase. Next, phosphoglucoisomerase is responsible for the conversion of fructose-6-phosphate to 
glucose-6-phosphate. Finally, glucose-6-phosphate dehydrogenase converts glucose-6-phosphate 6-
phosphogluconate while simultaneously reducing NADP+ into NADPH. 
6.9.3 Sodium borohydride reduction 
Approximately 1 mg/mL of MRSA N-acetylneuraminate lyase and MRSA N-























sialic acid and N-acetylmannosamine-6-phosphate respectively, for 30 minutes, at room 
temperature. The samples were placed on ice and 100 mM sodium borohydride, made up 
in 100 mM Tris, pH 8.0, was added over 15 minutes. The samples were incubated for a 
further 30 minutes on ice. The activity of MRSA N-acetylneuraminate lyase and MRSA N-
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NanE forward primer 
5’-CATATGTTACCACATGGATTAATAGTATCTTGTCAGGC-3’ 
NanE reverse primer 
5’-AAGCTTTTAATCTTCCATAATTTGAACAAAACGTTTCG-3’ 


























































































S. aureus SSS for sialic acid transport 
ATGAAAGAAGTTGGTTTTGGCACCCTGAATTGGGTTGCAGTTATTATCTATCTGCTGGCC
ATGCTGTTTATCGGTGTGTATTTTACCAAACGTGCAAGCCAGAGCACCAATAGCTTTTTT
	 198 
ACCGCAAGCGGTCGTCTGCCGAGCTGGGTTGTTGGTTTTAGCATTTATGCAACCACCCTG
AGCGCAATTACCTTTATGAGCACACCGGAAAAAGCATTTCTGACCGATTGGAGCTATATT
GCAGGTAATATTGCCATTGTTGCCATTATTCCGCTGCTGATCTATTTCTATGTGCCGTTC
TTCAAAAAACTGAAAGTTACCAGCGCCTATGAATATCTGGAAGCACGTTTTGGTCCGAGC
ATTCGTGTTATTGGTAGCCTGCTGTTTGTTGTTTATCATCTGGGTCGTGTTGCCATCGTT
ATTTATCTGCCGACCCTGGCAATTACCAGCGTTAGCGATATGAATCCGTATATTGTTGCA
AGCCTGGTTGGTCTGCTGTGTATTCTGTATACCTTTCTGGGTGGTTTTGAAGGTGTTGTT
TGGAGCGATTTTATTCAGGGCGTTATTCTGCTGGGTGGTGCACTGGTTATCATTATTCTG
GGTGTGATGAACATCAAAGGTGGCTTTGGCACCGTTTTTGCAGATGCAATTGAACATAAA
AAACTGATCAGCGCAGACAACTGGAAACTGAATACCGCAGCAGCAGCAATTCCGATTATC
TTTCTGGGCAACATTTTCAACAACCTGTATCAGTATACCGCCAGCCAGGATGTTGTTCAG
CGTTATCAGGCAAGCGATAGCCTGAAAGAAACCAATAAAAGCCTGTGGACCAATGGTATT
CTGGCACTGATTAGCGCACCGCTGTTTTATGGTATGGGCACCATGCTGTATAGCTTTTAT
GCACATGAAGCAGTTCTGCCGAAAGGTTTTAATACCAGCAGCGTTGTTCCGTATTTTATC
CTGACCGAAATGCCTCCGTTTGTTGCAGGTCTGCTGATTGCAGCAATTTTTGCAGCAGCA
CAGAGTACCATTAGCAGCAGCCTGAATAGCATTAGCGCATGTATTAGCATCGATATCAAA
CAGCGCTTTTTTGGTAAAGGTAGCGAACGTCATGAAGTGAATTTTGCCCGTTTCATTATT
ATCATTGCCGGTATCTTTGGCTTTGGTATGAGCCTGTATCTGATTGCCAGTAATAGCAAT
GATCTGTGGGACCTGTTTCTGTTTGTTACCGGTCTGTTTGGTGTTCCGCTGGCAGGCGTT
TTTGCCGTTGGTATTTTTACAAAACGTACCAATACCTTTGGCGTGATTTGTGGTCTGATT
CTGGGTATTATCTTCGCCTATGTTTATAATGGTGTGGGCAAAGGTAATAGCCCGTTTTAT
GTTAGCACCATCAGCTTTACCGTTGCCTTTGTTTTTGCATATATCCTGAGCTTTATTGTG
CCGAGCAAACACAAAAAAGATATTACGGGTCTGACCATCTTTGAAAAAGATAAACCGAGC
ACCTACATTAGCAAAACCGCAACCAAAAAATGA 
